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Abstract 
Mutagenesis, the technique of mutating individual amino acids on proteins and peptides, is an 
important part of protein engineering and analysis. By changing residues and measuring the 
effect of the mutation on the properties of the protein such as its structure and interaction, a 
deeper understanding can be gained, which can be used to design new, better biomolecules. 
However, when performed experimentally, mutagenesis can be expensive, time-consuming 
and a rate-limiting step in research. Computational tools can be used to aid within this 
context, but a review of existing methods revealed gaps in the current literature. The Parasol 
Protocol was developed in order to address these issues and provide a new method that would 
be suitable for virtual scans and which relied on molecular dynamics. 
The Parasol Protocol is a tool which utilises the AMBER package framework to mutate at 
will between any pair of natural amino acids, incorporating a wide range of possible different 
functional groups and transformations. It is cheap, quick and easy to use while still allowing a 
high degree of control. 
After the development, work focused on validating the protocol by applying it to various test 
cases. Experimentally observed interactions and structures were compared with those 
obtained via computational simulations, performed using the Parasol Protocol. Our 
understanding of those systems has deepened thanks to these studies and in some cases it had 
remarkable agreement with laboratory results, indicating predictive power. 
We think that the Parasol Protocol has performed well so far and could become a standard 
method used in molecular dynamics and protein design. 
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 [...] Sind wir vielleicht hier, um zu sagen: Haus, 
Brücke, Brunnen, Tor, Krug, Obstbaum, Fenster, – 
höchstens: Säule, Turm... aber zu sagen, verstehs, 
o zu sagen so, wie selber die Dinge niemals 
innig meinten zu sein. [...] 
[...] Are we here perhaps just to say: 
house, bridge, well, gate, jug, fruit tree, window – 
at most, column, tower... but to say, understand this, to say it 
as the Things themselves never fervently thought to be. [...] 
Rainer Maria Rilke, Duineser Elegien, Ninth Elegy, 32-36 (trans. C. F. MacIntyre) 
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Chapter 1: Introduction 
In proteins and other polypeptides, there is a fundamental relationship between the 
amino acid sequence and the structure that is adopted1. In turn, there is a less well defined 
and understood but equally present relationship between a protein’s structure and its 
function2. Therefore, by manipulating, or mutating, the sequence of a protein or peptide, one 
can control its function and its properties, such as its interactions or reactivity.  
This has led to the rise of the field of protein design and engineering3, whose benefits 
should be obvious: proteins are biomolecules of fundamental importance, involved in nearly 
every aspect of life as we know it4. Outside of that they play a huge role within medicine5 and 
have extensive applications in industry6, and as such it is paramount for us to understand their 
properties, behaviour and interactions with other biomolecules, many of which are still 
unexplained7. By establishing how a protein’s function is affected by its structure, custom 
proteins can be made with desirable properties. This is the aim of protein design: to 
comprehend the fundamental forces that govern proteins and exploit them to produce man-
made enzymes, probes, therapeutic agents and other peptide-based biomolecules for 
academic, medical and commercial purposes. 
One successful and widely used example of protein design is the directed evolution 
method8, which mimics natural selection by mutating residues, often randomly9, which are 
then selected based on screened properties10. However, what we want to focus on is instead 
the more challenging but more interesting approach of rational design11–14. This approach 
makes use of targeted or site-directed mutagenesis15 to manipulate specifically selected 
residues to obtain specific sequences. By using some guiding principles of protein design16, 
one can introduce wanted functionalities17, encourage a chosen folded state18, or engineer 
interactions sites with a target19. It is a complicated technique because, as mentioned before, 
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the exact relationship between sequence and function in proteins is unclear; predicting how 
proteins fold given a sequence is a long-standing problem in chemical biology20. 
To make matters even more difficult, one of the most important areas of investigation 
within protein design is that of protein-protein interactions (PPI)21, which are in themselves 
hard to analyse and regulate predictably22. Their broad, relatively featureless interaction 
surfaces23 do not easily lend themselves to manipulation or modulation via small molecules24. 
Thus, in order to properly study this immensely valuable class of interactions, there 
needs to be a veritable arsenal of different techniques to properly analyse, characterise and 
manipulate them. There are many different aspects to protein design within PPIs, but one of 
the most important requirements is the ability to generate mutant structures: by comparing 
how characteristics like the interactions with other species or the three-dimensional 
conformation change upon mutation, one can establish a link and hopefully use it to predict 
the effect of similar mutations in other systems. To this end, several mutagenesis techniques 
have been developed25, and they can be very powerful tools in the analysis of proteins. These 
techniques can vary greatly in scope and specific functionality, intervening at different stages 
of protein expression; some are experimental protocols, some are computational26, and some 
can be better suited for different approaches to protein engineering. This range can be very 
important when investigating a field as vast and diverse as that of PPIs: efficient protocols 
that can produce results rapidly and a solid understanding of what effects mutations have are 
necessary to bridge the gap between the theory and practice of polypeptide design. The end 
goal of this endeavour is to have many tools at one’s disposal when it comes to analysing and 
manipulating proteins, selecting the most appropriate ones for the job at hand, so that their 
application in industry27 and drug discovery28 is easier and cheaper. 
Our effort within this context has been to develop a new computational site-directed 
mutagenesis technique. As it will be outlined later, the importance of virtual screens in these 
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sort of studies is great, and we have identified an area where there was the need for a new 
protocol with certain specifications. In the course of this report, we will explain the 
background of PPIs, review some of the current techniques used to investigate them, and 
finally discuss our contribution to the field. This includes detailing the methodology we have 
elaborated and the various test cases we have used in an attempt to validate it. 
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Chapter 2: Protein-Protein Interactions 
2.1 – Principles of Protein-Protein Interactions 
A PPI is, of course, an interaction that involves two or more polypeptides29. What this 
definition fails to explain, however, are both the enormous importance of these interactions 
and their sheer number in even the simplest of organisms. 
In the same way the entire set of genes in an organism is known as its genome, and the 
proteins expressed by it are a proteome, the totality of interactions that these proteins engage 
in is known as the interactome30. Mapping an organism’s interactome remains a considerable 
challenge31, not only because current techniques might have insufficient sensitivity to detect 
some of these interactions, but also because interactomes are very large. Even for something 
as modest as D. melanogaster, with a relatively small genome of 13,600 genes32, the 
interactome comprises of an estimated more than 70,000 interactions33, while for humans, 
with a genome of roughly 30,000 genes34, the number of interactions balloons to between 
500,000 and 700,00033. 
The interactions that make that number are involved in virtually all cellular processes 
that occur within the organism, with a great variety of possible complexes formed by those 
interactions35. These complexes can be hetero- and homo-oligomeric, depending on whether 
proteins interact with other copies of themselves or different proteins; permanent or transient, 
depending on their occurrence; and while most PPIs are noncovalent in nature36, some use 
covalent bonds such as disulphide bridges and other posttranslational modifications. Many 
major processes are governed fully or in part by PPIs; these can range from many different 
kinds of signal transduction37, to protein synthesis via formation of the ribosome38, to 
inhibition of other proteins’ activity39, to the basis of antibody-antigen recognition itself40. In 
other words, it is not possible to understate the importance of PPIs in the context of biology: 
their misregulation in the body might cause any number of diseases and conditions from 
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sickle-cell anaemia to Alzheimer’s41–44. More generally speaking, a good knowledge of PPIs 
gives us a better grasp of how cellular mechanisms work45; being able to understand how 
PPIs happen, what factors are important for their occurrence, how they can be promoted and 
even what can be done to inhibit them, all of these are extremely important concepts when it 
comes to protein design. If we want to engineer specific PPIs, then we must comprehend their 
rules. 
Unfortunately, these rules may not be straightforward to understand, and, even if we do 
understand them, they may be difficult to exploit. The parallel in this case is with protein-
ligand interactions, where the ligand is a small organic molecule. Small molecules are 
extremely important in medicinal chemistry, making up the majority of marketed drugs46, and 
their properties and interactions tend to be better defined than those of large biomolecules 
such as proteins47. For one thing, the interacting interface between proteins and small 
molecules is relatively small, being between 100 and 500 Å2 for most compounds48, and the 
interaction tends to be dominated by electrostatic effects49, which are more readily 
predictable; by contrast, PPI interfaces are much larger and predominantly above 1000 Å2, 
some even reaching much larger areas50, with the driving force of the interaction thought to 
be the stability contribution from the burial of hydrophobic residues, but also from 
electrostatic complementarity, hydrogen bonding and Van der Waals interactions51. In other 
words, while interactions between proteins and ligands are relatively well understood and 
comparatively predictable52, PPIs have large, flat53 interfaces where a variety of different 
forces all contribute in different manners to the interaction as a whole. To understand existing 
PPIs and engineer new ones require untangling the roles of several contrasting effects on 
otherwise broad, featureless surfaces. 
Fortunately, investigations of PPIs do not need to start in the dark: it is known that 
some residues contribute more to the overall interaction than others. These specific amino 
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acids, termed hot spots54, are essential to have tight binding between interfaces, and their 
impact on the free energy of interaction can be measured to be of at least 2 kcal/mol55, which 
is approximately a difference of an order of magnitude in terms of the experimental binding 
affinity constant. By this definition, 9.5% of interface residues can be described as hot 
spots56, and by controlling those sites one can modulate PPIs, either with other proteins or 
with the use of small molecules. A general analysis has revealed that some amino acids are 
more likely to be hot spots (tryptophan, arginine and tyrosine) while others are 
underrepresented (serine, threonine, valine and leucine); additionally, hot spots tend to be 
clustered around each other in “hot regions” and to be structurally conserved across different 
interfaces57. All of this is extremely important in the study of PPIs, as being able to observe 
patterns and trends of how hot spots work allows us to understand how to control them. 
 
2.2 – Experimental Methods for the Analysis and Study of Protein-Protein Interactions 
2.2.1 – Methods of PPI Detection 
We have seen that PPIs are ubiquitous and of fundamental importance; it should 
therefore be no surprise that there is a large number of techniques with which it is possible to 
study them58,59. It would be difficult, not to mention beyond the scope of this report, to list 
them all in sufficient detail, but we will discuss the general principles of these methods and 
explain a few of the most important ones. 
Essentially, these techniques need to be able to determine two things: which proteins 
interact, and the strength of these interactions59. Sensitivity is an important factor, as weak or 
temporary interactions are harder to detect. In addition, the assays have to replicate the 
conditions under which these interactions occur, such as pH, ion concentrations and presence 
of other species. Because of the huge variety of interactions happening in different conditions 
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and with proteins from different environments, several alternative strategies can be adopted 
depending on the target PPI. 
To begin with, the PPI must first be observed, and the gold standard in PPI detection is 
considered to be co-immunoprecipitation60. Interestingly, the basis for this technique is 
another PPI, specifically that between an antibody and the target protein61. The method works 
by obtaining the cell lysate and precipitating a protein that is known to bind to an antibody. If 
any other protein also binds that first protein, it will be pulled down, or co-precipitated, along 
with it, which can then be analysed to determine what interaction is occurring. Co-
immunoprecipitation has the advantage that it extracts the specific binding partners from the 
cell in the state they would be found there, for example with necessary posttranslational 
modifications or in complexes. However, it is not an especially sensitive technique, and 
because it necessitates knowledge of the interaction between the antibody and the first 
protein, it cannot be used as a true scanning technique. Other similar methods are protein 
affinity chromatography62, which is extremely sensitive but may give false positives, affinity 
blotting64, analogous to chromatography and more suited for membrane proteins, tandem 
affinity purification65, designed to give data on interactions that happen in the native 
environment, and cross-linking66, which creates covalent bonds between interacting proteins 
to probe the structure of multi-subunit complexes. 
If one intends to find instead the interaction partners of a protein from a biochemical 
library, there are other techniques available. Notably, phage display is a widely used method 
for this purpose67, and it consists of forcing a bacteriophage to display protein or peptide 
sequences on its outside by linking their genes to the coat protein gene. When the coat of the 
bacteriophage is assembled, therefore, it will also express the intended proteins and peptides; 
in this way, they are conveniently arranged to interact with the target protein, and subsequent 
steps of purification can then reveal which sequences bound to it. Because many sequences 
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(even random ones) can be expressed simultaneously, actual libraries of polypeptides can be 
screened; this lends itself to a high-throughput application of the technique. 
Another similar protocol is the two-hybrid assay68, which works by hybridising a 
protein with a DNA-binding domain and creating a library of putative partners hybridised 
with a transcription-activating domain. If there is an interaction between the protein and one 
of the library’s proteins, these two domains come together, and this causes the expression of a 
gene. By using the gene necessary for survival, samples in which there is an interaction can 
be identified quickly as they are the only ones that live. 
 
2.2.2 – Methods of PPI Analysis 
As it can be seen, there is a large number of techniques available to detect PPIs, 
whether it is in a library screen format or if it is to probe the interaction between two 
suspected partners. The list presented here is in no way exhaustive, but intended to portray 
the variety of methods, which are the just first step in the study of PPIs: once the interaction 
has been detected, other important aspects are the structure of interacting complex, the 
physiological conditions necessary for it to occur, and, perhaps most relevantly, the strength 
of the interaction, measured as the free energy of binding. When measured in vivo, this free 
energy can also reveal the influence of cofactors and competition from other binding partners. 
As with the detection methods, there is a variety of possible techniques which can be 
used in different circumstances. Essentially, anything that can measure the concentration of 
bound and unbound protein can be used to estimate the association constant. Protein affinity 
chromatography, already mentioned above, can also be used to estimate the interaction 
strength63; surface plasmon resonance has seen extensive application in the analysis of PPIs69; 
fluorescence is also commonly used to measure the free energy of binding70; isothermal 
titration calorimetry is perhaps the most quantitative of the techniques available71. 
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2.2.3 – Hot Spots 
The last area of PPI analysis that we wish to discuss in this section is hot spot detection 
and mapping. As hot spots are often crucial if not indispensable to understand the mechanism 
of interaction, it is important that we are able to identify them and map their location across 
the interface72, and this is often done through Alanine Scanning Mutagenesis (ASM)73. The 
idea behind ASM is that alanine, being a small, nonpolar amino acid, often contributes very 
little towards the overall interaction; mutating any non-alanine residue to an alanine will 
therefore have a negative effect on the strength of binding, but the greatest effect will be felt 
if the hot spots’ contribution is removed. In other words, by systematically replacing one by 
one every amino acid in a sequence with alanine and measuring the effect of this mutation, 
one can identify the hot spots by seeing which lose the most activity. This technique can 
theoretically be used with glycine as well74, as it is similarly small and unlikely to interact, 
but this has the added complication that the glycine may induce conformational changes due 
to its unique backbone parameters, and therefore must be employed with caution. 
ASM is a widely used technique75, but it is not without limitations76: apart from the 
obvious case that it cannot be used on residues that are already alanines or glycines, the 
mutation may have an effect on the unbound form of the protein, which affects the binding 
constant without revealing information on the interaction complex. Additionally, it is 
sometimes reported that the alanine mutation instead increases the binding affinity77; this may 
lead to the conclusion that the residue has a deleterious effect on the interaction and should be 
substituted to achieve tighter binding, when it is possible that the site is in fact indispensable 
for recognition and specificity. Despite these considerations, ASM remains a very powerful 
technique and a standard tool for the identification of hot spots. 
There are other methods that can map hot spots but do not rely on this sort of 
mutagenesis to identify their location. An example of this is the Multiple Solvent Crystal 
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Structures protocol78, which analyses several crystal structures of the protein with different 
proteins and a probe to determine likely interaction sites; one can also use the tethering 
between cysteines on a target protein and a putative ligand to discover binding sites79; ASM 
can be complemented with spectroscopic data80. These methods, however, are more 
commonly used to determine small molecule ligands that disrupt PPIs rather than the 
identification of hot spots, though, indirectly, they can offer information on that as well. 
 
2.3 – Computational Methods in the Analysis of Protein-Protein Interactions 
The common thread of the methods that we have described so far is that they are all 
experimental techniques. All of these involve the expression, handling and analysis of 
proteins via laboratory tools to generate “real life” data. What we wish to discuss in this 
section are the benefits of complementing these experimentally obtained data with 
computational results and predictions, and the unique contributions that an in silico approach 
can give to the study of PPIs. 
The purpose of laboratory testing is obvious: as long as the procedure is sound and 
carried correctly, any data obtained this way can be regarded as “correct” and as an 
observation of natural laws and effects. However, experimental techniques can be expensive, 
time-consuming, requiring specialist knowledge, hazardous or complicated to perform. This 
is even more true in the case of proteins81–83, which often can only be synthesised with 
difficult procedures on top of any other costs regarding their analysis. While shorter peptides 
may be more manageable, the expense associated with full-fledged proteins and antibodies 
can be a significant barrier towards their research, and it is precisely in this regard that 
computational tools can aid the most. 
Computational methods have become standard practice in many scientific disciplines, 
and the study of PPIs makes no exception84–87. Computational tools are routinely used to 
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complement experimental results, screen otherwise intractably large libraries, provide more 
information about known interactions and fill in that data that would be too difficult or 
outright impossible to obtain in the laboratory. Ultimately, however, the true goal of 
computational tools in this field is to be able to predict PPIs. As the cost, time and expertise 
required to deal with proteins experimentally is high, it is necessary to ensure that the effort is 
not wasted on unproductive research. If in silico methods can predict and analyse PPIs at a 
fraction of the expense needed in the laboratory, this can be used to direct experimental work 
and focus it on the more interesting and computationally proven interactions instead of 
unknown, potentially worthless ones. Based on this principle, many computational 
approaches have been devised to attempt to predict which proteins will interact and how; for 
known PPIs, the challenge is to explain the nature of the interaction and perhaps improve on 
it. This brings us back to the stated goal of protein design and engineering. 
An enormous advantage that computational methods have is the combination of speed 
and automation. Often requiring minimal set up and supervision, computational tools can 
scan through huge libraries and generate great volumes of raw data that would be far harder 
to collect experimentally. Indeed, this practice, termed virtual screening, has become a very 
powerful tool in drug discovery88–92. 
In terms of PPI analysis and prediction, this can take the form of scanning through 
libraries of protein sequences or genes, using a predetermined algorithm to score or assess the 
analysed data and determine the likelihood of interaction. For example, the genomic context 
of a gene, meaning the set of regulatory signals and other genes that surround it93, can be 
used to extrapolate which genes it will interact with; the proteins expressed by those 
interacting genes are in turn likely to form a PPI94. The comparison of genomes from 
different organisms95 or the construction of phylogenetic trees between homolog and ortholog 
proteins96 can also be used to predict new interactions from known ones. Networks can be 
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built that integrate experimental data with genomic information in order to predict PPIs97. 
Docking protocols can try to establish the interaction interface between proteins using 
structural similarity and conformational alignment to determine the most likely form of the 
complex created by a PPI98. It is plain to see that there are many possible parameters that can 
be studied in order to generate more information, at nearly every level of research of a PPI. 
 
2.4 – Summary 
The study of PPIs is extremely important not only to comprehend how proteins behave, 
but also to predict interactions with relevant medical and industrial applications. In the 
previous sections we have seen how PPIs are ubiquitous, essential and yet poorly understood 
in many cases. Although there is a wealth of experimental techniques that can be used to 
detect them in vitro or in vivo, and an equally large number of methods that can be used to 
analyse them, sometimes they can be insufficient. The cost, time and complexity associated 
with these protocols make them more suited for research on already well documented 
systems; scanning large libraries to discover new interactions is much more difficult. An 
increasingly common way to help in the investigation of proteins is to complement 
experimental work with computational studies, whose speed and ease of use allow for much 
deeper research. They can aid in both analysing known interactions and especially in virtual 
scans, for which they can be particularly well suited. 
In the next few chapters, we will focus on a specific aspect of PPI research: the 
generation of mutant sequences. In order to engineer proteins with wanted functionalities, it 
is important to be able to predict how changes in the primary structure affect interactions and 
other properties. We will outline experimental approaches to this, and also how it can be done 
computationally.  
  
22 
 
Chapter 3: Protein and Peptide Design and Experimental Mutagenesis 
3.1 – Proteins and Peptide Therapeutics 
PPIs are crucial in many biological processes, and they are often the target of drug 
discovery. Thus, if one’s goal is to modulate an existing PPI, either to disrupt a problematic 
interaction or create a new binding partner, then one must design a molecule with the 
appropriate characteristics. This can take the form of a small molecule ligand22,99, which is 
indeed standard operating procedure in medicinal chemistry, but an increasingly attractive 
and common option is to employ peptides and proteins as therapeutic agents100,101. 
These sort of biomolecules is particularly interesting because of the great specificity 
and affinity that can be engineered for their target, which is a characteristic of both small 
peptides102 and antibodies103. Additionally, as their degradation simply results in amino acids, 
there are fewer cytotoxicity concerns. Whether as inhibitors or vectors, their properties have 
attracted much interest over the years, but there have been significant challenges in using 
peptides and proteins as drugs, especially when compared to small molecule ligands47, and 
this has limited their potential. Apart from the greater cost associated with their research and 
development, their delivery is consistently problematic: because of their biological nature, 
they tend to have poor bioavailability and react much more with the body, either via 
digestion, posttranslational modifications or by provoking an immune response, which of 
course impairs their ability to reach their target. Proteins and peptides are usually restricted in 
their application to a parenteral administration, which does not fully solve these availability 
issues and makes it a less exploitable option than small molecule ligands, which are instead 
far more amenable to oral routes. Additionally, proteins and peptides are traditionally limited 
to extracellular or cell surface targets. 
However, there have been several advances in recent years owing to a renewed interest 
in peptides and proteins, especially antibodies, as therapeutic agents. These advances have 
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mostly focused on improving delivery, for example by enriching the protein with salts or 
sugars to improve their biostability104, or using more sophisticated approaches to cross the 
cell membrane and expand their range of targets employing nanoparticles105 and 
immunotoxins106. 
With these and other innovations, proteins and peptides have become subject to new 
research. As their use in medicine becomes easier and the assumptions about their difficulty 
of bioavailability are challenged, new techniques and strategies are being developed, both 
experimental and computational. 
There are different stages in PPI engineering, starting with an analysis of the interaction 
to determine the complex structure and the regions of interest, using the methods described in 
the previous chapter. In order to design a wholly new interaction with a new binding partner, 
there needs to be the ability manipulate protein sequences and change the residues that make 
them; in other words, we need to generate mutated structures. This process is part of 
mutagenesis, and it is in fact one of the most powerful tools in the study of PPIs and proteins, 
being applied in many different kinds of research107–109. We have already described a specific 
kind of mutagenesis, ASM, and its use in hot spot identification; however, in order to make a 
fully custom peptide or protein or antibody, there need to be laboratory techniques to 
manufacture the desired sequences and can mutate to any amino acid, not only alanine. The 
next section will detail some of the various techniques that are used in laboratories to 
manipulate protein sequences. 
 
3.2 – Methods of Experimental Site-Directed Mutagenesis 
The most widespread and commonly used method to generate mutant structures in the 
laboratory is to intervene at gene level, before the expression of the protein itself110. This is 
because the chemical synthesis of proteins is still a relatively new and unrefined field of 
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study, and there are concrete restrictions to the length of polypeptides that can be produced in 
this manner111. For proteins longer than 150 amino acids, this approximately being the limit 
of the technique, genetic manipulation remains the better-established approach. This allows 
controlling the protein from a very early stage, with a variety of different techniques, at the 
cost of requiring more work and time.  
Most common methods for mutagenesis are however not site-directed at all, but rely 
instead on random mutations. It has been proposed that this might take the form of simply 
using chemicals with mutagenic properties112 or X-rays113 to induce mutations in a sample 
and then expressing the resulting, mutated proteins. Although easy in practice, it is very 
crude, hard to control and standardise, and more likely to give harmful mutations than not, 
and thus it is very rarely used in this context. 
Luckily, there are other more complicated but more controllable techniques for 
mutagenesis. Random diversity methods, for example, can be reliably used to generate 
mutant structures. An example of this is uses a modified version of the Polymerase Chain 
Reaction (PCR) protocol, which is widely employed in laboratories for the replication of 
DNA: the fidelity of the method, which is usually very high, can be interfered with to give 
error prone PCR (epPCR)114. As the name implies, the way a DNA sequence is replicated can 
be negatively affected by various stratagems115,116, with the result that the copied sequence is 
different from the native one: it has been mutated. A similar strategy is the one employed by 
recombination techniques117, in which the DNA sequences are shuffled to generate new, 
mutated sequences. These recombinant approaches are less straightforward but tend to give 
better results than a simple random diversity protocol like epPCR. However, neither of these 
methods gives any control on the generated structure, instead merely ensuring that it is in 
some way different from the original one; while this can be employed in the making of 
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libraries and when there is little data to guide the investigation, one needs a more reasoned 
approach to perform true rational design.  
This can be accomplished instead by directed diversity methods25,118. In this case, the 
mutation is localised in a region of interest; of course, this requires more extensive prior 
knowledge of the complex and more complicated procedures than the fully random approach. 
By using transposons119 or oligonucleotide cassettes120, a mutated codon can be inserted in 
the original sequence, with the result that a mutation is inserted. This can be very different 
from the substitution of an already existing residue for another one, and thus it presents its 
own challenge. Either way, these methods allow more control over both the site of the 
mutation and what is inserted, and thus can be considered true site-directed techniques. 
An alternative approach is the total chemical synthesis of the mutated protein121. This 
has the advantage of skipping the potentially very expensive DNA manipulation and 
expression, but it is not without its challenges. The basis of the method is the chemical 
ligation of smaller polypeptide chains, essentially building the whole protein block by block; 
the longer the overall chain, the costlier and more complicated the procedure. The main issue 
with constructing the protein piecemeal is the complexity of ensuring that the correct 
sequence is built, as the peptide segments need to avoid side-reactions that lead to the 
incorrect product. This can be overcome with careful planning or the use of peptide bond 
analogues122 to avoid the most common side-reactions and solve solubility issues. Even then, 
this process if far easier to do with shorter sequences, and in fact, for peptides, total chemical 
synthesis is a very commonly used option. Termed Solid Phase Peptide Synthesis (SPPS)123, 
it is a routine laboratory technique used to produce peptides up to a hundred residues in 
length. The sequence can be finely controlled, which means that the mutant structure of any 
known peptide can be easily made by simply inputting the changed sequence. It is a highly 
automated technique with great purity and yield124, and it has become a standard tool in 
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peptide synthesis. Another option that does not involve the total synthesis of the polypeptide 
is to carry the chemical mutation of individual amino acids in the final protein125, a sort of 
artificial posttranslational modification aimed at changing one residue into another; however, 
not all amino acids can be mutated this way, and it can be very challenging to select a single 
site for the mutation, so it is not very commonly used. 
What we have seen here is a very brief overview of the most commonly used 
experimental techniques for mutagenesis. For longer proteins, the manipulation at DNA level 
and subsequent expression of the mutated sequence is perhaps the most widespread option, 
although chemical ligation is also a possibility; for shorter sequences, SPPS remains a routine 
tool. In each of these cases, however, the associated expense, time and expertise are not 
negligible, especially when both DNA and protein have to be expressed, purified and 
characterised. In an investigative effort where many different mutations may have to be 
carried before an acceptable structure has been generated, the cost of performing these 
protocols in the laboratory could be very high and become a significant barrier, which makes 
scanning applications much harder to implement with these methods. For this reason, 
complementing and replicating these techniques with computational ones has become 
standard practice126: by exploiting the ability of in silico methods to cheaply and quickly 
produce great volumes of data and predict interactions and structures, experimental work can 
be given a direction that would be harder and costlier to find if it could only rely on 
laboratory data. Performing virtual screens before committing to experiment can be a very 
powerful tool, and with the advance of technology and the possibility to run very 
sophisticated simulations, it is an increasingly attractive option. 
Just as there are many different experimental techniques to carry out mutagenesis, there 
are also many different computational ones, depending on the infrastructure used and the 
situations in which they might be employed. The next section will explain the basis of 
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computational chemistry, specifically in its application in PPI investigation, and afterwards 
we will highlight some of the most important computational methods for mutagenesis and 
describe their strengths and weaknesses.  
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Chapter 4: Computational Analysis of Protein-Protein Interactions and 
Mutagenesis 
4.1 – Principles of Computational Chemistry and Molecular Mechanics 
In order to understand exactly how mutagenesis can be done with computer 
simulations, we first ought to explain how proteins are handled by in silico methods. 
Generally and somewhat simplistically speaking, computational chemistry can be thought to 
be divided in two major branches: quantum mechanics and molecular mechanics127. Methods 
that belong to the first branch solve Schrödinger’s equation to evaluate the wave function (the 
entity that contains the quantum mechanical description of a system), using this to calculate 
in electronic detail molecular orbitals and describe bonds and interactions. This is a 
theoretically correct approach that attempts to simulate atoms and molecules with the most 
accurate and current understanding of how very small particles behave and the quantum 
effects that influence them. 
However, this accuracy comes at a great computational cost. In order to treat each atom 
and orbital in a chemical system with a sufficient degree of realism, it is common to include 
more and more descriptors for each of these atoms and orbitals. More descriptors mean a 
more nuanced and precise representation, but when simulating such well-rendered systems, 
the computational load scales greatly with its size, or the number of atoms in it. Therefore, 
this approach can only be applied to small enough systems, generally no larger than few tens 
of atoms. Proteins and other macromolecules are far too large to be fully simulated even with 
the most simple quantum mechanical methods within an acceptable timeframe. For this 
reason, several approximations can be used to lessen this load, giving rise to the field of 
molecular mechanics. 
Molecular mechanics makes use of the Born-Oppenheimer approximation, which states 
that, because of the huge disparity in mass, the motion of nuclei and electrons can be 
separated128. This allows to neglect electrons altogether (though their effect is still felt 
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through charge and polarisability) and use Newton’s laws of motion to describe atoms, 
treating them with a “ball and spring” model that obeys a classical representation of forces. 
Specifically, Newton’s second law of motion is the basis for the calculation of forces: 
𝐹 = 𝑚
𝑑𝑣
𝑑𝑡
= 𝑚𝑎 
Equation 1: Newton’s second law of motion. The force (F) is proportional to the mass (m) of the object and its 
change in velocity (v) over time (t), or acceleration (a). 
While it would be a more faithful representation to include quantum effects, this 
approximation has proved to be sufficient to simulate proteins in a realistic enough way and 
in a short enough time to be used profitably in research. This is the approach used by 
packages such as GROMACS129, CHARMM130, NAMD131 and especially AMBER132,133, 
which is the molecular mechanics package of choice in this group and for this project. The 
purpose of these packages is to generate molecular dynamics (MD) simulations, which track 
the change in structure and energy of a system over time as dictated by the molecular 
mechanics representation of atomic interactions. Throughout our description of how this is 
done, we will be often referring to the specific implementation within AMBER due to its 
relevance to our own investigations; other packages may differ slightly, but nowadays most 
packages can use each other’s methods.  
 
4.2 – The Force Field Equation and Parameters 
4.2.1 – The Force Field Equation 
The calculation of the movement of atoms in a simulation is done by solving the force 
field equation; Equation 2 shows its general form in AMBER. The equation describes the 
possible interaction between any pair of atoms in the system, depending on the bond distance 
between them. By calculating iteratively this force for each pair over several time steps, an 
MD simulation is generated. 
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𝐸𝑇𝑂𝑇𝐴𝐿 = ∑ 𝑘(𝑟 − 𝑟𝑒𝑞)
2
𝐵𝑂𝑁𝐷𝑆
+ ∑ 𝑘(𝜃 − 𝜃𝑒𝑞)
2
𝐴𝑁𝐺𝐿𝐸𝑆
+ ∑
𝑉𝑛
2
[1 + cos(𝑛𝜑 − 𝛾)]
𝐷𝐼𝐻𝐸𝐷𝑅𝐴𝐿𝑆
+ ∑ [
𝐴𝑖𝑗
𝑅𝑖𝑗
12 −
𝐵𝑖𝑗
𝑅𝑖𝑗
6 ]
𝑖<𝑗
+ ∑ [
𝑞𝑖𝑞𝑗
𝜀𝑅𝑖𝑗
]
𝑖<𝑗
 
Equation 2: The force field equation as used in AMBER. 
There are five components to the equation, each describing a different possible pairwise 
interaction between atoms. The first term describes a bonded interaction, modelled as if it 
were a harmonic oscillator with a minimum in energy at the equilibrium bond distance and 
steep curves as the bond gets too short or too long. Again, this is an approximation of the real 
dynamics of a bond, which could be modelled more finely by introducing more terms or 
using a Morse potential134; however, the harmonic oscillator is much simpler to calculate and 
accurate enough to represent reality, especially around equilibrium distances. In a similar 
manner to bonds, the second term describes atoms that are at an angle (two bonds apart) and 
models their bend with another harmonic oscillator. Dihedrals (atoms three bonds apart) or 
torsions are written as a Fourier series, and can include parameters for out-of-plane bending 
to enforce planarity in rings and other similar structures. Finally, the last two terms describe 
the interaction between any two atoms that are more than three bonds apart: the first 
modelling Van der Waals forces with the Lennard-Jones potential135 (repulsion having a R-12 
dependence and attraction a R-6, where R is the distance between the atoms in question), and 
the second term modelling electrostatic forces as the Coulomb potential. 
 
4.2.2 – Parameters 
A fundamental component of the force field equation is represented by the parameters, 
which must be supplied prior to the simulation. In the case of the bond term, for each possible 
bond there are an equilibrium distance and a force constant, which represents the strength of 
the bond and the energy penalty for deviating from equilibrium. There are similar parameters 
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for the equilibrium angle width and its force constant, while dihedrals have a force constant, 
equilibrium torsion, and periodicity. For non-bonded interactions, the parameters are the 
point charges of the atoms (calculated from their electron distribution) and their Van der 
Waals coefficients. These parameters are generally derived empirically, which is a departure 
from quantum mechanics methods, where this sort of data is instead calculated as a result of 
solving the wave function. Somewhat confusingly, the set of these parameters is also known 
as a force field, and it is up to the user to choose the most appropriate force field for the 
system that is being simulated. 
This is because different force fields contain different parameters that have been 
derived for specific chemical systems. As AMBER is used to perform molecular dynamics of 
biological systems, its force fields contain information on the bonds, angles, dihedrals and 
non-bonded interactions commonly encountered in proteins, DNA, lipids and carbohydrates. 
Starting from the first modern AMBER force field, ff94136, and continuing with later sets 
such as FF99SB137, FF12SB138 and the most recent, FF14SB139, each new iteration modifies 
the parameters that are employed as better experimental data or new ways to describe them 
become available. For systems that include species such as lipids and carbohydrates, more 
dedicated sets such as LIPID14140 and GLYCAM06141 can be used to take advantage of 
extensive calculations aimed at obtaining those species’ specific parameters. GAFF (general 
AMBER force field)142 is instead, as the name implies, a generalised, catch-all force field to 
be used when specific options are unavailable. 
The development of a force field is not a trivial matter143. Transferability144, which is 
the degree to which the parameter for a type of feature can be used to describe that feature in 
different chemical contexts, such as C-H bonds in different molecules, is a key factor. In 
particular, it can be hard to strike a balance between broad applicability and specific cases. A 
perfect force field would contain parameters for every possible bond, angle, dihedral and 
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non-bonded interaction in the analysed system, but even a small system can present hundreds 
if not thousands of different combinations, each of which would have to be obtained 
experimentally. In addition, such a force field would be excellent for those particular cases 
but would describe poorly any other system; it would be overly specialised and of limited 
application. On the other hand, a parameter set that is too general could perhaps describe 
semi-adequately many different systems, but not be specific enough to give the needed level 
of accuracy when examining those systems in detail. 
In protein systems, which are of course those we focus on when discussing PPIs, these 
concerns are lessened. Force fields may encounter the problems described above when 
attempting to handle unknown molecules, as it would be the case in drug discovery with 
different, previously unparameterised ligands. However, as proteins and polypeptides in 
general are made of the same, well-documented twenty amino acids, the established force 
fields are generally well optimised and expertly validated. This problem would instead 
present itself when trying to include residues or species outside of the natural twenty, and 
their parameters would need to be obtained from external sources or derived from scratch, 
using protocols such as the RESP (Restrained Electrostatic Potential) algorithm145,146. As it 
will be explained later, this has been necessary in the course of our investigation. 
 
4.3 – Principles of Molecular Dynamics Simulations 
4.3.1 – Simulation Algorithms 
Now that we have discussed the force field equation, its various terms and the 
parameters that are necessary for its operation, we will explain how it is used to generate MD 
simulations. What a simulation consists of, essentially, is of an interaction potential (given by 
the equation) acting on a set of initial coordinates and velocities to generate a time-dependent 
evolution of the system’s dynamics. The simulation is divided in many small time steps, and 
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at each the energy function is calculated to determine how the forces affect each atom’s 
position and velocity; these are used to generate a new set of coordinates, on which the 
interaction potential can act again. By repeating this process over the many short steps, the 
overall behaviour is obtained as it changes through time. The collection of positions as they 
move in the simulation is known as a trajectory. 
One thing that must be noted is that calculating the equation involves integrating 
Newton’s laws of motion, which cannot be done analytically. Instead, AMBER uses a variant 
of the Verlet algorithm147, called the leapfrog algorithm148, to solve this problem numerically. 
Without delving into a detailed mathematical explanation of its operation, it involves 
calculating the position of atoms at time t and from that their velocities half a time step 
afterwards, at t + δt/2, δt being the time step. The velocities are then used to generate the 
positions at time t + δt, which are used to generate the velocities half a time step afterwards, 
and so on. Velocities and positions are not known at the same time t, but calculated at a half 
step offset, as positions ‘leap’ over velocities and then velocities ‘leap’ over positions; this is 
the origin of the name leapfrog. The leapfrog algorithm presents greater numerical accuracy 
when compared with the Verlet algorithm and an explicit calculation of velocities, which is 
important in molecular dynamics simulations, as velocities often affect the thermostat. 
 
4.3.2 – Simulation Time and the Ergodic Hypothesis 
The size and number of time steps end up therefore determining the length of the 
simulation as a whole, which is one of the most important variables that the user must 
consider. In order to obtain information about some property of the system, such as its free 
energy, that property should be measured as the system explores its conformational space, or 
phase space, giving the ensemble average. The phase space can also be considered as being 
mapped onto a potential energy surface, with some regions having very high energy and 
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some being at a minimum; as molecules attempt to minimise their overall free energy, they 
will try to reach these minima. However, even though proteins at equilibrium will prevalently 
be found in these regions, phase space is extremely large: even for a very small system, there 
is an enormous amount of configurations that the system could be found in, most of which at 
a very high energy, and it would take eons to sample every point and measure the property. 
Instead, we must rely on the ergodic hypothesis149, which states that for a property, its time 
average, which is measured by observing how that property evolves throughout a trajectory, 
and its ensemble average, which is measured by observing that property in many disparate 
states, are the same. While this may difficult to prove, it is a fundamental assumption in MD 
simulations. In other words, instead of sampling many different states, if we simulate a few 
for long enough we will reach the same outcome. Deciding what constitutes ‘long enough’ is 
why the choice of time is so important. 
Another reason why the time step and overall simulation length are important is that the 
motion of proteins have been measured experimentally, and we know that in order to observe 
certain behaviours, we must allow more or less time150.  While bond vibrations occur on a 
femtosecond scale, dynamics that occur in proteins such as the rotation and motion of side 
chains, functional groups and secondary structures can happen from the pico- to the nano- 
and even microsecond scale. The motion of domains and the folding of the protein as a whole 
require more time, taking more commonly microseconds to seconds. Because state-of-the-art 
molecular dynamics simulations can only reach the microsecond timescale151, such motions 
are generally inaccessible, and prospective researchers must be conscious and realistic about 
the dynamics that a protein can undergo in the simulated timeframe. 
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4.3.3 – Extending the Timescale: GPUs 
There are some strategies that allow extending that timescale, either through enhanced 
sampling techniques or better hardware that allows for longer simulations. For example, 
replica exchange152 and locally enhanced sampling153 are methods that can be used to 
artificially increase the conformational space that is visited by the simulation without actually 
extending the simulation time. The use of supercomputers154 or large parallel computer 
clusters155 can of course offer longer simulations, but this requires the access to such 
computational power, which may be expensive or not available to all researchers. In the 
absence of such resources, a very attractive, cost-efficient and increasingly used option is that 
of Graphical Processing Units (GPUs). 
Traditionally, the heart of a computer is its Central Processing Unit (CPU)156, which 
has the task of performing the various calculations needed for the functioning of the machine; 
this is also what is used for simulations. When it comes to those, the speed of the processor is 
the rate-limiting step, and a slow processor will hinder research by lengthening simulation 
time. As technology improved and more powerful CPUs became available, so did the 
capabilities of molecular dynamics as a tool progress; unfortunately, we have reached the 
point where the needs of a simulation cannot be satisfied by a single modern CPU. The way 
to improve them has tended to be to make them smaller and smaller, but there are definite 
issues with heat dissipation and quantum tunnelling effects that have limited how much 
smaller they can be made. Clusters and supercomputers can get around this by using many 
CPUs together to perform simulations faster, but GPUs are an interesting alternative. 
The purpose of a GPU is to render images on a screen. Monitors are divided in pixels, 
each of which can have a single colour; as what is on the screen changes, the GPU has to 
calculate how the colour of each pixel changes to match the new image. Primitive GPUs 
could only do that for a limited number of pixels, but the demand for more realistic and 
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graphically impressive video games has driven the development of powerful processors that 
can handle many thousands of parallel computations. Fortuitously, this sort of hardware lends 
itself perfectly to molecular dynamics simulations. As we have discussed, a trajectory is 
generated by the application of the force field equation to each pair of atoms; while a CPU 
would calculate each pair sequentially, a GPU can do this in parallel, calculating many 
pairwise interactions at the same time. While in its usual function a GPU computes two 
numbers to give a single pixel’s final colour, in MD simulations that process is “hijacked” to 
instead solve the force field equation, with the result that the calculation proceeds much 
faster157. This has been an extremely important breakthrough that has allowed for much 
greater simulation speeds; the Compute Unified Device Architecture (CUDA) platform156, 
the interface used to develop software on GPUs, has been implemented on AMBER to allow 
the package to take advantage of this new technology158,159. Our group has made extensive 
use of GPU-based calculations, which have enabled much faster computations at a fraction of 
the time and resources that would normally be needed. 
 
4.4 – Principles of Free Energy Calculation and Challenges  
4.4.1 – The Thermodynamic Cycle 
We have here seen the force field equation, the way it is implemented and calculated 
within AMBER, and explained the importance of time in simulations. An important topic that 
we want to address before heading into the discussion of the various existing methods for 
computational mutagenesis is the issue of measuring free energy changes in molecular 
dynamics simulations. The simulation in itself is of little value unless we can extract from it 
data that can be used and compared with experiment. Some of it can be structural 
information, but in the context of PPI analysis, the most important is of course a 
measurement of the strength of the interaction, and especially a measurement of how it 
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changes after a mutation. This is done by calculating the free energy of the system of the 
native and mutated forms of protein. As we have already established, we can have faith in the 
measurement of a property in a simulation only if we hold the ergodic hypothesis to be true, 
meaning that we either have to sample a conformation for a long time or many conformations 
in order to determine the free energy. However, a system’s free energy is made of 
contributions from many regions of phase space, most of which are very high in energy, and 
the typical molecular dynamics simulation samples low energy regions; estimates from these 
simulations are bound to be imprecise and not representative. We must therefore find 
alternative strategies to measure the free energy, and, fortunately, we are not interested in the 
free energy in itself, but rather how it changes upon mutation, which is far easier to 
determine. Let us imagine that the free energy G of a PPI system changes by a factor of ΔG 
between the bound and unbound states of the interaction; if we mutate one of the proteins 
involved and measure the change in free energy again we will obtain a second change, termed 
ΔG’. It is the comparison between these two changes ΔG and ΔG’ that reveals the relative 
change in binding free energy, the ΔΔG, which is a quantitative measure of how the mutation 
affects the interaction. If the two conformations (native and mutant) are going to be similar 
save for the changes in the mutated area, they will occupy similar regions of phase space, and 
as long as the simulation samples those regions, estimates of the free energy difference 
between them can be obtained with sufficient accuracy. 
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The way this is done is through the use of thermodynamic cycles160, which allow to 
estimate the changes in the binding free energy that would otherwise be complicated to 
calculate computationally. A typical thermodynamic cycle that can be used in PPI analysis is 
shown in Figure 1. 
In the case of this thermodynamic cycle, we desire to know the change in free energy 
upon binding in solution, termed ΔGbinding, sol which is a measure of the strength of the 
interaction between the two proteins. However, this is hard to calculate directly, because of 
the conformational changes that may be necessary to have the interaction, and other factors 
such as solvent effects. Because in a thermodynamic cycle, by definition, the sum of the 
energy is zero, we can calculate ΔGbinding, sol by instead calculating the other terms, which are 
easier to obtain computationally. We calculate the energy change of solvating the individual 
components of the interaction, ΔGsolvation, rec+lig, the change in free energy upon binding in 
vacuo, ΔGbinding, vac, and the energy change of solvating the complex as a whole, ΔGsolvation, 
Figure 1: A thermodynamic cycle that can be used to determine the change in free energy upon binding in 
solution. The semicircle represents the receptor (rec), the circle is the ligand (lig), and together they make a 
complex (com). In the case of a PPI, they are both polypeptides. The light blue indicates in solution, while the 
white indicates that is in vacuo. As the sum of all the free energy changes in the cycle is zero, by using the 
other values, which are much easier to calculate, the wanted term can be obtained. 
ΔGbinding, sol 
ΔGbinding, vac 
ΔGsolvation, rec+lig ΔGsolvation, com 
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com. The binding free energy is much easier to obtain for a system that neglects solvent 
effects, and the energy of solvation is equally simple to calculate, and thus with the following 
equation the ΔGbinding, sol can be derived: 
∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔,𝑠𝑜𝑙 = ∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔,𝑣𝑎𝑐 + ∆𝐺𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛,𝑐𝑜𝑚 − ∆𝐺𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛,𝑟𝑒𝑐+𝑙𝑖𝑔 
Equation 3: How the binding energy in solution is calculated. Because it is a state function, it is independent of 
path and therefore can be derived from other quantities. 
It is important to note that ΔGbinding, vacuo is impossible to calculate in the laboratory, as it 
is of course impossible to conduct protein experiments in vacuo, but we are still able to 
obtain it computationally: this is an example of applying theory and in silico tools to 
complement lab work. 
 
4.5 – Methods of Solvation and Free Energy Calculation 
4.5.1 – Explicit Solvation 
We have here seen how the thermodynamic cycle represents the basics of the strategy 
used to measure changes in free energy in molecular dynamics simulations, and it is 
employed in many different methods for this purpose.  
Before we can discuss how these techniques are applied for the calculation of binding 
strengths and interactions, we must address how solvation is handled within AMBER and 
related packages. This is important for experimental accuracy: proteins do not exist in a 
vacuum, but in a variety of physiological conditions, depending on their role, the cell or 
organ they are in, and even the specific location within a cell. This means that their 
environment consists of a mixture of a great variety of biomolecules161, each of which may 
interact or in some way affect the dynamics of the protein, and to fully replicate in vivo data 
with computational methods, these ought to be accounted for. Unfortunately, the range of 
possible interaction partners is too large to replicate accurately with MD methods, as the 
number of atoms that would be required to reproduce a typical cytoplasm far exceeds the 
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current capabilities of the technique. There have been attempts to investigate these effects 
using advanced strategies162,163, but a far more common approximation consists of performing 
simulations on single protein systems sourrounded by solvent and counterbalancing ions. 
Computationally, it is an analogous approach to studying the properties of proteins in vitro as 
opposed to in vivo, where clarity and simplicity are favoured over a system that is more 
accurate but potentially harder to analyse. 
The usual solvent used in these studies is water, as it is prevalent in physiological 
conditions, and there is a variety of different ways which can be used to represent this sort of 
solvation. Perhaps the simplest way to do this is by adding atomistic representations of water 
molecules to the system and around the protein; this is known as the explicit solvation 
approach, where water is treated as a collection of actual, physical entities, and contrasted 
with the implicit approach, in which water is instead modelled through the use of field 
equations. 
There are many different models which can be employed to simulate water molecules, 
depending on which properties need to be measured and the degree of accuracy one seeks164, 
but for most common MD simulations, the TIP3P model is well-balanced by having 
sufficient detail but also being easy to use165. In the TIP3P model, water is treated as a three 
point, rigid body where the oxygen and two hydrogens are each connected to each other by 
bonds (including a fictitious H-H bond); each atom has electrostatic charges, but only the 
oxygen has Van der Waals parameters, which are set to model the molecule as a whole. 
These approximations, the H-H bond that confers rigidity and the use of a single value to 
represent three atoms’ interactions, are used to simplify the representation and lessen the 
computational load needed to simulate such a system. This is crucial, because adding a 
solvent shell around a protein means surrounding it with water molecules and adding 
thousands of atoms to the system. 
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This is perhaps the greatest challenge of explicit solvation: the fact that it dramatically 
increases the size of the simulation, forcing a simulation to model a huge number of atoms, 
only a fraction of which are the protein itself. The choice of how water is represented 
becomes then a very important one, because the addition of extra parameters, such as 
polarisability, need to be done for every molecule introduced in the system, which 
consequently makes the whole simulation more laborious. Other than using the simplified 
TIP3P, there are other stratagems that can be used to lessen the computational requirements. 
One common solution in AMBER to approximate the infinite number of waters that 
would be needed to fully solvate a protein is to use periodic boundary conditions. With this 
tactic, the system is confined in an endlessly tessellating periodic box, which means that 
atoms that, through the dynamics of the simulation, would exit the box from one side re-enter 
it instead from the opposite one. In other words, the box repeats itself infinitely, but each box 
contains only a single copy of the solvated protein. This allows the system to freely explore 
in any direction, without artificial barriers and experiencing an effectively infinite number of 
solvent waters without actually having to simulate them all.  
While this technique is very useful and common practice in AMBER simulations, it 
imposes some requirements, the most important of which is the interaction cut-off. If each 
pairwise interaction were to be computed correctly, then under periodic boundary conditions 
each atom would interact with itself from an adjacent box, which is obviously an absurd 
situation. To avoid this, a cut-off is introduced to limit the explicit calculation of non-bonded 
interactions between atoms that are less than a predetermined value, usually between 8 and 
16 Å; beyond this, an atom’s non-bonded interactions are evaluated as happening with a 
diffuse field, which is the Particle Mesh Ewald (PME) approach166. 
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4.5.2 – Implicit Solvation: GB and PB 
Simulating solvent explicitly has become a standard way of modelling the effect of 
water in MD simulations. Because the interactions between waters and protein are calculated 
in atomistic detail, it allows for a greater degree of accuracy and bulk properties of the 
solvent can be modelled correctly. As it is the paradigm in computational chemistry, greater 
accuracy always comes at the cost of increased computational demand, and it may sometimes 
be better to use implicit solvation to lessen the load. For our investigations, we have always 
used explicit solvation during molecular dynamics simulations using TIP3P and periodic 
boundary conditions in the manner described above, but there was one very important 
application of implicit solvation: for the calculation of the free energy. 
As mentioned before, solvation effects can be modelled implicitly through the use of 
equations that simulate a uniform polarisable continuum of electrostatic and non-electrostatic 
terms. Solvating the system, in our case the protein or protein complex, in the continuum 
requires its destabilisation by creating a suitably shaped hole and placing the solute in it, with 
additional destabilisation or stabilisation given by the solute-solvent interactions. There are 
many aspects to this process, such as how the hole is calculated, how the interactions are 
modelled, and what properties are given to the continuum, and for this reason there may be 
many reaction field models; for our purposes, we have used and will detail the Poisson-
Boltzmann (PB) and Generalised Born (GB) models. In these methods, there are two main 
components: the electrostatic term and the non-polar term. The latter is related to the energy 
needed to create the hole and to Van der Waals solute-solvent interactions, and is generally 
estimated to be proportional to the solute’s Solvent Accessible Surface Area (SASA), hence 
relatively easy to calculate analytically. It is obtained by solving several equations that arise 
from the geometric constraints of overlapping spheres, which is how the protein is modelled 
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in order to determine which regions will be in contact with the solvent167. The electrostatic 
term, however, can be computed in different ways. 
The PB method of doing this relies on a combination of two equations, the Poisson 
equation and the Boltzmann distribution168. The first equation relates the electrostatic 
potential to the charge distribution, and it can be used to describe a protein in water as a 
region of low dielectric constant placed in a region of high dielectric constant. The second 
equation is added to simulate mobile charges, in this case ions, in the water. The result is the 
following equation169: 
∇ ∙ 𝜖(𝒓) ∇𝜑(𝒓) − 𝜖𝐾2 sinh[𝜑(𝒓)] +
4𝜋𝑞𝜌𝑓(𝒓)
𝑘𝑇
= 0 
Equation 4: The Poisson-Boltzmann Equation. ε is the dielectric constant, φ the electrostatic potential, q is the 
proton charge, ρf the fixed charge density, k the Boltzmann constant and T the temperature. K2 relates the Debye 
length to the ionic strength of the bulk solution. All variables save for T are functions of the position vector r.  
Solving this equation for φ leads to the calculation of the electrostatic potential at any 
point of the solute-solvent system; it can be linearised when the potential is small (usually a 
correct assumption, but it may lead to errors and artefacts when considering biomolecular 
systems with strong charges), giving a simpler form that requires less computational power to 
be handled. Even in its linearised form, however, it still must be solved iteratively with great 
expense as the potential of any one point is affected by the potential of the surrounding 
points, and therefore it may need many successive computations before convergence is 
achieved. This makes it a relatively expensive tool for this purpose, but also relatively more 
accurate when compared to other implicit solvation techniques170,171. As in other areas of 
computational chemistry, more power and time are needed to measure with greater accuracy, 
and determining what level of precision is needed by an investigation is something that 
should be analysed carefully. For the purposes of our studies, we employed PB fully knowing 
that it was a more complex and time-consuming technique, because with our hardware and 
set up we were able to obtain data in a reasonable amount of time. We complemented it with 
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another implicit solvation technique that is considerably easier to calculate but may lack in 
accuracy. 
That technique is the GB model, which is much faster to solve than PB as it was 
developed to be an approximation. It is a calculation of the electrostatic potential with 
modifiers to account for the solvent and solute such as the dielectric constant and the 
separation, and, in AMBER, it takes this general form: 
∆𝐺𝑒𝑙 =  −
1
2
∑
𝑞𝑖𝑞𝑗
𝑓𝐺𝐵(𝑟𝑖𝑗𝑅𝑖𝑅𝑗)
(1 −
𝑒𝑥𝑝[−𝜅𝑓𝐺𝐵]
𝜀
)
𝑖𝑗
 
Equation 5: The Generalised Born equation. qi and qj the partial charges of atoms i and j, which are separated by 
a distance rij and have effective Born radii Ri and Rj; κ is the Debye screening parameter, which is the inverse of 
the Debye length; ε is the dielectric constant for the solvent; fGB is a function of the effective Born radii.  
The key to solving that equation is the fGB function
172, which relates the distance 
between the atoms in question and their effective Born radii. The effective Born radius is that 
which would give the electrostatic solvation energy of a system using the Born equation if 
that system had the same dielectric boundary between solvent and solute and a single charge. 
Stated more simply, it is a measure of how buried an atom is within the solute, or of the 
distance between that atom and the surface of the protein. As a protein’s shape changes 
throughout a simulation, how far inside and buried any given atom might be also changes, 
and this value must be calculated at every time step of the simulation. There are many 
different methods of doing this for biomolecules and proteins that have been implemented 
within AMBER173, and a correct calculation of the effective Born radii of the atoms in 
question is fundamental to determine the solvation energy174. 
Despite the need to determine radii at every structural change, the GB method remains 
analytically fast and simple to solve, and it is therefore sometimes preferred to PB due to its 
speed. It is, however, an approximation, and therefore an inherently less accurate method to 
determine the electrostatics of solvation175. 
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It would be possible to use either of these techniques, as well as others, to implicitly 
solvate our investigated proteins and greatly reduce the number of atoms in our simulations, 
with consequent reduced need for computational power, but we have settled on explicit 
solvation for our studies. The access to sufficient hardware and the size of the investigated 
systems allowed us to afford the more realistic option of adding physical water molecules, 
but we still used implicit solvation for free energy calculations. 
 
4.5.3 – MMPB(GB)SA 
The models that we have described above are integral to the MMPBSA (Molecular 
Mechanics Poisson Boltzmann Surface Area) and MMGBSA (Molecular Mechanics 
Generalised Born Surface Area) methods176, which were widely used throughout our studies. 
These methods use the following equation177: 
𝐺 = 𝐸𝑖𝑛𝑡 + 𝐸𝑒𝑙 + 𝐸𝑣𝑑𝑊 + 𝐸𝑝𝑜𝑙 + 𝐸𝑛𝑝 − 𝑇𝑆 
Equation 6: The free energy of a state is given by the sum of its internal energy given by bonds, angles and 
dihedrals (Eint), the electrostatic (Eel) and van der Waals interactions (EvdW), and polar (Epol) and nonpolar (Enp) 
interactions with the solvent. The first three terms are calculated from solving the force field equation (the MM 
part of the MMPB(GB)SA), the polar contribution via either PB or GB, and the nonpolar contribution taken to be 
proportional to the solvent accessible surface area (SA). Additionally, entropy effects (TS) can be included. 
To calculate the interaction strength between two polypeptides, these methods rely on 
the thermodynamic cycle introduced in a previous section, where the experimentally relevant 
but computationally hard to calculate binding energy in solution is instead obtained via the 
appropriate addition and subtraction of more easily measured energies. Some of these 
energies are the energy of solvation of the species involved, which is measured using the PB 
and GB models described above. From an MD simulation of a PPI, the trajectory of the 
complex is extracted, followed by the trajectories of the receptor alone and the ligand alone. 
For each of these, the energy of solvation is obtained and then used in the thermodynamic 
cycle. PB estimates of this energy tend to be slower to calculate but more accurate, whereas 
the GB ones are the opposite. 
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Although this is an approach that we have used several times within the group on many 
different systems, it is one that brings many challenges and assumptions that must be 
addressed in order to have faith in the data obtained this way. After all, the interaction 
strength of a PPI is going to be one of the most important metrics that we will use when 
analysing proteins, and therefore an appropriate tool must be used for the job. 
The first consideration is that the method we have just described makes assumptions 
about the structure of the proteins involved. The energies of solvation of the components of 
the interaction are measured with conformations taken from the overall trajectory, but the 
solvation terms are calculated while they are on their own. This is correct only if they adopt 
the same shape whether they are in a complex or not, which is of course not necessarily true 
in every case. 
However, this is a necessary assumption. A more rigorous method would perform three 
trajectories, one each for ligand, receptor and complex, whose solvation energy calculations 
would then be used in the thermodynamic cycle; but, apart from the added computational 
expense of performing the same simulation three times, this would perhaps introduce even 
more sources of uncertainty in the calculation. The inherent variability of a molecular 
dynamics simulation would be multiplied by three, and it would be difficult to achieve 
enough overlap in conformational space to properly account for solvation energy changes178. 
Instead, a single trajectory allows to cancel errors and minimise the risk of large fluctuations 
because the dynamics of the complex, ligand and receptor are identical; it is an 
approximation, but it must be done in order to reduce error and obtain meaningful results in a 
short enough amount of time179. 
Another important aspect to consider is entropy, which can contribute enormously to 
the computational cost of a free energy calculation and be a significant source of error180. The 
Gibbs free energy is made of enthalpic and entropic terms, and therefore both should be 
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considered and implemented within a protocol that attempts to measure it. In MMPB(GB)SA, 
the entropy can be obtained either via the quasi-harmonic (QH) approximation method181 or 
via normal mode analysis (NMA)182. However, neither QH nor NMA are especially quick or 
accurate techniques183,184: though relatively simple to implement, the correct evaluation of the 
entropy requires the analysed conformations to be appropriately converged, and extensive 
sampling is often needed for any estimation of this property. To include entropy in the 
calculation means devoting significant amounts of time and power to this effort, and even 
then entropic contributions to the free energy may create statistical noise that makes it hard to 
discern the enthalpic contributions185, which are those that need to be measured in PPI 
comparison and analysis. The single trajectory approach described above that assumes no 
conformational changes between bound and unbound forms of the interacting proteins helps 
in this regards, as it nullifies any entropic difference between the complex, the receptor and 
the ligand. Even this is often not enough, and including entropy in one’s investigations will 
be expensive and problematic. 
A solution to this issue has been to mostly ignore the entropy within the context of our 
studies. The assumption in this case is that point mutations at interfaces will have little impact 
on the overall entropy of the complex, and thus the difference between native and mutant in 
that regard should be negligible. We are able to make this choice because we are not 
interested in the absolute free energy of the investigated systems, but only in relative changes. 
Our aim is to determine how mutations affect the interaction strength, as well as other 
properties, and therefore the relative change in free energy, the ΔΔG, is our goal for the 
application of the MMPB(GB)SA method. As in other cases where approximations are used, 
it would be more rigorous and theoretically exact to compute the entropy too, but this is 
neither required of us nor is it feasible for us to do, and thus entropy effects are neglected. 
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4.5.5 – Challenges of MMPB(GB)SA 
Overall, the MMPB(GB)SA approach to free energy calculation has many flaws and in 
some regards it may not actually be the preferred method for this purpose186,187. The 
approximations intrinsic to MD calculations and those necessary to run MMPB(GB)SA and 
obtain meaningful data can add up quite quickly, and it can be hard to employ it and have 
faith in the generated results. In many ways, it is unsuited to determine absolute, quantitative 
estimates of the free energy, and even a qualitative analysis can be insufficient, as it may be 
unable to distinguish between similar systems if they are very close in energy. 
The reason why we use this method even though it has assumptions and approximations 
that make it too unreliable in many cases is that it is the most suited tool that there is for our 
purposes. Unlike other methods such as FEP and TI, which we will describe in detail later, it 
is relatively inexpensive and simple to implement; another contender is the Linear Interaction 
Energy (LIE) protocol188, a widely used method that however relies on extensive 
parameterisation of the investigated protein system189. In a virtual screen or scanning 
application, speed and generality become very important characteristics, and absolute 
accuracy is not required. The method needs to be able to handle large volumes of potentially 
very diverse interactions, quickly assess them and generate preliminary data. While more 
precision is always a benefit, it would not be a necessity if only rough, initial results are the 
aim; if the purpose is to scan large libraries and indicate where experiment should be 
directed, a qualitative assessment would be enough to identify which regions would merit 
more investigation. Further work, both computational and experimental, can then be planned 
with this data in mind. The issue that it would not be able to discriminate between systems 
are too similar is of no importance as long as the method can distinguish between very 
dissimilar systems: if more precise data is needed or it becomes crucial to accurately define 
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differences, a more expensive method can be employed. For the first scan, MMPB(GB)SA is 
a sufficient tool. 
This is why MMPB(GB)SA is our protocol of choice in the calculation of free energies 
in PPI systems. Other methods offer different advantages, but, to scan through different 
interactions, this is fast, versatile and accurate enough for our purposes. There is still the 
question, however, of how these mutant structures are generated computationally. Before we 
delve into existing methods, we will describe the challenges associated with this procedure 
and what we require in a protocol of this kind. 
 
4.6 – Challenges in Computational Mutagenesis 
One of the most problematic issues in computational mutagenesis is the mutation from 
a small amino acid to a larger one. A change that involves substituting a large residue for a 
smaller one is, conceptually, very simple: the atomic coordinates of extraneous atoms can be 
easily erased to generate a new structure. There may be problems with how this gap is filled, 
if at all, but these are secondary concerns. 
The reverse is not true, however: when a mutation requires that atoms must be added 
onto a pre-existing conformation, there is the obvious question of where the new atoms can 
be positioned with respect to the current ones, in a way that does not create clashes and 
reflects the true nature of the mutation. One program that is part of the AMBER package, the 
editing tool LEaP, has templates for the standardised structure of natural amino acids, and 
other packages have similar functionalities; it would therefore be possible to just use these 
templates to build a new amino acid structure. However, as these tools were not developed 
with mutagenesis in mind, but simply to fill in minor missing features like the placing of 
hydrogen atoms, the risk of accidentally superimposing new atoms onto existing features is a 
serious concern. This is especially true if the location of the mutation is at a tight, sterically 
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crowded interface. As interfaces are, logically, the location of most interest when examining 
an interface, barring allosteric regions, then it is clear why using this template approach to 
mutagenesis is less than ideal: as simple as it is, just adding atoms has the chance to create 
non-chemical structures with atoms that are too close to each other or intersecting rings, and 
these may cause instabilities and failures. The repulsion term, both in terms of electrostatic 
charges and Van der Waals interactions, creates immense forces if atoms are too near, and it 
would react violently to this situation by causing the atoms to quickly move to relieve the 
stress. In most cases, this excessive force is enough to generate numerical errors which in 
turn cause the simulation to crash. Even if this does not occur and, fortuitously, the atoms 
added via a template do not overlap or otherwise clash with the pre-existing structure and the 
simulation reaches completion, it might have been because the new structure has gotten stuck 
in a local minimum of the potential energy surface. It is hard to determine when that may be 
the case, but attempting to fit a large residue in the pocket of a smaller one may lead to 
unusual conformations that do not reflect the true structure that would have been adopted if 
the mutation had been introduced experimentally. The true, global minimum may require 
backbone shifts and rearrangements of the atoms around the mutation that cannot be 
replicated by simply adding the needed extra atoms via template. 
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Therefore, it becomes clear that, as simple as this approach is, it presents several issues, 
and there must be a strategy to introducing mutations computationally. Not only must we add 
or remove the correct atoms, we must do that in a reasoned manner that produces a stable 
structure and allows predicting correctly the effect of the mutation on the overall 
conformation and interaction. Several protocols have been developed for this purpose, relying 
on different theoretical basis and with different levels of implementation. The next sections 
 1 
 1A 
 1B  1C 
 3 
 2 
Figure 2: A somewhat exaggerated cartoon to represent challenges in mutagenesis. In 1, top left, a methyl group 
needs to be mutated to a phenyl ring. If this is done by simple templating, the resulting structure might be 
accidentally superimposed onto existing features, as in 2, top right, leading to clashes and instabilities. Instead, 
by using a slow approach as shown in 1A, 1B and 1C, where the phenyl ring is added gradually, a structure 
which can accommodate the newly formed ring is generated, as in 3, middle right. 
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will detail the most common strategies to computationally deal with a mutation and illustrate 
why, even though there is a plethora of possible methods, we have found it necessary to 
develop a new one. 
 
4.7 – Summary  
To summarise this chapter, we have described the basis of molecular mechanics and 
many of the fundamental concepts behind it, from the equations that govern it to the 
estimation of free energies. It is a potent tool that has been widely used in the analysis of 
proteins and other biomolecules, and even though many assumptions are necessary to 
simulate systems of that size, molecular dynamics remains a robust method that can be 
applied in a wide variety of scenarios to extract relevant information and complement 
experimental work. We have used it in its AMBER implementation several times in the 
group190,191 and we have extensive expertise of the protocols and techniques involved. It is 
because of this experience that we have noticed a gap amongst the current methods for 
computational site-directed mutagenesis. As we will detail in the next few sections, existing 
protocols lack certain characteristics or underperform in certain regards, and we found it 
necessary to develop a new one that would satisfy our needs.  
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Chapter 5: Review of Existing Methods for Computational Site-Directed 
Mutagenesis 
In this section we will describe several protocols that may be currently used to perform 
computational site-directed mutagenesis. Drawing from a wide variety of theoretical 
backgrounds and featuring a great range of different implementations, this review will show 
that this is a very diverse field. It is possible to use disparate approaches for this problem 
which may be applied to tackle different challenges, but even with the current level of 
technology we felt modern methods could perhaps be improved in a certain area, the 
application in a virtual screen.  
 
5.1 – Computational Alanine Scanning Mutagenesis 
The first and perhaps simplest method of computational mutagenesis is the in silico 
application of one that we have already discussed: computational alanine scanning 
mutagenesis192, which is widely used and well implemented on most platforms and 
computational simulation packages, including AMBER. It is very easy to implement, as 
almost all natural amino acids (save for glycine, of course) can be computationally “cut 
down” to the β-carbon and the extra hydrogens added according to pre-determined templates. 
However, just as the experimental technique is primarily used in hot spot identification and 
general PPI analysis rather than as a true mutagenesis tool, so does the computational version 
serve this purpose too. Since it can generate mutated structures, it can technically be used to 
modify residues this way, but alanine mutants are of limited value, and, for a true protocol 
that encompasses all possible amino acids, we must look elsewhere. 
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5.2 – Rotamer Library Approaches 
One broad category under which we can find mutagenesis tools is that of the rotamer 
library approach193. Each side chain rotamer (short for rotational isomer) for any given 
residue represents a different possible conformation generated by the rotation of the bonds of 
the residue’s side chain194. While it could theoretically fold into an infinite number of 
different structures, it is in fact found that the dihedral angles of an amino acid tend to be 
quite constrained and cluster around certain values. These conformations are thought to be 
local minima on the potential energy surface and thus favoured above all others, and they can 
be very important to determine the overall folding state that the polypeptide adopts. By 
performing statistical analysis over many relevant samples, the most likely structures of each 
side chain can be identified and collected in libraries; when predicting an amino acid’s 
preferred structure, these libraries can be used to determine what conformation that is. These 
libraries can be very sophisticated: they can take into account just the side chain or include 
the backbone and even the secondary structure to include all possible conformations. 
The application of this strategy in protein design and computational mutagenesis should 
be obvious: when substituting one amino acid for another, it is necessary to predict the 
resulting structure, and scanning through a library of statistically sampled conformations can 
help generate a likely folded state for the mutant. This is the approach of the ORBIT 
(Optimization of Rotamers By Iterative Techniques) package195, which also uses force field 
parameters to attempt to determine favourable interactions and potential clashes, and software 
such as PyMol196, which can provide an easy interface to accomplish this sort of mutagenesis. 
The use of rotamers templates to predict tertiary protein folding states197 has been applied in 
the generation of mutated structures198,199. The application of rotamer libraries in this sense is 
very quick and easy, done in an instant and at the press of a button. This is however 
dependent on the library used: a larger library will mean sampling a larger and more accurate 
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conformational space, but it also requires much more computing power. The one used by 
PyMol or similar software like Chimera200 is so fast because it only looks for rotamers of the 
side chain, fitting it in the pre-existing pocket; while this ensures great speed, it does not take 
into account the changes that may have occurred as a result of the mutation in the 
environment around the amino acid, which may not be negligible. Furthermore, the mutation 
carried by these programs does not affect the backbone, and it is recommended to use 
libraries that include it in order to have better predicting power193. However, this would 
significantly lengthen the time needed to create a mutated structure, and the ease and speed of 
this kind of software are its main selling points. As a tool, it is better suited to optimise side 
chain conformations on an already established protein scaffold, but the process of 
determination of that scaffold structure is less refined.  
An additional remark that must be made is that this approach is not based on an MD 
simulation. The change introduced in this manner remains “cosmetic” (in that it is simply a 
change of the single amino acid coordinates in a snapshot) until the resulting structure is 
simulated to generate ensemble dynamics. Because this change is done on a static image and 
it often does not take into account changes in the environment around the mutation or on the 
backbone, there is a significant chance to generate highly unstable structures: as the rotamer 
library approach simply tries to fit the new side chain into the existing pocket, it lacks the 
ability to reduce unwanted contacts that a simulation would avoid due to unfavourable steric 
clashes or electrostatic interactions. For this reason, these newly generated structures may be 
poor starting points on the potential energy surface, and may require extensive simulation to 
reach an optimised structure, and, even then, they may get stuck in a local minimum, never 
fully sampling the conformational space to its true global minimum. Thus, while quick and 
easy, they may be of less use than other more sophisticated methods.  
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5.3 – Molecular Dynamics Based Methods: PPM and MULES 
5.3.1 – Post-Process Modification 
In this group we had already examined, developed and tested new mutagenesis 
protocols before the beginning of this project190,191. This has given us considerable insight on 
the requirements of such a tool, especially in the context of MD simulations, and even more 
especially within the AMBER package. In a previous section we discussed how the free 
energy change is hard to determine from simulations alone, as small changes are likely to be 
drowned out in the noise of larger conformational shifts. Our work in past studies was aimed 
at addressing this problem, trying to minimise the sources of error when examining mutations 
so that we could establish that a difference in interaction arises solely from the mutation that 
we have introduced rather than from unrelated effects. 
To this end, Post Process Modification (PPM) was one of the techniques that we 
employed. This method is conceptually similar to ASM, though more versatile. It consists of 
running a normal molecular dynamics simulation of the interaction of interest, the strength of 
which is then measured. The simulated trajectory is then modified after the process, which 
gives the name to the protocol. The modification is aimed at generating a different amino 
acid: by removing and relabeling atoms in the residue, another structure can be generated, as 
it can be seen in Figure 3. 
 
 
Taking as an example an interaction in which we are interested in mutating a single 
isoleucine, we can modify the resulting simulation trajectory to generate five other amino 
Figure 3: An example of the possible mutations of isoleucine that can be made using PPM. In the original 
structure (left), all the bonds and atoms are left untouched, shown in bold. In order to generate mutated amino 
acids, bonds are selectively deleted and atom labels are changed. This gives, from left to right, norvaline (Nva), 
valine (Val), aminobutyric acid (Abu), alanine (Ala) and Glycine (Gly).  
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acids, after we have determined the strength of the native interaction. By deleting atoms 
appropriately and relabeling some of them, other structures can be made: if the δ-carbon is 
changed into a hydrogen and the hydrogens attached to it are ignored, the resulting 
conformation is the same as that of a valine. The resulting trajectory can then be analysed 
again using a free energy calculation protocol to determine the interaction strength of the new 
conformation, with the mutated amino acid in place of the original one. A comparison of the 
two binding energies determines how the interaction changes upon mutation. 
Although this approach has some merit and we have used it with some success, it has 
two major flaws which hinder its widespread use. The first is that not all mutations would be 
supported: as this protocol only removes or at best re-labels atoms to make new structures, it 
cannot create anything larger than the original amino acid. This consideration ties back to the 
challenge that we had identified in mutagenesis, which was mutating from a small residue to 
a larger one. PPM cannot help in this regard, only offering large to small changes. While an 
amino acid such as isoleucine could potentially support many mutations with the correct 
deletions, as shown above, it would impossible to do with most other natural residues. 
Furthermore, as labels but not trajectory positions are changed, some of the bonds are going 
to have an incorrect length. To take the same example, some C-C bonds of isoleucine in 
Figure 3 have been changed to C-H bonds, while keeping the same bond length throughout 
the simulation. Even if in a minor way, this may affect the calculation of the free energy. 
The second major issue of PPM is a sampling problem. As the trajectory remains 
unchanged, there is the assumption that the mutated amino acid has the exact same motions 
as the original one: all we are doing is ignoring some of the atoms in the simulation, not 
generating a new trajectory. Of course, this leads to a strong bias in favour of the native 
residue, as its dynamics are used as a basis for the dynamics of the other amino acids. It 
would not be unreasonable to assume that similar amino acids may have comparable motions: 
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to use the same case used throughout, as isoleucine and valine have similar size and are both 
non-polar, aliphatic residues, they will probably behave in the same way during the 
simulation and the error may be small. Introducing different functional groups, however, is 
far more problematic, as they will have vastly different interactions with the environment that 
would not be captured using this method. 
All in all, while PPM has been a valuable tool, it has given a lot of information on how 
to handle mutations in molecular dynamics simulations and it was an important learning 
experience, it is lacking in several regards and thus discarded as a potential protocol for 
mutagenesis. However, some of its shortcomings were overcome by the next method that we 
developed. 
 
5.3.2 – Mutational Locally Enhanced Sampling 
One of the techniques used in molecular dynamics to increase the amount of data that is 
generated about a system without significantly increasing the amount of time and 
computational power that has to be devoted to the task is Locally Enhanced Sampling 
(LES)153. The aim of this method is to focus research on a specific region of the analysed 
protein by duplicating of that area, known as the LES region. The simulation is therefore run 
with multiple copies of the same segment, each of which does not interact with the others but 
interacts normally with the rest of the system; the system only sees an average of the LES 
region. This is done to increase sampling of that region of interest: more data can be obtained 
for it without simulating a whole new trajectory. Commonly, this is done on the part of 
interface that might contribute more to the overall energy or structure, so that more of it can 
be simulated while avoiding the less relevant regions of the system. 
Our work on this technique hinged on the realisation that this enhanced sampling 
method could help us solve one of the major problems of free energy calculations in MD 
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simulations. It has already been mentioned how the difference in binding strength caused by a 
single amino acid mutation can be of relatively small magnitude, far less than the 
contribution of other elements to the overall free energy. Loop motions, domain dynamics 
and solvent effects can all affect the calculation of the free energy, and this makes the 
comparison of the interaction strength before and after mutation more complicated. It can be 
hard to be certain that any difference between the two derives from changes introduced by the 
mutation itself, as the noise of the other effects can drown it out. The LES approach, 
however, can help with that. 
By using the 
already existing 
architecture that allows 
creating more copies 
of certain regions of 
the system of interest, 
it is possible to have a 
simulation where the 
area around the 
intended mutation is 
duplicated, as shown 
in Figure 4. One of the 
two can then be 
mutated prior to the simulation using the PPM procedure shown above, by deleting the bonds 
as appropriate and changing the labels of certain atoms. In this manner a system is generated 
where both the native and mutant are present, which can then be simulated. In the resulting 
trajectory, the LES region is sampled twice with the two different structures, while the rest of 
Figure 4: Example of a Mutational LES region. The amino acid in the centre has 
been duplicated to a valine (blue) and an isoleucine (red). Each copy ignores the 
other and only sees certain other residues. Nearby amino acids that are in the LES 
region appear as duplicated as well, while amino acids that are further away only 
see an average of the two LES regions. 
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the system is constant. This trajectory is then manipulated to separate the two conformations, 
native and mutant, which will differ only in the dynamics of the LES region; thus, differences 
in the binding energy will necessarily arise solely from differences in the LES region, where 
the mutation has been introduced. As the rest of the system remains the same, the impact on 
the free energy of other motions will be kept constant, which allows for a more precise 
measurement of the difference between native and mutant. 
This technique, termed Mutational Locally Enhanced Sampling (MULES)170, 
represents a marked improvement over the use of PPM on its own. This approach allows both 
native and mutant to sample semi-independent dynamics while minimising the source of error 
deriving from non-mutation related effects, and the result is a far more quantitative prediction 
of free energy changes. It is not, however, without flaws. The first issue is that it is still 
limited by the PPM method to generate the initial mutation structure, and thus only smaller 
mutations can be made and only if resulting from deletions and relabeling. It is possible to 
access other types of amino acids, but the procedure is far more complicated, and the protocol 
struggles with changes between residues with different properties, such as polar and 
nonpolar. Additionally, despite encouraging preliminary data, there still might be the need to 
extensively test it to determine precisely how to handle the LES regions. As they differ 
between them, and the rest of the system interacts with an average of the two, this might lead 
to skewed dynamics. Another major problem is that this technique is still in its infancy, and 
not well developed. The protocol is not automated nor is it scripted in any way, and so far all 
manipulations have to be done by laborious, time-consuming manual editing of the files 
involved, which does not lend itself to a rapid, virtual scan approach. 
While MULES represents a big step forward with respect to PPM and it has been 
employed with success, it is still in many ways an unproven method that requires much work 
before it can be used routinely. Apart from the automation, absolutely indispensable if the 
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tool has to be used by non-specialised personnel and for high-throughput purposes, the 
correct implementation of the LES regions needs to be determined, which can only be done 
with more testing. The most appealing aspect of MULES is the way it can separate the 
dynamics of the region of interest with the rest of the system, allowing to cancel the noise 
that arises from dynamics unrelated to the mutation; this has the potential to allow 
quantitative analysis of the free energy, which is a traditionally problematic issue in 
molecular dynamics180. At this stage, MULES is limited by being at an early level of 
implementation and by requiring PPM as a method to generate the mutated structure. If it 
were possible to use another way to manipulate amino acids and other issues were solved, 
MULES could become a potent tool to help analyse the effects of mutations. For now, it can 
only be used as a learning exercise, but we can keep it in mind for further implementations.  
 
5.4 – Homology Modelling Approaches 
As has already been mentioned in the introduction, there is a definite relation between 
the sequence of the amino acids in a protein and the overall conformation that the protein 
takes, the tertiary structure202. Even though there is a staggeringly large number of 
conformations a protein can adopt, it will reliably fold into the “correct” structure that is the 
most stable and minimises strain203. Many of the mechanisms through which this occurs are 
still unknown: whether it is an intrinsic property of the polypeptide chain or it is affected by 
environmental factors, what dynamics and motions are necessary for folding to occur, why 
sometimes misfolding happens and what causes it, all of this is still open to much debate and 
the subject of extensive investigations203. However, even though we are not sure of the 
underlying causes of this relationship and it is complicated to predict how a completely 
unknown sequence would arrange itself, structural and crystallographic information on how 
known structures do fold is widely available. If indeed there is a set of rules that governs the 
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dynamics of protein folding, it is not unreasonable to assume that they would apply in similar 
ways to similar sequences, and thus by comparing mutated structures to known ones, we may 
be able to predict the conformation they would adopt. It is this concept, the idea that new 
structures can be derived from comparison with known ones, that is the basis of homology 
modelling204. 
It is an established fact that predicting the 3D conformation adopted by the mutant 
structure is crucial in the process of mutagenesis, and homology modelling, like the rotamer 
library approach, attempts to do just that. By scanning through libraries of known protein 
segments and comparing chemical environments with the mutated sequence, programs like 
MODELLER205 can generate the needed data to predict the structural effects of the mutation. 
The graphical software package TRITON206 then makes use of this information to produce a 
final conformation, which then has to be simulated and then analysed through a free energy 
protocol to see how the binding energy changes upon mutation. Another package that uses 
homology modelling is SWISS-MODEL207, which shares many of the principles and 
workings of TRITON. Though rarer than other methods, homology modelling has been used 
for protein design and analysis208,209. 
On paper, the homology modelling approach seems to be a good candidate for a 
mutagenesis protocol: it has an already established infrastructure, dedicated programs and a 
well-researched theoretical premise. It is relatively easy to use and the graphical interface 
allows even non-specialised personnel to use it as a scanning tool. Nevertheless, there are 
some issues with the methodology that hinder its use as a routine protocol. Simply put, the 
basis of homology modelling is not as solid as it seems210. As a technique, it performs better 
at determining the structure of small, localised mutations on an already rigid frame, while 
large-scale mutations on the more flexible part of a protein are harder to predict. Also, as a 
purely structural method, it may be unable to detect environmental effects and intramolecular 
63 
 
interactions that can affect the conformation, although these can instead be detected in the 
simulation that follows. Another very important limitation which is very relevant in the 
context of our research is that homology modelling can perform poorly in predicting 
interaction interfaces211. While it can be a powerful tool to determine the structure of proteins 
on their own, the way that two polypeptides might arrange themselves in relation to each 
other is much harder to predict from structural information alone. In the case of PPIs, a 
protein’s conformation is determined not only by its own backbone dynamics and 
intramolecular forces, but, perhaps even more importantly, by the interaction with the other 
protein it is in a complex with. The influence they have on each other’s structure can hardly 
be predicted by looking at comparable sequences if those sequences are in isolation. Even 
looking at a similarly structured interaction can be of little help, as, as it was established in 
the discussion of hot spots, most of the strength of the interaction resides in less than 10% of 
interface residues, and a difference of just a few amino acids can have a great impact on the 
overall conformation. 
Because the main purpose of our intended mutagenesis protocol is to specifically model 
and investigate mutations in PPIs, homology modelling becomes a less than ideal approach to 
the problem. While it can still be used as an auxiliary tool to help probe individual 
conformations, a more robust method is needed for this specific application. Regardless of 
the underlying theory behind these programs, they can be still helpful for the development of 
a new protocol. The manner in which they are presented is indicative of an effort to make this 
a cross-discipline product, meant to be employed by experimentalists without extensive 
computational training, as a tool that can be used to complement laboratory research and 
become a standard feature of the arsenal of anyone studying protein mutations. The graphical 
interface and ease of use are commendable features that we should replicate if possible, 
although the basis of a new protocol should have more of an eye towards PPIs. 
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5.5 – Rosetta and RosettaDesign 
One very well established protocol for computational mutagenesis is that offered by the 
Rosetta package212, specifically in its RosettaDesign implementation213. The program uses a 
sophisticated combination of different techniques in order to predict the mutated protein’s 
conformation214,215, and it is a method that has been used with success to aid in rational 
design and protein engineering216–219. The basic strategy of the protocol is to divide the 
polypeptide in question in segments, analogues of which are then retrieved from structural 
libraries of known protein fragments. These fragments are then combined using a Monte 
Carlo approach that generates different structures, which are scored in terms of 
conformational energy and favourable or unfavourable internal interactions. The backbone is 
optimised via the analysis of the torsion conformational space, while it employs rotamer 
libraries for the side chains. A variety of interaction data is examined, such as hydrogen 
bonding networks, Van der Waals parameters and solvation effects; a coarse-grained 
description can be employed for a quicker but less reliable result, with an explicit, atomistic 
representation of the system and computational capability allow it, or through a calculation of 
pre-determined parameters. Particular emphasis is given to closely packing all available space 
and the burial of hydrophobic surfaces. Simulated annealing is then used to fully sample the 
whole structure’s phase space, as well as optimise individual regions. Through many 
iterations of this process, each time minimising the internal energy and attempting to reach a 
minimum in the PES, a final, mutated conformation can be generated. 
On paper, the Rosetta package is an excellent mutagenesis protocol, and the widespread 
use it enjoys is a testament to that. It has the support of an already established repertoire of 
tools with other functionalities such as RosettaDock to determine the structure of interaction 
complexes220, Robetta to predict de novo protein folding states221, and the newer, more 
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generalised RosettaRemodel to take advantage of more advanced techniques222. Its use of 
crowdsourcing as a way to harness otherwise unexploited computer power allows it to 
expand its capabilities beyond that of a single researcher’s machine, and potentially even 
surpass high performance computer clusters. All in all, it is a very valid tool in protein design 
and engineering. 
However, Rosetta is not without problems223. One concerning aspect of the 
methodology is the reliance on rotamer libraries and homology modelling, as well as the use 
of pre-computed library parameters to assemble and determine an unknown structure’s 
conformation. As we have discussed before, there are issues with those approaches that may 
not allow them to have true predictive power. Even when used in combination, it may not be 
enough to overcome the fact that sometimes the mutated structure folds in a very different 
way from established patterns and may therefore not be predictable from comparison with 
known conformations.  
There is an additional methodological issue which concerns how the protein is 
optimised. The way Rosetta operates is done through simulated annealing and Monte Carlo 
methods127, which are algorithms that rely on iterative random sampling of the conformation 
to eventually produce an energetically minimised structure. Their approach is to 
stochastically modify the conformation, by randomly selecting new coordinates or simulating 
a sudden increase in temperature, which allows the atoms more freedom to move, followed 
by a rapid return to physiological conditions, where the energy of the system can be more 
accurately measured. By sampling many different configurations and scoring them based on 
the wanted parameters, it is probable that at some point a configuration that minimises the 
overall energy will be produced, which is then used as a new starting point for further 
optimisations. Essentially, it is the mirror approach to the one used by molecular dynamics. 
The ergodic hypothesis states that the average of a property within a system can be measured 
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by observing how a single conformation behaves over a sufficient amount of time, or by 
observing that property in many different conformations: while molecular dynamics methods 
represent the first choice, Monte Carlo methods represent the second. The latter are a 
commonly used strategy and in fact it may be a better approach in some specific systems224, 
but the huge conformational space accessed by proteins may be a serious bottleneck that 
prevents it from having truly predictive power225,226. An additional concern regards inter- and 
intramolecular forces, which are often important in understanding and predicting 
conformations, and are obviously crucial within the context of PPIs. The Rosetta energy 
function may sometimes use faster but less detailed approaches to compute them, or even use 
non-specific libraries for the sake of speed, with the result that they may be sometimes 
misestimated, which consequently means that the overall conformation is flawed. 
Our final concern about the Rosetta package is that it does not work with AMBER. 
While conformations can be transferred easily enough, the methodology is essentially 
different and the two simulation suites are not especially compatible. In light of the issues 
that we have highlighted in the previous sections, we would prefer an approach that is fully 
based on solving a force field equation. While molecular dynamics may be more expensive, 
its use of empirical parameters and calculation of forces from natural laws would allow 
avoiding the pitfalls of relying on libraries of predetermined values.  
 
5.6 – Alchemical Methods: FEP and TI 
The methods that we have discussed so far are mostly concerned with generating a 
mutant structure. However, the idea of mutagenesis is not limited to that. The full way in 
which it should be applied is by measuring some kind of observable property of the protein in 
its native state, such as the structure or the interaction with another entity, then introducing a 
mutation followed by measuring the property again in the new conformation; keeping all 
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other variables constant, any change is assumed to have been caused by the mutation. With 
the methods seen above, there still need to be molecular dynamics simulations on the native 
and mutated structures to generate the desired data. Other techniques can however calculate 
the difference in free energy at the same time while introducing the mutation itself. 
We have already discussed free energy in the context of MD simulations, although we 
have not touched upon the specific methods that can be used to calculate it. Two of these are 
the free energy perturbation (FEP)227 and the thermodynamic integration (TI)228 protocols, 
which are considered to be alchemical techniques229,230 and which can be applied in 
mutagenesis. As stated above, MD simulations on their own cannot give free energy 
estimates of a system, and calculating the difference in free energy between related systems 
can be monumentally challenging, even with a thermodynamic cycle. FEP and TI can help in 
this endeavour, and as such they can be used to generate mutated structures and measure how 
the mutation affects interactions. 
The principle behind both FEP and TI is that the difference in energy between two 
related states A and B can be calculated by an ensemble average231, which derives from the 
ergodic hypothesis mentioned before. This is shown generally in Equation 7127.  
〈∆𝐺𝐴→𝐵〉 = −𝑘𝑇 ln 〈𝑒
−(𝐸𝐵−𝐸𝐴)
𝑘𝑇 〉 
Equation 7: The difference in energy ΔG between states A and B is given by an equation involving the Boltzmann 
constant k, temperature T and the energy of states E. 
If the difference in free energy between states A and B is too large, however, then 
Equation 7 cannot be used directly; this is because the perturbation is run in both directions, 
A→B and then B→A, with the difference in energy between forwards and backwards 
trajectory indicating the degree of convergence. A small difference indicates that the sampled 
space overlaps enough and the calculation has statistically converged, but if the difference is 
too large, this may never happen in a reasonable time. This is normally the case if one residue 
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were to be mutated into another, as the difference in phase space between native and mutant 
is great. 
A solution to this issue can be to go through a series of intermediate steps that instead 
differ very little between them: if these intermediate steps overlap in phase space, it will be 
easier to converge and calculate the difference in free energy between each pair of those 
steps. By taking the sum of these individual differences, calculate the overall difference 
between A and B can be calculated. Thus, using this perturbation approach, we can know the 
overall ΔG for a mutation. This is shown pictorially in Figure 5. 
 
 
 
 
 
 
 
 
 
 
Using the same A and B, where A is the native protein and B is its mutated form, it is 
unlikely for a calculation of the difference in free energy using Equation 7 to converge 
because they occupy very different parts of the phase space. Instead, we can use a coupling 
parameter λ to describe the difference in conformation between A and B, with 0 being the 
former and 1 the latter. Intermediate values (0.1, 0.2, etc) represent intermediate states, which 
overlap in conformational space. Because they are closer, calculating the energy difference 
between them is easier and more likely to converge. It is important to note that these 
B 
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λ = 0 
λ =1 
Figure 5: A pictorial representation of the FEP approach to free energy calculation. In 1, A and B are very far apart 
in phase space, and therefore a calculation of their free energy difference is unlikely to converge. In 2, by using 
several overlapping intermediates that differ by a coupling parameter λ, the overall difference can be calculated by 
calculating instead smaller ones. 
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transitional steps have “unreal” conformations that are neither A nor B, but instead possess 
intermediate characteristics. In the case of a chemical species such as an amino acid, this may 
include half-formed bonds and atoms that only partially exist, all of which do not of course 
occur in reality. Because the transition proceeds from these intermediate, hybrid states, it is 
termed alchemical, evoking the nonchemical nature of the species sought by alchemists of the 
past and their attempts to transmute one substance into another. 
A similar way of tackling this problem is the one-step perturbation method232. Instead 
of several calculations sampling different states A, A’, A’’, etc, on their way to B, one 
reference state R is used that has overlap with many different endstates, including A, B and 
possible intermediates. R is not a physically real state, but is chosen to sample the correct 
conformational space to overlap with other relevant configurations and provide information. 
This method is much faster than the standard FEP protocol, but it includes the complication 
of having to choose a reference state R that is appropriate for the system at hand, which may 
not be straightforward233. 
This perturbation approach presents its own set of challenges. To begin with, the 
coupling parameter λ is one of the most important factors to consider. When choosing 
intermediates, they need to be close enough so that convergence can be achieved in a 
reasonably short amount of time, but if they are too close they may not sample enough space, 
converge too quickly and estimate the overall difference incorrectly. The time employed to 
run the simulation is also very important, and several independent simulations may have to be 
produced to obtain an acceptable result234. Additionally, the alchemical intermediates can 
converge poorly when nonchemical atoms with very weak Van der Waals parameters get too 
close and create instabilities in the simulation; soft-core potentials may be used to avoid such 
problems235. Finally, extreme care must be taken in order to adequately sample the 
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conformational space: in some cases, alternative free energy strategies should be used to 
ensure that the full effects of the mutation instead of sampling restricted phase space236. 
A related approach is TI, which instead uses this general equation127: 
∆𝐺0→1 = ∫ 〈
𝛿𝐸(𝜆)
𝛿𝜆
〉 𝑑𝜆
𝜆=1
𝜆=0
 
Equation 8: The difference in energy between the initial (λ=0) and final (λ=1) states can be given by integrating 
the energy at each intermediate step (λ=0.1, λ=0.2, etc.) 
The difference between Equation 7 and Equation 8 is that the first calculates the 
average variation in free energy between neighbouring λ states, while the second calculates 
the average derivative of the potential of each λ state and then integrates the total to obtain 
ΔG, the difference in free energy. To expand on that, it means that where FEP had a single 
simulation in which λ is varied to give intermediate steps whose differences are used to give 
the overall ΔG, TI needs a different simulation for each λ state, calculates the derivative of 
energy of each, and integrates to obtain the overall ΔG. This is a more complicated set up, but 
it allows more control over the λ states that are used in order to have better overlap and more 
easily reach convergence, or to vary λ in a non-linear fashion to sample different routes 
between initial and final states234. 
While the primary application of these protocols is in the calculation of free energy, 
especially between a protein and a small binding ligand, we are more concerned about their 
use in mutagenesis. Alchemical methods can be used for this purpose237,238, but they do 
present significant problems which can hinder their use in protein design and drug discovery 
in general239,240. The main issue is that while they are theoretically correct and will eventually 
give the quantitatively exact result for the free energy difference between a native protein and 
a mutant, they are too complicated and time-consuming to be used routinely. Essentially, the 
time it takes for overlapping λ states to converge and give a free energy estimate can be 
extremely high, and handling these methods can be a daunting task for anyone who does not 
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have an extensive background in computational chemistry241,242. Even with implementations 
such as fast growth243, which allows to parallelise the simulations and shorten the overall 
simulation time, handling protein systems and their inherent variability can be a frustrating 
endeavour that requires very careful planning if one wishes to obtain meaningful data244. 
Furthermore, comparison with other non-alchemical methods reveals that a cheaper 
simulation at the expense of lessened accuracy is often a very reasonable trade off: a simple 
technique such as computational ASM can give approximate results which are accurate 
enough to direct or validate experimental work but at a fraction of the cost needed to perform 
the same task with TI245. To apply these methods successfully, it would be best to employ 
them on single case studies and with massive computational resources at one’s disposal246, 
and scanning through large libraries with these protocols is unfeasible. Ultimately, while 
these methods can offer great accuracy, this comes at a great computational cost, which 
makes their use as a routine tool unlikely except for very specific cases. 
However, even though the implementation of FEP and TI eschews speed and usability 
in favour theoretical accuracy, it is the use of an alchemical transformation as a concept that 
is perhaps the most interesting here. Unlike the other tools that we have seen, the new 
structure is not generated by comparison with existing ones, but via exploration of the phase 
space forced by changing the parameters of the molecules at hand. Controlling λ to switch 
between structures allows a more organic, freer mutation, whose dynamics and conformation 
are dictated by the system’s own properties rather than being determined by those of other, 
potentially inapplicable systems. 
It is true that the result will still have some degree of bias associated with it: the 
conformational space it is allowed to explore will still be close to the starting structure 
because of the limits of the method, and, for this reason, it will struggle to reach the true 
global minimum that would be observed experimentally if this differs significantly from the 
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initial conformation. Despite this, if the mutated configuration is expected or hoped to be 
close enough to the native one, it seems to us that an application of the natural laws of motion 
and interaction is a better approach than the use of libraries. Even though the latter strategy is 
potentially quicker and it has been employed with considerable success, we would prefer to 
use the former as we feel it is more theoretically rigorous. 
This is why the analysis of methods like FEP and TI has been very important in our 
review of mutagenesis techniques: a gradual, alchemical approach to mutation would allow 
us to introduce changes while letting the system adapt to them dynamically. More than any 
other technique we have reviewed, this has been our guide and our example for how 
mutations should be carried out. 
 
5.7 – Summary of Techniques and Requirements of a New Protocol 
In the previous sections, we have detailed a number of different approaches to 
predicting the conformational effect of mutations in PPIs, so that the change in binding 
strength may be measured. Some of these methods rely on libraries of predetermined values 
or structures, based on the assumption that similar sequences will fold in similar ways, while 
others are theoretically exact and attempt to determine mutants based on calculations of the 
free energy. Neither of these two approaches fully suits our needs. The first, despite being 
relatively quick and cheap and reaching a high level of sophistication in some packages, can 
sometimes fail to predict conformations that have no analogues in existing libraries. The 
second is very expensive and unsuited for our stated purpose of a rapid, quantitative virtual 
screen. 
We were therefore left wanting by existing methods, especially by the fact that these do 
not rely and are not especially compatible with AMBER. We wanted a method that could 
predict conformational changes that result from the natural behaviour of a system rather than 
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from comparison with existing interactions, which may have significant bias and be limited in 
application. Keeping in mind the challenge of growing residues, especially at tight interfaces, 
we wanted a method that could gradually modify parameters so that both the mutation and 
the environment around the mutation can sample the correct conformational space. We have 
seen how alchemical methods handle this sort of transformation, and therefore we know that 
it is possible to use and it is a valid way of mutagenesis; rather, our challenge is to implement 
it within the confines of a molecular dynamical interpretation of forces and atoms. We have 
described our previous attempts at developing mutagenesis protocols and especially at 
addressing the problem of free energy calculations, and we think that the application of a 
method for gradual, dynamic change may allow us to surpass the limitations of our earlier 
work.  
This is therefore what we have done: we have taken the alchemical strategy for 
introducing mutations, which consists of a careful manipulation of parameters that leads from 
a native structure to a mutated one via non-chemical intermediates, and applied our expertise 
and knowledge of molecular dynamics and the AMBER package to produce a new protocol 
for computational site-directed mutagenesis. Our efforts have led to development of the 
Parasol Protocol. 
 
5.8 – Aims and Objectives 
The overall aim of this project is to develop a protocol for computational site-directed 
mutagenesis that is robust, reliable, quick, cheap and easy to use. In particular, after a 
thorough analysis of existing methods, it was determined that a tool was particularly needed 
in the context of the AMBER MD suite, which lacks a specialised tool for this purpose. The 
alchemical methodology was identified as one of the most valid approaches, and we resolved 
to implement it within molecular modelling. As for the applications of the new protocol, 
74 
 
particular care was given to the analysis of the PPIs, especially as a tool for fast and efficient 
virtual screening. Therefore, these were the overall objectives: 
 - To apply the alchemical methodology in AMBER, understanding how nonchemical 
structures can be generated and manipulated using prmtops and other tools to mutate from 
one residue to another. 
- Once a reliable protocol has been established, to apply it so that a wide variety of 
different functionalities can be used, encompassing both natural and non-natural amino acids. 
- To script the protocol in a manner that is efficient and usable by non-specialised 
personnel, as well as making it as quick and cheap as possible. The final product should aim 
to become a tool not only of the computational chemist, but also for a laboratory scientist. 
- To validate this protocol via comparing the mutations it generates with real life 
experimental data, examining a wide variety of possible systems in order to both further our 
understanding of such systems and determine the limits and capabilities of the new protocol. 
- To keep the protocol updated as technology improves, taking advantage of new tools 
and advances, as well as integrating it as much as possible with the AMBERTools suite. 
- To compare the results given by this protocol with other computational packages, if 
possible. 
- To eventually produce a computational tool that can be used reliably and easily to 
mutate between any pair of amino acids, giving data that can be used to complement 
experimental work and direct it in an efficient manner.  
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Chapter 6: The Parasol Protocol 
6.1 – The Parasol Protocol: General Principles and Strategy 
We have seen many different existing mutagenesis protocols, and identified some flaws 
in them that we feel should be improved on in a method that ought to be used in a virtual 
scanning capacity. Amongst the characteristics that an ideal protocol should have, the one we 
consider most important is that such a method should allow the entire system, and 
specifically the environment around the mutated residue, to adapt to the change. We have 
seen before that some of the existing techniques only consider the residue’s side chain, and 
often do not take into account its backbone or the residues in its immediate surroundings; this 
approach, while quicker and simpler, may be insufficient to generate a proper mutated 
structure. It is known that single point mutation may have profound effects on the overall 
conformation of a protein41,247, and thus it seems more rigorous to have a mutagenesis 
method that allows the entire system, not just the one residue, to adapt to the change. This 
also becomes important when considering one of the main challenges in mutagenesis, 
mutations of small amino acids to larger ones: in those cases more than others, how the 
surroundings arrange themselves to the new atoms and charges is fundamental to predict the 
conformation of the mutation. 
It is for these reasons that our intention was to develop a gradual, dynamic method that 
would slowly introduce the mutation; our inspiration for this aim was the approach of the 
alchemical methods, FEP and TI, in which, through non-chemical intermediates, the new 
structure is created. This can be done by the careful manipulation of the parameters that 
govern the force field equation: as those parameters define bond lengths, angle widths, 
torsions and non-bonded interactions, these can be adjusted to give a steady change between 
the initial structure and the final one. Just as it happens with the alchemical methods, this will 
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proceed through structures with partial parameters, where they will not correspond to either 
the native or the mutated amino acid, or indeed to any chemically accepted conformation. 
We have attempted many different approaches to accomplish this. In this report, we 
will not detail the failed strategies that were at one time employed during our development of 
what would become the Parasol Protocol, and we will simply describe its final, functioning 
form. They were extremely valuable learning experiences that allowed us to probe the limits 
of the AMBER package regarding the simulation of non-chemical structures, and thanks to 
them we were eventually able to develop a working algorithm to handle this problem. 
 
 
An example of the structure used by the Parasol Protocol is shown in Figure 6, 
specifically the structures used in a mutation from a hydrogen atom to a methyl group. As the 
image shows, the two are side by side, and both are physically present in the system 
throughout the simulation. However, by carefully controlling the parameters, we are able to 
determine their interactions with the environment around them, each other and the rest of the 
amino acid. Let us assume that the mutation proceeds in a forward direction from the 
hydrogen to the methyl, as it would be the case of a mutation from valine to  isoleucine; our 
initial structure would be the first one on the left. In this structure, the mutation occurs by 
changing one of the γ-hydrogens on the γ1-carbon to give the δ-methyl group (γ and δ refer to 
Figure 6: The core strategy of the Parasol Protocol. On the left, the structure 
with an “existing” hydrogen and a methyl modified to occupy the same volume 
as it. On the right, an “existing” methyl with the hydrogen next to it. In between, 
the intermediate structure, which isn’t chemically real. By using such 
intermediates, the mutation from one to the other can be accomplished. 
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the internal numbering of the atoms within the amino acid and are used for clarity purposes; 
this numbering is specific to the valine to isoleucine mutation). The γ-hydrogen atom that we 
are going to mutate in this instance is “real”: it has the correct bond length between it and the 
carbon, it has the appropriate charge it would have in a normal valine, it has the appropriate 
Van der Waals parameters that allow it to interact in the usual way with the atoms around it. 
On the other hand, a methyl group has been artificially introduced next to it. The δ-methyl 
hydrogens have been added to the original conformation, almost exactly superimposed onto 
the hydrogen (if they had the same 3D coordinates, this would cause numerical errors and 
crash the system, and thus a tiny offset of a thousandth of an Å is introduced to avoid this). 
The δ-methyl carbon is instead added halfway between the γ-hydrogen and the γ-carbon, with 
its coordinate being geometrically interpolated. The connectivity between the atoms of the δ-
methyl is as it normally would be, with the δ-carbon being bonded to the three δ-hydrogens 
and to the γ-carbon, but the bonds and angles are different. In nature, it would of course adopt 
a tetrahedral conformation, but in this case the bond parameters for γC-δC have been 
constrained to be half the length of the γC-γH bond, while the angle parameters have been set 
to be 180° for the γC-δC-δH angle, indicating a straight line, and 0° for the δH-δC-δH, to 
force them to be close together. This is to ensure that the methyl, at the beginning of the 
simulation, starts by occupying approximately the same volume as the γ-hydrogen it is going 
to replace. Additionally, the interaction parameters of the δ-methyl have been set to zero, for 
the charge, the potential well and the Van der Waals coefficients, although the masses of the 
atoms are as normal. Since none of the atoms in the methyl group have any charges, their 
interactions with anything else are null; in other words, the methyl group is “unreal”, non-
existent, and it cannot affect the dynamics of any other atom as the force it generates is 
always zero.  
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We have therefore artificially introduced a methyl group onto the amino acid, confined 
to the same space as the hydrogen and lacking the ability to interact with its surroundings. 
When we simulate this system, it will behave in the same way as the original residue, valine. 
However, we then change the parameters that govern the amino acid, and thus change the 
bond lengths, angle widths and interactions of both the γ-hydrogen and δ-methyl. By using 
different parameters files, we are able to slowly introduce these changes in a sequential, 
gradual manner. In a way that resembles the λ parameter of FEP, the protocol scales bonds, 
charges and everything else between the initial and final values, with a linear interpolation 
between them that progresses through 10% increments between steps. The result is that at 
intermediate steps the system is made of non-chemical structures, with partial charges and 
half-formed bonds, which go from a complete non-interaction with the surroundings to a 
modest interaction to a full interaction as the δ-methyl becomes more “real”. At the same 
time, the γ-hydrogen loses its charge, again in a linear, gradual fashion, while its bond 
changes to match the length of the γC-δC bond, becoming “unreal”. Because this process is 
gradual and proceeds through intermediates, both the environment around the mutation and 
the amino acid itself have the time to adapt their behaviour to accommodate the new 
functional group that is being grown. The result is that where there was a hydrogen, a methyl 
group has been added. The reverse is also possible: taking the same mutation but backwards, 
from isoleucine to valine, where a methyl group has to be mutated to a hydrogen, we add the 
γ-hydrogen onto the already existing δ-carbon. As in the forward reaction the hydrogen went 
from reality to non-existence while the methyl did the opposite, in this case the methyl 
gradually disappears as the hydrogen become increasingly more “real”. We have previously 
discussed how it is easier to remove atoms, and therefore it would be a valid strategy to 
simply delete the methyl group and substitute it for a hydrogen, avoiding the procedure of 
gradual manipulation of the parameters. However, we have decided to adopt this approach 
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even for shrinking mutations, firstly to be consistent in our methodology, and also because 
we believe that dynamic changes lead to a better representation of the system than sudden 
alterations. 
This is therefore the basic strategy of the Parasol Protocol: a hydrogen atom and the 
functional group that is being added or removed are side by side in the system, and their 
parameters are manipulated to grow or disappear them, as appropriate. While it is 
theoretically possible to use two different functional groups in the same mutation, for 
example, changing a methyl to give a hydroxyl while mutating from valine to threonine, we 
have found that this kind of setup is more prone to fail, perhaps due to the greater forces 
caused by two functional groups being so close together. For this reason, we decided that 
every addition or removal of a functional group would proceed via the established 
mechanism of simultaneously removing or adding a hydrogen atom, as appropriate. 
In our development of the protocol, the methyl mutation was the first we attempted, and 
the one we used as a template for further work. In fact, we named the method Parasol after 
the apparent motion of a growing methyl, which looks like the opening of an umbrella or 
parasol. After we had established that this approach worked, we expanded the range of 
possible mutations by scripting and testing changes involving different amino acids and 
functional groups. 
 
6.2 – Expanding the Range of Mutations 
For most nonpolar residues, the simple addition or removal or methyl groups is enough 
to yield a new amino acid, and thus these were amongst the easiest mutations to script. In 
addition to the natural amino acids glycine, alanine, valine, leucine and isoleucine, 
aminobutyric acid (Abu), norvaline (Nva) and norleucine (Nle) were also added to the 
repertoire of residues. For some of the non-natural amino acids, charges and parameters were 
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taken from the literature248,249, while in other cases, as it will be detailed later, these were 
derived with ab initio calculations. Mutations between these residues may involve the 
simultaneous growth of multiple methyl groups, or even the simultaneous growth and 
shrinking of methyl groups in different parts of the molecule; the protocol has been scripted 
to be able to perform these mutations too. Mutations involving groups such as thiols 
(cysteine), hydroxyls (serine and threonine), guanidines (arginine) and amines (lysine) are 
handled in the same way those involving methyls are, by substituting individual hydrogens as 
appropriate. In each case, the end atoms are almost exactly superimposed on the hydrogen 
that is being mutated, and the other atom is placed in the middle of the C-H bond. Mutations 
that involve the change of the charge, such as going from a neutral to a positive or negative 
species and vice versa, also incorporate a dummy ion atom in the mutation. At the beginning 
of the simulation, the atom has no charge, but it gains, stepwise and in a gradual fashion, a 
charge to match that of the amino acid being mutated. It possesses the electrostatic 
parameters of a chlorine mono-atom if it becomes more negative and of sodium if it becomes 
more positive. For example, in a mutation from alanine (neutral) to aspartic acid (negative), a 
dummy atom is inserted with no charge but which gradually becomes more positive as the 
mutated residue turns into aspartic acid. In this way, the overall neutrality of the system is 
maintained. 
Some mutations are approached in a different manner from the one described above. 
The first in this case are those involving carboxylic acids (glutamic and aspartic acid) or 
amides (glutamine and asparagine). Because these functional groups have multiple, strongly 
charged heteroatoms, the electrostatic parameters have to be scaled differently. During the 
course of a simulation run with the Parasol Protocol, when we start changing the parameters, 
the atoms of the grown functional group are still relatively close together and have small 
charges on them. For methyl groups, which are nonpolar and hence rarely very positive or 
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negative, the scaled charges do not strongly interact with 
each other and the rest of the amino acid. In amides and 
carboxylic acids, a tenth of the charge they would 
normally have is still sufficient to generate strong forces, 
especially when the atoms start the simulation so close 
together. For this reason, it was decided that, for these 
functional groups only, their electrostatic charges would 
be scaled quadratically between zero and the final value 
so that the introduction of forces would be gentler. This 
is true as well for when these groups are being shrunk, as the protocol foresees that they will 
get closer but still have significant charge to create instabilities, and thus their charges will 
also be scaled quadratically. There is another small difference, which is specific to amides, as 
shown in Figure 7: because three bonds have to be inserted (the C-C, C-N and N-H bonds), to 
divide the original C-H bond in three would mean that the bonds are just a third of that at the 
beginning of the simulation, 0.363 Å. Because AMBER struggles with excessive forces when 
handling such short bonds, it was deemed necessary to insert the C halfway through the C-H 
bond, the O and the N superimposed onto the H, and the hydrogens a half-bond distance from 
that, with the position extrapolated from existing coordinates. Although this means that this 
arrangement occupies volume beyond that of the original hydrogen, it is a small enough 
volume to rarely be of relevance in terms of creating clashes with existing features. Other 
than these aspects, amides and carboxylic acids are handled in exactly the same way as 
methyls and other mutations.  
Figure 7: Two possible structures of an 
amide. The one on the left is tighter and 
occupies less space, but it needs very 
short bonds and is thus problematic. The 
one on the right juts out more but it is 
easier to handle and is therefore the one 
that is used. 
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This is not the case for ring mutations, which are instead approached in very different 
way. Figure 8 shows the strategy used for this kind of mutations in a graphical representation 
of how a linear bond is turned into a ring. Instead of growing atoms at the ends of amino 
acids, they are grown sideways from already existing bonds, using intercalated carbons. 
These carbons are placed halfway through the C-C bond and bound to both existing carbons. 
The C-C bond is in this case deleted. Then, as the simulation proceeds, these move out the 
sides as the angles widen to create a ring shape, in this case a four-membered, square ring. 
We have experimented with having two intercalated carbons on either side, so that the 
simulation might generate a six membered ring, but, as in the case of amides, the bond 
distances that would be needed at the beginning are too short to be handled smoothly by 
AMBER. The result is that from a single C-C bond a four-membered analogue of 
phenylalanine is generated. The amino acid is not used in the laboratory and in fact probably 
quite hard to synthesise, but we have called it annuline (from annulus, Latin for ring) and we 
use it as an intermediate and precursor towards the other aromatic residues. Such mutations 
are carried in the same manner, with intercalated atoms and grown bonds as appropriate, as 
shown in Figure 9.  
Proline is also grown in a similar way, through an intermediate, non-naturally occurring 
amino acid. In this case, we generate quadrine, a four-membered analogue of proline, starting 
Figure 8: The strategy used for ring mutations. Instead of adding atoms at the end of the structure, the mutation 
is accomplished via intercalated carbons placed in the middle of existing bonds, which then grow sideways. In 
this example, we begin with an ethyl-like fragment, where the bond between the two carbons is effectively 
replaced by two other carbons bonded with them. These then grow sideways to give a square structure. When 
extraneous atoms are deleted, this yields a four-membered ring version of phenylalanine, which we call annuline 
and is used as a precursor towards other aromatic amino acids. Those mutations are shown in Figure 9. 
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from alanine and adding a methylene group bonded between the nitrogen and the β-carbon. 
Once the square structure has been made, an extra methylene group is added to yield proline. 
The process is shown in Figure 10. We also employ an intercalated methylene group to give 
homocysteine from cysteine. 
Regardless of the different structures and strategies used to mutate between different 
amino acids, the core of the Parasol Protocol remains to gradually and slowly change the 
parameters and allow the environment around, as well as the residue itself, to adapt to the 
change. We believe that with such an approach, we can more realistically simulate the effect 
of a mutation on a native conformation.  
Figure 9: Mutations from annuline to other aromatic amino acids. By inserting intercalated carbons, changing 
the type of some atoms (identified with s in front) and adding other features, the four-membered analogue of 
phenylalanine can be mutated to other residues. 
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6.3 – Parasol Protocol: Detailed Workflow 
In this section, we will describe the scripts that we 
use to manipulate the initial structure, generate new 
parameters, and make the input files that are then simulated 
to carry out the mutation. As in the previous section, we 
will only give details on their final and current form; as our 
expertise in coding and scripting increased throughout the 
project, as well as our understanding of how to handle 
these systems in AMBER, the algorithms that we use were 
updated to reflect that. Additionally, we incorporated new 
AMBER software and functionalities that were released 
during the project’s course, each one making our protocol 
faster, leaner, more consistent and less prone to error. 
Although there are still many features that could be added 
and many aspects of Parasol that could be improved, we 
feel that the current implementation is at an acceptable 
stage of development and is robust enough to be used for 
testing, even outside of our group. 
The Parasol Protocol consists of a series of bash 
scripts (bash is the shell language of many UNIX systems) 
which manipulate text files and generate new ones through 
a combination of awk, sed and other simple commands. A 
Figure 10: The transformation from alanine (top) to proline (bottom) using 
the Parasol Protocol, passing through quadrine (centre). By adding a 
methylene group halfway through selected bonds, a ring structure with a 
greater number of atoms in it can be generated. 
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more rigorous implementation would have them written instead in one of the coding 
languages that AMBER itself is written in, such as FORTRAN or python; for our purposes, 
such simple scripts are sufficient. 
There are many different scripts in the Parasol Protocol, each with a different, specific 
function; however, the user will only employ one of them, the overarching, controlling script 
that automatically regulates the workflow. This script requires the user to input four 
variables: the protein system that is going to be manipulated in PDB form, the site and name 
of amino acid that is going to be mutated, and the destination amino acid. With this 
information, the scripts run in an automated manner from beginning to end. 
The protocol is structured in a very modular way, accessing a variety of possible one-
step changes and combining them to give the overall mutation. For example, both the 
mutation from alanine to valine (which is scripted to grow two methyls on the β-carbon) and 
the mutation from valine to isoleucine (which, as shown above, grows a single methyl on the 
correct γ-carbon) have been added and scripted. A mutation from alanine to isoleucine cannot 
be done by the Parasol Protocol in one step, and so, if asked to perform this change, it will 
first use the scripts for the mutation from alanine to valine and then perform the mutation 
from valine to isoleucine on the resulting structure.  
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Figure 11: A schematic depiction of how the Parasol Protocol generates the input files. Starting from the PDB file of the protein 
system of interest and specifying which amino acid is going to be mutated and to what, the Parasol Protocol creates the input 
files that are then simulated to give the mutated structure. The process of the simulation is given in Figure 12. 
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The overall method workflow is shown in Figure 11. The first step is determining 
which steps the mutation needs, as described in the previous paragraph: some mutations 
might proceed through several intermediates. Once these have been identified, the first 
mutation can occur, which will be followed by further modifications if needed. 
The first thing that is done is the generation of a scaling table using the two amino acids 
in question. For each residue, there is a file that contains all of that amino acid’s AMBER 
parameters, which are the bonds, angles, dihedrals, impropers (if relevant), non-bonded 
information and electrostatic charges. The amino acids involved in a mutation will have those 
parameters as they would be at the beginning and at the end of the transformation, labelled 
using custom atom types. To take the same example as before of the methyl growth, both the 
valine parameter file and the isoleucine parameter file will contain information on the γC-δC 
bond: this value will be 1.09 Å in the valine file (as it has to match a standard C-H bond 
length) while the value will be 1.526 Å in the isoleucine file, the standard C-C bond length. 
The same will be true for all other parameters. This first script’s purpose is to take these 
parameters and scale them linearly from beginning to end. As mentioned earlier, this is done 
in 10% increments, for a total of eleven values, stored in an ad hoc scaling table. 
The second script creates forcemod files, which are necessary to introduce the 
parameters into LEaP, the AMBER package tool that is used to make the input files required 
for a molecular dynamics simulation. As we are going to manipulate these parameters and 
change their values, the modified parameters must be loaded into the program so that they 
can be read, and this is done through forcemod files. The script extracts the values for each 
parameter at each step from the scaling table and formats it in the way required by LEaP. 
This creates a forcemod file for each combination of parameters, from 0-100 (0% final 
parameters, 100% initial parameters, so equivalent to the original amino acid) to 100-0 
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(equivalent to the final amino acid), passing through 10-90 (scaled 10%), 20-80 (scaled 20%) 
and all the others. 
 The third script modifies the input PDB file to add the extra atoms. Depending on the 
mutation at hand, the script locates the residue that is going to be changed and artificially 
introduces the atoms to be grown into the structure. In some cases these will be placed 
halfway between bonds, and in some cases they will be almost exactly superimposed onto 
existing atoms. To take the same example we have been using throughout, the script will add 
the methyl in the correct position on the valine, with the carbon in an interpolated position 
and the hydrogens on the γ-hydrogen. The script also changes labels as appropriate, making 
sure that the naming of the mutated residue and its atoms is consistent and correct. 
There is then the fourth script, which is specific to the mutation at hand. There are 
different versions whether the mutation is alanine to valine, valine to isoleucine and so on. 
The purpose of this script is to write input scripts for LEaP and parmed.py, another AMBER 
utility, to use in the generation of the parameter files themselves. The script takes information 
about the mutation, such as which custom atom types should the atoms in the mutated residue 
have and the connectivity of the mutated residue, and creates machine-usable scripts.  
Once all of this has been done, the writing of the actual parameter files used by 
AMBER to accomplish the mutation can commence. LEaP runs first the script to create the 
.lib file for the custom residue, which contains information on the atom types, their bonds 
between them, and how the residue is connected to adjacent amino acids; this file is necessary 
to introduce unknown residues into LEaP, and it is the last step before the parameter files can 
actually be generated. LEaP then loads the lib file, the 0-100 forcemod file and the modified 
pdb. If the pdb has not been solvated before and does not have a solvent shell and 
counterbalancing ions, the overall charge of the protein is calculated so that the appropriate 
ion may be chosen (Na+ to balance a negatively charged protein, Cl- for a positive one) and in 
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the correct number, and after that it places the system in an octahedral box of TIP3P water. If 
the protein has already been solvated, then it assigns it the correct box dimensions. 
At this point, the system is ready, and the parameter file is saved. Two files are 
generated this way, the 0-100.inpcrd file, which has the atomic positions, and the 0-
100.prmtop file, which instead has all the parameters. LEaP then loads the 10-90 forcemod 
file and saves new files, generating the 10-90.prmtop file, which has slightly modified 
parameters, linearly scaled and obtained according the method outlined above. This process is 
repeated with every other forcemod file, creating .prmtop files with appropriate parameters 
from 0-100 to 100-0, for a total of eleven files plus the .inpcrd file, which describes the initial 
coordinates of the system. However, there are still steps to done before they can be used for 
the simulation of a mutation. 
For the next stage, parmed.py is employed. This is a program part of the AMBERTools 
suite that is used to manipulate .prmtop files, and it is necessary for an extremely important 
modification, which is the removal of certain interactions. As we have discussed above, the 
structure to be grown or shrunk exists alongside the hydrogen throughout the process; 
logically, the two should not interact with each other in any way. Even if we proceed via non-
chemical intermediates, the two should not be able to affect the other’s dynamics and 
potentially introduce bias in how the mutation is handled, because there is no point in time in 
which they are both “real”. However, according to the force field equation, there still may be 
interactions between them. Firstly, there is the angle force that keeps them close together, 
which is unavoidable; far more problematic are non-bonded interactions. We have mentioned 
before that non-bonded interactions are calculated between pairs of atoms that are further 
than four bonds apart and not connected by a bond, angle or dihedral, but, strictly speaking, 
that is not true. 1,2 pairs (atoms separated by bonds) and 1,3 (separated by angles) do not 
have their interaction calculated, but 1,4 pairs (separated by dihedrals) do, although it is 
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scaled. This poses a problem, because, as it 
can be seen in a standard Parasol Protocol 
diagram, the hydrogen and some of the atoms 
on the neighbouring structure are separated 
by four bonds, meaning that their interaction 
will be calculated, even though it should not 
exist. Indeed, we have observed that if no 
strategy is adopted to address this issue, 
when those atoms are close, as it would be 
the case at the beginning of a methyl growth, 
the force generated by this interaction is very 
strong and it causes the simulation to fail. In 
order to prevent this from happening, we use 
parmed.py to modify the parameter files and 
artificially set this interaction to be zero at all 
times. parmed.py is also used to set the 
charges of the individual atoms in the 
mutated residue. 
Once all of these steps have been taken 
and following some minor clean up and 
proper formatting of the files, the input files 
Figure 12: A schematic representation of the mutation 
simulations employed by Parasol. Starting from the 
initial coordinates and the 0% parameters, which 
correspond to an alanine in this example, the system is 
first equilibrated and then stepwise simulated until it 
reaches 100%, in this case valine. If the system has 
already been previously equilibrated and minimised, 
then it starts directly below the dotted line with the 0% 
parameters and the initial coordinates to give the 0% 
coordinates. 
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are ready to be simulated in order to carry out the mutation. The procedure is shown in Figure 
12. If this is to be done on a crystal structure or otherwise on a conformation that has not been 
simulated before, then the first step is the minimisation, which is done to remove small 
instabilities in the structure. This is carried with the 0-100 parameters, meaning that the 
system is being simulated as if it were the native residue. A very quick process, minimisation 
can fix the most evident structural problems, such as atoms being accidentally too close to 
each other or enforce the planarity of rings that may have been bent. Minimisation prepares 
the system for the next step, the equilibration, during which it is gradually heated to reach the 
desired temperature (usually 300K) and pressure (1.0 bar). Then, the system is ready for the 
mutation proper: the minimised and equilibrated structure is simulated with the 0-100 
parameters to sample the dynamics of the native amino acid, when the structure that is going 
to be grown is still “unreal”. Once this has been done a conformation has been produced, this 
is used as a starting point for a simulation with the 10-90 parameters: it is now that we start to 
introduce changes in bond lengths, charges and so on. Once the 10-90 structure has been 
obtained, it is then simulated with the 20-80 parameters, whose result is simulated with the 
30-70, and so on, until the 100-0 is simulated. This final structure represents the mutant 
protein, where, gradually and dynamically, an amino acid has been transformed into another 
one. This structure can be extracted in PDB form and then manipulated to remove all the 
atoms that are “unreal” at the end of the simulation, such as the hydrogen in the case of the 
methyl growth. With this, the simulation is complete and the mutant has been generated. This 
can be used for analysis and further investigation; in the case of sequential mutations, as it 
would be the case when changing an alanine to an isoleucine with valine as an intermediate, 
this structure is manipulated with the Parasol Protocol again, undergoing the same process 
but for a different transformation. Because it will have already undergone solvation, 
minimisation and equilibration, these steps are skipped to save time; additionally, keeping the 
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solvation shell constant around the protein allows reducing the source of error by avoiding 
large fluctuations in the free energy that may be caused by continuously changing the number 
of waters in the system. The specific parameters of these simulations are reported in a 
successive section. 
6.4 – Parameterisation of Missing Amino Acids 
As mentioned before, some of the amino acids used as intermediates in longer 
mutations are not natural residues, meaning that they are not included in the canonical 
twenty. Whereas the twenty natural amino acids have been used extensively in AMBER 
before, meaning that their parameters have been derived and refined over many generations 
of AMBER force fields, the non-natural amino acids are not as well catalogued. This does not 
apply much to parameters involving bonds, angles or dihedrals, as AMBER has been 
developed to be general, and bonds commonly found in amino acids such as C-C, C-H, C-O 
and many others have been standardised: for new residues, especially the simpler ones that 
are conformational isomers of existing ones, these parameters are often transferable. This has 
been our approach for our intermediate, non-natural residues: we have taken these parameters 
from the existing force field and applied them as appropriate. Amino acids that were treated 
this way are aminobutyric acid, norvaline, norleucine and homocysteine, as well as the ones 
“invented” for the purpose of the Parasol Protocol, the four-membered analogue of 
phenylalanine annuline and the four-membered analogue of proline quadrine. As it will be 
explained later, there was however one major parameter that had to be derived specifically 
for the purposes of this project, which was done employing paramfit, a specialised program 
part of the AMBERTools package. Other than that, these parameters are all taken from the 
standard force field set.  
Where the non-natural amino acids have to be parameterised individually is in their 
electrostatic charges, which are different from residue to residue. In some cases, especially 
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during the very early phases of testing, charges for unknown amino acids were taken from 
similar existing residues and slightly adapted to have makeshift values to use temporarily. 
Eventually, all amino acids were given their own charges, calculated ab initio. The program 
used for these calculations was Gaussian with its graphical interface Gaussview250, a software 
package that can be employed for many purposes in computational chemistry but which is 
more commonly used for quantum mechanical methods. The structure of each of the amino 
acids was loaded into the program, capped at the N-terminal with an acetyl subunit and at the 
C-terminal with an N-methyl subunit, and was subsequently geometrically optimised first 
with the Hartree-Fock (HF) method using the 6-31G* basis set, and then with the B3LYP 
method using the 3-21G* basis set. HF/6-31G* conditions were then employed to generate 
the potential points, which were then used by the RESP program of the AMBERTools 
package to calculate the individual charges on the amino acids’ atoms. Atoms in the same 
chemical environment (such as hydrogens on the same methyl) were constrained to have the 
same charge, and some charges were taken from existing residues, such as in the case of 
backbone atoms, which have the same charge across all uncharged residues. 
This process of parameterisation was generally fairly simple to accomplish (although 
done at a relatively low level of theory), and it is a testament to how well implemented and 
integrated the different programs of the AMBER and AMBERTools package are. It is very 
quick to calculate the charges in this manner, and it can become a routine procedure to 
incorporate non-natural residues into AMBER and the Parasol Protocol. As we expand the 
capabilities of our method, it may become necessary to use more and more non-natural amino 
acids, and the infrastructure that is already in place allows this to be an easy task.  
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6.5 – Technical Aspects 
The development of the protocol and related work was carried on two computers 
running Linux operating systems (Fedora 12 and CentOS 6), each using two Intel® Dual-
Core E5700 CPUs cores running at 3.00 GHz. On different machines, we had access to a 
single GTX 680 NVidia GPU, and to two GTX 780 NVidia GPUs. The AMBER 12 and the 
AMBERTools 12 package138 were used for simulation and analysis, using the FF99SB force 
field137. 
The PMEMD (Particle Mesh Ewald Molecular Dynamics) program (part of AMBER) 
was used to run simulations, specifically in its CUDA133,156 implementation, although sander 
was also occasionally used. As mentioned before, the TIP3P model was used to solvate 
systems, employing a solvation shell shaped like a truncated octahedral box in which no part 
of the system was closer than 8 Å from the edge. This is has been the standard used by the 
Parasol Protocol, but it can be changed to fit the needs of the investigated system. Periodic 
boundary conditions were used, with an 8 Å radius; beyond that radius, non-bonded 
interaction terms were calculated with the Particle Mesh Ewald method166. The SHAKE 
algorithm251 was used to constrain bonds including hydrogen atoms, which has the effect of 
allowing longer simulations.  
Minimisation within the Parasol Protocol is performed in 1000 steps (500 by steepest 
descent, 500 with conjugate gradient), followed by the first equilibration (50,000 steps of 0.5 
fs time step, used to raise the temperature from 0 to 300 K in 40,000 steps followed by 
10,000 steps at 300 K) in the NVT ensemble, followed the second equilibration (12,500 steps 
of 0.5 time step, used to set the pressure at 1.0 bar) in the NPT ensemble. The temperature is 
controlled throughout the simulation with the Langevin thermostat252 (using a collision 
frequency of 1.0 ps-1) while the pressure is controlled with the Berendsen barostat253 (using a 
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coupling time of 2.0 ps). Mutations are performed in eleven phases (0-100, 10-90,… 100-0) 
of 5,000 steps of 1 fs time step. In every simulation, a random seed (ig=-1) was used. 
Other programs of the AMBERTools package that were used for support and analysis 
include LEaP, cpptraj, RESP, paramfit, ante-MMPBSA and parmed.py, as well as many other 
minor ones. Visual inspection and further analysis of the investigated systems was done with 
the VMD suite254. 
The calculation of the free energy was done with the MMPBSA.py module of AMBER. 
For GB calculations, the GB5 parameters were used (mbondi2 radii, LCPO calculation of the 
SASA and 0.005 kcal/mol/A2 surface tension offset), while for PB calculations, the PB4 
parameters were used (mbondi radii, Molsurf calculation of the SASA and 0.0072 
kcal/mol/A2 surface tension offset). Both of these are as suggested in the AMBER manual. 
For most preliminary studies, we employed a system of bovine trypsin with a Bowman-
Birk peptidic inhibitor255 (PDB code: 1SMF). The relative simplicity of the interaction, the 
size of the complex, which made possible to have fast simulations, and the wealth of 
expertise within this group with this system made it an ideal model to test and develop the 
Parasol Protocol. Although other proteins were also used to test the protocol in different 
situations and validate that it could be applied to different systems, the 1SMF complex was 
the main one used.  
 
6.6 – Analysis of the Parasol Protocol and Comparison with Other Mutagenesis 
Methods 
In terms of what we had identified as necessary characteristics for a mutagenesis 
method, the Parasol Protocol accomplishes everything we had set out to achieve. It can carry 
mutations in the gradual, dynamic manner that allows handling both growing and shrinking, 
while at the same time letting the residue and the environment around it adapt to the change. 
It does this within the framework of the AMBER package, and it uses the force field equation 
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to determine motions and sample conformational space. It successfully copies the alchemical 
approach of using non-chemical intermediates, which is of fundamental importance when 
introducing mutations slowly. All natural amino acids have been scripted and automated, so 
that Parasol can handle any mutation on any polypeptide, and, additionally, a few non-natural 
amino acids have been incorporated into the protocol. Overall, the Parasol Protocol carries 
mutations in the manner we had envisioned, and it can be used in the analysis of PPIs and 
proteins in general. 
During development, particular care was given to the use of Parasol in virtual screens. 
The stated purpose was to have a tool that could be used to quickly generate high volumes of 
data, in an automated fashion that could be used by experimentalists of otherwise researchers 
without extensive knowledge of computational chemistry. In this regard, we feel that the 
Parasol Protocol delivers what we need and works as intended. While it lacks the simplicity 
and speed of the rotamer library or homology modelling methods, which can generate 
structures in a matter of seconds and through an easily understandable graphical interface, it 
is still a remarkably quick and inexpensive method. The Parasol Protocol does not rely on 
computer clusters or especially powerful hardware; in fact, it works using some of the 
cheapest available options for increasing computational power. GPUs can speed up MD 
simulations by huge factors (in our case, simulations were twenty times faster than the 
equivalent done with a CPU), and we took advantage of that when developing Parasol. 
It depends on the size of the system and the number of atoms in it, but our protocol can 
introduce mutations in a matter of minutes; furthermore, the speed of the simulation is 
completely customisable, and it can be changed to better suit the needs of the investigation. 
As we have said, it accomplishes this using easily accessible hardware that does not require 
specialist knowledge or an expensive set up, and can be employed in any kind of research 
endeavour.  
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Throughout our development process, we have used the alchemical methods, especially 
FEP, as a guide, and, in fact, a collaborator has defined the Parasol Protocol as an “FEP-like 
prmtop-based scheme”, which is a fairly apt way of describing it. It could be thought of as a 
molecular mechanics equivalent of FEP, but there are significant differences that we have 
made to that approach in order to fulfil certain requirements at the expense of others. We 
have outlined how FEP works in a previous section, and the basis of that technique is a 
gradual change of the structure via manipulation of parameters, which is how the Parasol 
Protocol also operates. However, one crucial dissimilarity is that FEP uses a lot of 
computational resources to repeat transformations back and forth in order to converge the 
free energy difference between intermediate states. The result is that, as we have said, FEP is 
more accurate but also very expensive. In the end, this is related to the familiar dichotomy of 
computational chemistry: better, more theoretically rigorous results are always more 
expensive to obtain. For the Parasol Protocol, we have decided to sacrifice the extra accuracy 
in order to have a leaner, faster method. This was a conscious choice, brought on by the 
necessity to develop a protocol that would be used in virtual screens. 
 
6.7 – Validation of the Parasol Protocol 
The original intent of the project was to have a method that could generate rough, 
qualitative data on PPIs, quickly and cheaply enough to be applied on a large scale. With 
current methods, handling mutations experimentally can be very time-intensive82 and 
expensive256, and thus resources must be used judiciously to concentrate investigative efforts 
on mutations that have a higher chance of leading towards the desired outcome and avoid the 
potentially useless or deleterious ones. By applying the Parasol Protocol, preliminary data can 
be collected in order to guide laboratory work, and it allows giving a direction to what may 
otherwise be a frustrating search. 
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Our work after the development of the protocol has been to determine whether that was 
the case. After having scripted and automated the various procedures used for mutation, we 
were convinced and satisfied with our ability to manipulate functional groups at will. Given 
any starting amino acid, we were able to transform it into any other, with a sequential, 
programmed algorithm that needs little input from the user and can perform the needed 
operations autonomously in a relatively short amount of time. The question at that point was, 
of course, whether the structures we were making could be used to generate meaningful data. 
If we were to compare the conformations generated with the Parasol Protocol and those 
observed experimentally, how close would they be? Could we use them to measure free 
energy changes accurately and rapidly enough to be suitable in a research environment? What 
sort of predictive power does the method have, and how much confidence can we have in it? 
In other words, we need to validate the Parasol Protocol. 
In the next few chapters, we will be detailing a number of case studies that we have 
analysed and investigated using the Parasol Protocol in order to determine its capabilities and 
limitations. In each case, we have chosen systems where mutations had been experimentally 
introduced and there was enough interaction and/or structural data about them. The aim of 
our studies was to replicate this data computationally, and attempt to observe the same 
behaviours and trends that had been measured in the laboratory. If the method were perfect, it 
would be able to generate mutants whose conformations exactly match the crystal structures, 
which would lead to accurate interaction analysis, but this is likely impossible for a number 
of reasons. 
Firstly, the protocol that we use to calculate the free energy difference, MMPB(GB)SA, 
is not accurate enough to discern between systems if the difference between them is too 
small201. In order to have more precise data it would be necessary to use something like FEP 
or TI, which are theoretically exact, but we do not need to have that level of accuracy in our 
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measurements. However, as we have discussed at length previously, great accuracy is neither 
allowed by the inherent limitations of the method nor one of our requirements for a 
mutagenesis tool primarily devoted to a scanning function. For our purposes, MMPB(GB)SA 
should suffice and be able to give us the qualitative, preliminary data that we seek. 
Additionally, protein crystal structures are known the be at times problematic257: the very act 
of crystallising a dynamic, moving biomolecule can add intrinsic error to the reported 
structure that may lead to a poor model. Computational studies based on such flawed 
depictions will be in themselves flawed, and comparison with experiment may perhaps never 
have the wanted correlation; but, once more, exact correspondence and prediction of 
experimentally observed data is not the purpose of our investigations. 
In the studied cases, therefore, it was sufficient to obtain qualitative agreement for us to 
be convinced of the goodness of our method. Indeed, given the premises of our methodology 
and assumptions in our techniques, we expected we could not do more than that, although in 
some cases we did obtain quantitative agreement. 
To validate our protocol, we looked for known studies of protein mutagenesis, where 
polypeptide systems had been in some way experimentally manipulated and mutated, and 
their properties had been measured before and after the transformation. These test cases were 
selected based on the availability of experimental data, especially protein structures and 
binding energies, and on the broader relevance and significance of the systems. Our aim was 
to computationally replicate the experimental results: the systems were simulated and their 
characteristics measured, and then changed by introducing mutations with our Parasol 
Protocol, after which their properties were measured again. The quality of our data, whether 
we can detect trends and whether we can shed more light on known interactions were all 
metrics that we used to determine the predictive power of the Parasol Protocol. We were also 
careful to observe if there were classes of amino acids that were more problematic to 
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simulate, what improvements could be added to the existing implementation and how the 
protocol could be applied in a realistic research setting. The test cases that we investigated 
gave us considerable insight on our method, mutagenesis and molecular dynamics 
simulations of proteins in general, and we improved the Parasol Protocol at every 
opportunity.  
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Chapter 7: Test Case 1 — Stapled Peptides  
7.1 – Background and Principles of Stapled Peptides 
The use of proteins as therapeutic agents has been hindered due to many issues, from 
poor delivery to digestion in the body104, but several new technologies and developments 
have helped to overcome these challenges and have expanded the possibilities of proteins and 
polypeptides. One such new tool for the study of proteins is the use of chemical staples to 
give certain properties and enhance stability258,259. 
Short peptides possess properties that make them attractive in drug development, but 
they are also problematic to work with260. Firstly, they have very ineffective cell membrane 
penetration and are therefore unsuited for intracellular targets; additionally, they are easily 
digested, degraded or cleared from the body, which all contribute to a poor ability to reach 
the intended protein. Another problem is that if they are too short, they seldom retain a stable 
structure, but instead revert to random coil261. Whereas large proteins have long-range effects 
that can help enforce local conformations such as α helices and β sheets, peptides often are a 
lot less constrained, and they will therefore adopt unpredictable, disordered structures. This is 
true even in the case of peptides that have been obtained as a fragment of larger proteins: 
without the rest of the conformation to keep them in place, it is far more likely that they will 
unravel rather than remain in an ordered structure, which would be entropically unfavourable. 
All of these issues can be solved by the use of peptide staples, which has already seen 
several successful applications262–265. The basis of this technique is to create an artificial 
chemical bond between two amino acids of the peptide, usually by incorporating non-
standard residues in the sequence and making their side chains react, although, theoretically, 
many different designs are possible. It is this versatility that makes the method attractive, as 
staples can be introduced between pairs of residues in different possible positions on the 
peptide, or incorporating different chemical structures and functional groups, or even adding 
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extra functionalities in custom locations266,267. Perhaps the most common application of these 
staples, however, is via the synthesis of an all-hydrocarbon, aliphatic chain between residues 
in i, i+4 (meaning four amino acids apart) positions of peptides known to have α helical 
conformations, in order to stabilise such a structure when the peptide would naturally be in a 
disordered state268. Combinations of i, i+3 and i, i+7 residues can also be used, but the i, i+4 
combination represents the standard distance between amino acids in a helical turn. With the 
use of this crosslink, a macrocycle is created between the different regions of the loop, and 
most designs of this kind of staple also substitute the α-hydrogens on the residues that make 
the crosslink with two extra methyl groups; these steps help enforce a helical structure and 
give rigidity269. In addition to this, the added stability makes the peptide less likely to be 
degraded, it imparts a greater ability to penetrate cells and it increases the affinity for its 
target, as well as strengthening the interaction; furthermore, the staple has been shown to not 
be toxic and to be safe and efficacious to use270. It should be clear to see why this can be an 
attractive option in the field of peptide design, as it represents a reliable and well-established 
method to solve many of the problems associated with their development, from delivery to 
clearance. 
 
 
 
 
 
 
 
The experimental procedure used to introduce stapled peptides, shown in Figure 13, 
however, is not particularly straightforward, cheap or easy271. The first step is the synthesis of 
Figure 13: A schematic representation of the synthesis of peptide staples that can be used to stabilise peptide 
helices. Starting from two norleucine derivatives with methyl groups on the α-carbons and terminal double bonds, 
they can be tethered using a Grubbs catalyst to create a bond between them.  
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the peptide, usually via solid phase peptide synthesis, where amino acids in i, i+4 positions 
have been substituted with non-natural residues: as mentioned, this residue has the α-
hydrogen substituted with a methyl group, while its side chain is a straight aliphatic chain of 
variable length where the last C-C bond is a double bond272. If the i, i+4 combination is used, 
the side chain is usually four carbons long, effectively making it an analogue of norleucine 
(unbranched version of leucine and isoleucine). After the necessary purification steps, the two 
residues are tethered to each other by reacting the terminal alkenes in a ring closing 
metathesis  catalysed by a metal Grubbs catalyst, which is followed by further purifications 
and modifications. 
While this process is well known and established, it is still a relatively complicated, 
expensive and time-consuming technique that requires trained personnel in order to be 
carried. Though the aliphatic chain version has been employed several times and is well 
documented, other types of staple will suffer from a lack of expertise and support, and may 
therefore be harder to implement. The chemical species employed in the synthesis of stapled 
peptides may also have a high cost due to the fact that they find little application in anything 
else and must be made for this niche purpose. 
Another major challenge with this technique is the question of where the staple is 
placed along the peptide. The two non-natural amino acids need to replace existing ones to 
preserve the correct length of the chain and the interactions between different regions of the 
helix, which means that two residues have to be sacrificed to introduce the staple. 
Determining which is not an easy task, as extensive data needs to be gathered and analysed to 
indentify which amino acids are important for the interaction or the specificity, and if the 
staple in that location is effectively going to increase the activity and allow the peptide to act 
the way it should, and not perhaps have different reactivity. In case this data is unavailable or 
inconclusive, it might be necessary to experiment by placing the staple in different positions, 
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testing the activity of the resulting peptide and finding this way which substitutions give the 
wanted results. 
Despite these considerations, staples remain an attractive method to improve peptides 
for activity, stability and delivery. Their most common application, the i, i+4 staple to 
enforce helicity, has seen widespread use and has helped several investigations; given the 
versatility of the concept, which allows for different kinds of staples arranged in different 
structures that can have different functionalities, this technique has seen widespread 
acceptance and employment in research. There have been computational studies aimed at 
analysing staples and elucidating their nature and interactions, examining existing structures 
and complementing those results with in silico work273. We think that the Parasol Protocol 
can be used with success within this field, as its ability to manipulate the structure of proteins 
can also be applied to the growth of stapled peptides, which can be generated and analysed 
computationally before committing to the lab. Our test case has been to replicate a known PPI 
involving a stapled peptide, the MCL-1 and MCL-1/BH3 system.  
 
7.2 – The MCL-1 and MCL-1/BH3 System: Background and Experimental Results 
7.2.1 – Previous Experimental Work 
MCL-1 (Myeloid cell leukaemia 1) is an anti-apoptotic protein of the BCL-2 (B cell 
lymphoma 2) family that has attracted considerable interest due to being implicated in several 
forms of cancer274. The protein and other members of that family interact with a specific 
domain belonging to pro-apoptotic BCL-2 members, the BH3 (BCL-2 homology domain 3) α 
helix that is fundamental to induce cell death or apoptosis275. This is done to ensure cell 
survival, and, when healthy, the cell carefully balances pro-apoptotic and anti-apoptotic 
proteins to suit its needs. In cancer cells, however, this process is deregulated and the pro-
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apoptotic proteins are constantly blocked, leading to an immortal, cancerous cell that can 
grow out of control. 
One strategy to combat this is to develop mimics or analogues of the BH3 helix that can 
target the MCL-1 protein and interact with it in the same way it would with the pro-apoptotic 
proteins276: by inhibiting the protein that inhibits the proteins that would result in cell death, it 
may lead to defeating the cancer and may prove to be a possible targeted therapy technique. 
One relatively simple way to obtain an MCL-1 inhibitor would be to using the BH3 helix it 
interacts with as the basis for a shorter peptide that can then be used as a drug-like molecule. 
This complex is shown in Figure 14. However, as we have mentioned before, fragments of 
larger proteins may struggle to retain the structure they had when they were part of a bigger 
whole, and the BH3 helix is not an exception. Researchers found that it could not reliably 
enter the cell and could not adopt the helical conformation that it needed to inhibit and thus it 
displayed relatively poor activity against its target. To obviate this problem, they decided to 
introduce a chemical staple to give rigidity and hopefully improve the inhibitor’s strength, 
Figure 14: MCL1 (in red) in complex with the BH3 
helix (in cyan) and the staple highlighted (blue). 
(PDB: 3MK8) (Image taken with VMD) 
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using the same all-hydrocarbon, aliphatic i, i+4 staple described in the previous section. By 
using alanine and glutamate scans of the peptide sequence, they analysed the structure and 
tried to determine which positions could be substituted in order to place there the custom 
residues and introduce the staple; they chose five different combinations of amino acids that 
they believed would preserve activity and specificity while also incorporating the crosslink. 
These results are shown in Table 1. 
Experimental 
Identifier 
Computational 
Identifier 
Peptide Sequence KD (nM) 
MCL-1 BH3 Native 208KALETLRRVGDGVQRNHETAF228 245 ± 29 
MCL-1 SAHBA 148-152 208KALETLRXVGDXVQRNHETAF228 43 ± 16 
MCL-1 SAHBB 144-148 208KALXTLRXVGDGVQRNHETAF228 18 ± 4 
MCL-1 SAHBC 150-154 208KALETLRRVXDGVXRNHETAF228 >1,000 
MCL-1 SAHBD 154-158 208KALETLRRVGDGVXRNHXTAF228 10 ± 3 
MCL-1 SAHBE 156-160 208KALETLRRVGDGVQRXHETXF228 33 ± 10 
Table 1: The experimental results found by Stewart and coworkers when investigating MCL-1 inhibitors276. A total 
of five variants plus the native, unstapled conformation were tested. The Experimental Identifier is the name used 
throughout the laboratory work carried in the literature, while the computational identifier is the one used n our 
simulations. X identifies crosslinked residues, whose structure is shown in Figure 13.  
Starting from the native sequence taken from the BH3 α helix structure, five different 
stapled peptides were generated by substituting five pairs of amino acids with the custom 
residue, which were then crosslinked to create the staple. Circular dichroism was used to 
determine the helical character of the peptides and in every case the stapled peptides adopted 
a regular helical conformation whereas the unstapled version did not. Following these 
preliminary studies, the inhibitory activity of the native sequence was tested and compared 
with that of the stapled variants, and in every case but one the presence of the staple 
correlated with increased activity. As it can be seen in the table, the SAHBD (stabilised alpha 
helix of BCL-2 domain) peptide showed the best inhibition, while in SAHBC the staple 
completely killed all the activity; the other peptides show intermediate values, which is an 
expected result for this kind of assay.  
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7.2.2 – Computational Studies 
The aim of our computational studies was to replicate this data using the Parasol 
Protocol. We obtained the crystal structure of the system in question (PDB: 3MK8) and then 
simulated it and manipulated with molecular dynamics tools. The crystal structure was that of 
their best inhibitor, SAHBD, and therefore our initial conformation already had a staple, 
which we removed and filled in with templated amino acid side chains to give the native 
sequence. Furthermore, some residues, most notably the terminal amino acids of the peptide, 
were not present in the crystal, and thus we simulated the system without them. 
Our procedure, shown in Figure 15, for the study of the stapled peptides was to take the 
original sequence and apply the Parasol Protocol to mutate two amino acids in i, i+4 
positions to norleucines. A long range tether was then created between the two residues’ ε-
carbons in the form of a bond. This bond has no force constant, so it cannot affect the 
dynamics of the peptide or the norleucine side chains, and its equilibrium length is set to be 
the interatomic distance between the two carbons at the beginning of the simulation. As the 
stapling simulation progresses, the force constant of the bond increases while the length 
decreases, pulling them together, until the staple structure is made as it is in experiment. The 
charges for the overall staple were calculated in the manner described above for non-natural 
amino acids, employing quantum mechanical optimised conformations and the RESP 
protocol of AMBER. In true Parasol Protocol fashion, the process of generating the staple 
and pulling the two halves together is gradual and linear, in 10% changes of the force 
constant and bond length from step to step, so that the system can adapt to the introduction of 
the staple. While the tether eventually becomes a double bond, AMBER cannot really 
distinguish between single and double bonds in terms of bond parameters: in order to enforce 
the correct cis structure that is used in the experimental staple, appropriate dihedral 
parameters were generated using the paramfit protocol of AMBER. This was done by 
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optimising the staple structure (with acetyl and n-methyl groups capping the peptide portion 
of the staple at the N- and C-termini respectively) with B3LYP/6-31G* conditions while the 
central double bond was in the cis conformation, which means that the H-C=C-H dihedral 
had an angle of 0°. The same structure was then taken and optimised with the same method 
ALA-LEU-GLU-THR-LEU-ARG-ARG-VAL-GLY-ASP-GLY-VAL-GLN-ARG-ASN-HIS-GLU-THR-ALA 
142         145                 150                 155                 160 
ALA-LEU-GLU-THR-LEU-ARG-ARG-VAL-NLE-ASP-GLY-VAL-NLE-ARG-ASN-HIS-GLU-THR-ALA 
ALA-LEU-GLU-THR-LEU-ARG-ARG-VAL-NLE-ASP-GLY-VAL-NLE-ARG-ASN-HIS-GLU-THR-ALA 
ALA-LEU-GLU-THR-LEU-ARG-ARG-VAL-NLE-ASP-GLY-VAL-NLE-ARG-ASN-HIS-GLU-THR-ALA 
Figure 15: Schematic representation of the protocol to grow staples on peptides. Starting from the native conformation, 
at the top, two residues are mutated to NLE, tethered and then brought together to form the aliphatic chain. 
109 
 
and basis set with that angle set to 15°, then 30°, and so on until it reached 360°, always at 
15° intervals, producing a total of twenty-five conformations. Through an analysis of this 
rotational profile of the double bond, the paramfit module of the AMBER was able to 
generate parameters that would join the two ends of the tether in the correct conformations 
and ensure that the double bond has a cis geometry throughout the simulation. 
In addition to the double bond, the α-hydrogen is replaced by a methyl group, grown 
simultaneously using the standard strategy described in a previous section. The end result was 
that a staple with the same structure as the one is in laboratory work was placed between 
residues at i, i+4 positions, but it had been grown piecemeal and computationally using our 
protocol. The resulting stapled peptides were then minimised, equilibrated and simulated for 
ten runs of 1 ns each, and for each run the interaction between the peptide and the protein was 
measured with MMPB(GB)SA; the free energy data was averaged and ranked. 
The original work on this peptide and its staples, as seen above in Table 1, included 
data on only five of the possible fourteen places where the staple could be placed, as all of 
these had to be synthesised and tested in the laboratory. As it is a relatively complicated and 
expensive procedure, it limited the scope of the experiment, only revealing part of the 
possible stapled peptides that could be generated from the native sequence; and although it 
directed work towards a good inhibitor that deserved further study, a non-interacting and 
presumably not very useful peptide was also made. The computational investigation of the 
same system, however, was not constrained by having to perform all of these mutations 
experimentally, and thus we were able to fully scan the peptide and cycle through all different 
possible combinations of the staple in i, i+4 positions along the sequence. The results are 
shown in Table 2, where they are compared with the corresponding experimental data. 
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Identifier Sequence Experiment KD (nM) Rank 
GB 
(kcal/mol) 
Rank 
PB 
(kcal/mol) 
Rank 
Native ALETLRRVGDGVQRNHETA 245 ± 29 N/A -49.7 ± 6.0  -68.4 ± 6.2  
143-147 AXETLXRVGDGVQRNHETA No experimental data -43.5 ± 6.0 10 -59.5 ± 6.1 10 
144-148 ALXTLRXVGDGVQRNHETA 18 ± 4 2 -54.1 ± 5.4 5 (3) -71.3 ± 5.4 5 (3) 
145-149 ALEXLRRXGDGVQRNHETA No experimental data -55.2 ± 5.5 3 -71.9 ± 5.5 4 
146-150 ALETXRRVXDGVQRNHETA No experimental data -42.4 ± 5.0 11 -57.7 ± 5.3 11 
147-151 ALETLXRVGXGVQRNHETA No experimental data -26.9 ± 4.8 14 -43.2 ± 5.0 14 
148-152 ALETLRXVGDXVQRNHETA 43 ± 16 4 -49.8 ± 6.1 8 (4) -66.5 ± 6.3 8 (4) 
149-153 ALETLRRXGDGXQRNHETA No experimental data -53.8 ± 5.4 6 -68.6 ± 6.1 7 
150-154 ALETLRRVXDGVXRNHETA > 1,000 5 -33.4 ± 5.1 12 (5) -49.3 ± 5.6 12 (5) 
151-155 ALETLRRVGXGVQXNHETA No experimental data -31.6 ± 5.6 13 -47.8 ± 5.8 13 
152-156 ALETLRRVGDXVQRXHETA No experimental data -51.0 ± 5.3 7 -70.9 ± 5.6 6 
153-157 ALETLRRVGDGXQRNXETA No experimental data -59.2 ± 5.5 1 -77.1 ± 5.3 1 
154-158 ALETLRRVGDGVXRNHXTA 10 ± 3 1 -56.8 ± 5.3 2 (1) -74.4 ± 5.3 3 (2) 
155-159 ALETLRRVGDGVQXNHEXA No experimental data -45.5 ± 6.0 9 -63.2 ± 6.1 9 
156-160 ALETLRRVGDGVQRXHETX 33 ± 10 3 -54.6 ± 6.6 4 (2) -76.9 ± 6.6 2 (1) 
Table 2: The collected results of the computational investigation of stapled peptides in the MCL-1 and MCL-
1/BH3 system. The results are compared with the experimental findings. Peptides highlighted in grey have also 
been synthesised and tested in the laboratory. The colours in the GB and PB rankings are used to visually 
represent how well they perform: the red is the one with the worst performance, followed by the oranges, the 
yellows, the greens and the blue, which is the best. In the GB and PB rankings, data points that have an 
experimental counterpart have also been compared to each other, with this internal ranking denoted inside 
brackets. 
As we have said, the GB and PB data was used to rank the peptides from best to worst 
inhibitor, simply taking the absolute value of the interaction strength. There is good 
agreement between the two methods, and the two rankings are extremely similar. The native 
peptide has been measured too, but it has not been ranked with the others because in this case 
there is a sampling problem: the crystal structure already has the peptide in a complex with 
the protein in a helical structure, and thus there is a conformational bias that does not take 
into account the entropy of folding into the correct state and docking, which affect the 
activity in vitro.  
The computational results show remarkable agreement with the laboratory data. If we 
rank internally the ones that have experimental counterparts, we can see that the 150-154 
peptide (equivalent to SAHBC) is the worst out of the five, which was also the conclusion of 
the original experiment, and even in the overall rankings it performs rather poorly. The fourth 
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out of those variants, 148-152 (SAHBA) is also identified as the fourth in the computational 
ordering. The correspondence is less exact when examining the top three inhibitors, and 
neither GB nor PB values quite replicate the order determined experimentally. 
However, as we have discussed at length, getting a perfect agreement with the literature 
result is neither likely nor needed. The relatively high error bars make absolute comparisons 
between those values difficult, which is expected given the flaws of MMPB(GB)SA and how 
close they are. On the other hand, the difference between those three and 148-152 and 
especially 150-154 indicates a definite, unmistakable gap in the binding strength, revealing 
perhaps “tiers” of activity that actually find correspondence with experimental data. 
A simple visual analysis of where the staple is located along the peptide reveals that the 
interaction is a balancing act between making sure that the hydrophobic staple is not too 
solvent exposed and avoiding potential steric crowding. For example, the staple of 151-155 is 
jutting towards the outside, while that of 150-154 is straight down against the protein; neither 
has good activity, indicating that it is not simply a matter of where the staple is positioned. 
The peptides with the strongest interactions (144-148, 145-149, 153-157, 154-158, 156-160) 
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Figure 16: The linear correlation between experiment (X axis) and computational results 
(Y axis), collected only for stapled peptides for which both sets of data are available. The 
blue results are those obtained from GB and have an R-squared of 0.97, while the red are 
the PB, with an R-squared of 0.87. All units are in kcal/mol. 
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all have staples that are at the ends of the sequence, where mobility is higher and the 
conformation can adapt to the rigid structure being introduced in a way that minimises 
clashes but creates a favourable contact. Furthermore, this may mean that the residues 
towards the centre of the sequence are important for specificity and interaction and therefore 
should not be substituted or otherwise interfered with by a staple. All in all, this profile 
reveals important information about the peptide and its activity. 
Although we do not get an exact match, we believe that this information could be of 
great value in future investigations. Even before committing to laboratory to perform a 
preliminary alanine scanning of the peptide, this computational study could have been used to 
obtain initial results to guide the experiment. Not limited by the same requirements that the 
original authors had, we were able to produce a full computational scan of the peptide in less 
than a couple of weeks, in a completely automated fashion. Our first test gives us a certain 
degree of confidence in being able to determine the effect of the position of the staple in this 
particular system, as our results compare very favourably with the ones measured 
experimentally. Figure 16 shows the correlation between experiment and simulation for 
peptides for which both sets of data are available, and the results are very good. Furthermore, 
as we tested peptides that were not originally considered, we can actually make predictions, 
and we observe that the 153-157 staple is consistently a better inhibitor than any of the ones 
that were analysed in the laboratory. It would be interesting to synthesise and test that 
particular peptide to determine if our protocol has true predictive power. Overall, 
disregarding those data points that we cannot compare with literature values and 
concentrating on the ones for which comparison is possible, the Parasol Protocol performs 
remarkably well, correctly generating structures that can be identified as being better or 
worse inhibitors in accordance with experiments. This data makes us believe that the Protocol 
would be a real asset in an unproven scenario. 
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7.3 – Comparison between FF99SB and FF12SB  
As stated, the generated stapled peptide structures were simulated for ten runs of 1 ns 
each. The results shown above are referring to those simulations, performed using FF99SB as 
a force field. However, those were not the first simulations we had performed on this system. 
In fact, the force field of choice for much of the development of the Parasol Protocol had 
been the newer version, FF12SB. However, the results obtained with this force field had been 
decidedly less remarkable than what we had been expecting. While there was agreement 
between experiment and our protocol regarding the worse inhibitors, the 156-160 staple 
(SAHBE) was shown to be unmistakeably better than the 154-158 one, which was found to be 
have the best activity out of those that they tested. The gap between the two made us doubt 
our methodology, and, as we had been having doubts about the FF12SB force field that we 
had been employing, we decided to look for alternative solutions. 
The main difference between FF99SB and its successor FF12SB is that the latter 
describes dihedrals much more finely. Whereas FF99SB would have a generic parameter for 
dihedrals involving four carbon atoms connected by bonds, as there would be in leucine, 
isoleucine or lysine, FF12SB has parameters that are specific to each of those amino acids, 
ostensibly for greater accuracy. We have discussed how overparameterisation may be a real 
issue in force fields, and how it may be hard to strike a balance between being too general 
and not describing anything with the needed accuracy, and being too specific and having poor 
transferability. We had believed for a while that FF12SB might have some problems with its 
parameter set, especially as we could not find reliable sources to determine how the more 
specific parameters had been derived, and therefore decided to test the same system with the 
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old, reliable FF99SB force field. These results, which we analysed previously in comparison 
to the experimental ones, are shown with the FF12SB results in Table 3. 
 FF99SB FF12SB 
Identifier GB (kcal/mol) Rank PB (kcal/mol) Rank GB (kcal/mol) Rank PB (kcal/mol) Rank 
Native -49.7 ± 6.0  -68.4 ± 6.2  -47.5 ± 6.8  -67.5 ± 7.7  
143-147 -43.5 ± 6.0 10 -59.5 ± 6.1 10 -52.6 ± 6.0 6 -67.5 ± 6.3 8 
144-148 -54.1 ± 5.4 5 (3) -71.3 ± 5.4 5 (3) -50.5 ± 5.7  8 (3) -66.6 ± 6.4  9 (3) 
145-149 -55.2 ± 5.5 3 -71.9 ± 5.5 4 -56.2 ± 6.4 2 -74.5 ± 7.0 3 
146-150 -42.4 ± 5.0 11 -57.7 ± 5.3 11 -44.1 ± 5.3 10 -59.1 ± 6.1 11 
147-151 -26.9 ± 4.8 14 -43.2 ± 5.0 14 -33.1 ± 5.4 14 -49.5 ± 5.4 14 
148-152 -49.8 ± 6.1 8 (4) -66.5 ± 6.3 8 (4) -43.5 ± 6.7  11 (4) -59.5 ± 7.6  10 (4) 
149-153 -53.8 ± 5.4 6 -68.6 ± 6.1 7 -53.7 ± 5.7 5 -69.5 ± 5.9 5 
150-154 -33.4 ± 5.1 12 (5) -49.3 ± 5.6 12 (5) -34.2 ± 5.5  13 (5) -51.4 ± 6.6  13 (5) 
151-155 -31.6 ± 5.6 13 -47.8 ± 5.8 13 -35.0 ± 6.6 12 -54.0 ± 7.3 12 
152-156 -51.0 ± 5.3 7 -70.9 ± 5.6 6 -53.8 ± 6.4 4 -71.7 ± 7.1 4 
153-157 -59.2 ± 5.5 1 -77.1 ± 5.3 1 -58.1 ± 5.3 1 -78.2 ± 5.6 1 
154-158 -56.8 ± 5.3 2 (1) -74.4 ± 5.3 3 (2) -51.1 ± 6.1  7 (2) -68.6 ± 6.9  6 (2) 
155-159 -45.5 ± 6.0 9 -63.2 ± 6.1 9 -50.3 ± 7.4 9 -68.1 ± 8.5 7 
156-160 -54.6 ± 6.6 4 (2) -76.9 ± 6.6 2 (1) -56.6 ± 5.6  3 (1) -75.3 ± 5.9  2 (1) 
Table 3: A comparison of the simulations of the stapled peptides performed with FF99SB and FF12SB. As in the 
previous table, peptides highlighted in grey are those that have experimental data to compare with, and the 
colours of the rankings indicate their position. The numbers in brackets are the internal ordering for those 
peptides with experimental data. 
It can be seen that the two force fields agree very well on the first and last positions in 
the rankings, although most other data points change in values and ordering. The comparison 
between two sets of computational results, however, is not enough to determine their absolute 
reliability: only a comparison with equivalent experimental data can do that. For that reason, 
it seemed to us that FF99SB was the better force field, as the results for the 144-148, the 154-
158 and the 156-160 staples are significantly closer to each other, as is expected by 
experiment. Of course, there is no way to determine if FF99SB or FF12SB give the correct 
order for data points that do not have a laboratory counterpart other than testing those stapled 
peptides too, but given how FF99SB seems to perform better with the ones that have been 
tested, as seen in figures 16 and 17, we would trust its rankings more. 
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Based on these results and coupled with the lack of reliable literature to back FF12SB, 
we decided to employ the FF99SB force field for the remainder of this project. This is not a 
value judgement on whether FF12SB should see use as a force field; rather, we felt that 
FF99SB performed better, at least within the confines of our investigations. 
 
 
7.4 – Summary and Outlook 
Staples, as we have discussed, represent a novel and exciting way to manipulate 
peptides and perhaps proteins, allowing adding rigidity, enforcing certain conformations and 
even introducing new functionalities. They can be very versatile in their range, but they might 
suffer from relatively expensive protocols that leave little leeway for error: venturing beyond 
the established procedures can be difficult, and even working with known quantities might 
lead to poor results. 
The Parasol Protocol can aid in this regard by being an inexpensive, quick method to 
manipulate proteins and experiment with different staple designs. In our investigations, we 
have only worked with one staple, an all-hydrocarbon unsaturated straight chain with 
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Figure 17: The linear correlation between experiment and computational results, with the 
simulations carried with the FF12SB method. GB is in blue and PB in red. The R-squared 
values (0.73 and 0.58 respectively) indicate poorer correlation than FF99SB. 
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additional α-methyls, but it would easy to experiment with different structures and systems. 
The data that we have gathered for our first test case makes us believe that the Parasol 
Protocol correlates with experiment well, and that it can have qualitative predictive power 
when it comes to determining the optimal position of the staple. It is a relatively simple 
system, being of small size and with the binding between protein and peptide clearly 
dominated by the burial of the large hydrophobic staple, but our match with experiment is 
still a very encouraging result. Although further studies can be done to fully analyse each 
variant and establish the contributions to the binding strength change, the aim of our protocol 
was to quickly generate preliminary results that could be used to direct laboratory work, and, 
in that regard, we believe that it has succeeded. 
In the future, expanding our range of possible staples seems to be a relatively easy step, 
but it would involve the correct parameterisation of the new staples, as it has been done for 
the one used in the studies above, and the implementation of scripts to grow those structures. 
An easier venue of new research would be to apply the computational tools that we have 
developed to other systems that make use of the same staple, to elucidate their effect on the 
peptide and to perhaps complete the sets of data by testing conditions that have not been 
tested yet experimentally. As it was in the case of the MCL-1 system analysed above, it may 
be possible to discover possibilities that were not considered by the experimentalists that 
could nevertheless be worthwhile to pursue. One system that has attracted considerable 
interest has been that of p53, whose stapled peptides have been the object of many 
investigations262,263,265,277,278. In future endeavours, it would be an attractive and interesting 
area of research, as the ample data collected in the literature can be used to further benchmark 
and test our protocol. 
In conclusion, we feel that, in its first test case, the Parasol Protocol has proven itself to 
work well. Our aim was to quantitatively analyse a stapled peptide system, faster and cheaper 
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than it would have taken to do the same experimentally, and that is precisely what we have 
done: we have generated preliminary data that correlate well with the existing results, and 
that could have been very useful prior to committing to the laboratory. The versatility of 
stapled peptides as a tool means that there are still many unexplored venues in the field and 
many potential improvements that can be done on the Parasol Protocol. For our first test case, 
we are satisfied with our protocol’s performance. 
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Chapter 8: Test Case 2 — Peptide Binding to OppA Protein 
8.1 – Background and General Principles 
In several organisms, from E. coli to staphylococcal species, the uptake of 
oligopeptides inside the cell is performed by a family of enzymes called oligopeptide-
transporting ATPases, otherwise known as oligopeptide permeases (Opp)279–281. They have 
very broad specificity and a wide range of interaction partners, being able to catalyse the 
uptake of substrates composed of two to five amino acids, although the affinity may vary 
wildly between different substrates. 
These enzymes do not have any particularly 
relevant medical applications, but they have 
nonetheless attracted considerable interest as a 
system used to benchmark computational studies of 
conformations and interactions. The binding pocket 
of the enzyme tends to be structurally very well 
conserved across complexes with different 
oligopeptides, which aids in its analysis, and it can 
be used to determine structure-activity relationships 
by examining how the oligopeptide composition 
affects the binding. It is a particularly useful system 
to study the effect of water molecules in the binding 
pocket, which tend to have a very strong effect on the 
overall strength of the interaction282.  
Because there have been many investigations on the structure and interaction of 
different binding partners, a wealth of experimental data gathered on this system can be 
accessed in the literature. Out of these, there is a study that is of particular relevance to the 
Figure 19: The OppA system. The protein (in 
green) interacts with a tripeptide (in orange) 
embedded in its active site. 
Figure 18: A close-up of the tripeptide in the 
active site. It is embedded very deeply inside 
the protein. 
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validation of the Parasol Protocol, which used the oligopeptide permease A (OppA) of Gram 
negative bacteria. In this system, OppA interacted with a tripeptide with the general formula 
Lys-X-Lys, where X has been resolved for each of the twenty natural amino acids, and for 
each residue, the interaction between the tripeptide and the protein has been measured, as 
well as the structure of the corresponding complex283.  
This system represents a perfect test case for our Parasol Protocol: starting from the 
“native” structure, which is the Lys-Ala-Lys (KAK) system, we can manipulate the sequence 
of the tripeptide to generate mutant structures. Thanks to the experimental data of both the 
conformation they should adopt and how strong an interaction they should have, we can 
assess the goodness of our simulations. By comparing the results of our computational 
mutagenesis protocol with what is observed in the laboratory can tell us what kind of 
predictive power our method has and if there are classes of amino acids that are described 
more or less poorly within our technique. 
This system was also chosen because previous work in the group had briefly touched 
upon it, albeit without great success284. Another possible test for the Parasol Protocol is to 
attempt to replicate earlier studies accomplished with different techniques, to determine if our 
understanding and methods have improved since then. 
 
8.2 – Methodology of the Comparison between Computational and Experimental 
Results 
The structure of the complex was taken reference cited above (PDB code: 1JET), which 
had crystal structures for each of the twenty analysed residues as well as calorimetric data on 
the interaction. 
Taking the KAK complex as the “native”, this structure was minimised with 1,500 
steps of the steepest descent method, followed by 3,500 of conjugate gradient. The 
equilibration was done in two steps, first heating the system in 125,000 steps of 2 fs each, 
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increasing the temperature from 0 to 300 K in 100,000 steps, and then equilibrating the 
density for another 125,000 steps of 2 fs each. After this, the system was simulated for 150 ns 
in order to fully allow it to equilibrate the dynamics, which were monitored throughout. At 
this point, the final, fully converged structure was simulated in ten runs of 1 ns each, before 
being mutated from its original KAK sequence to each of the other nineteen conformations, 
varying of course the central amino acid. Each of these resulting structures was simulated in 
ten runs of 1 ns each. 
Two overall studies were carried: in one case, the KAK complex taken from the PDB 
repository was stripped of the crystallographic waters that were included in that structure and 
a wholly new solvation shell was added, while in the other the solvation shell was added on 
top of the crystallographic waters. Given that the effect of the waters in the active site of this 
system is well documented, it is an interesting metric to keep track of. 
Table 4: Experimental data on the OppA system, as recorded in the literature. For each tripeptide with the 
formula KXK, where X is every natural amino acid, the interaction energy was measured and decomposed in 
Peptide KD (nM) ΔG (kJ/mol) 
ΔG 
(kcal/mol) 
ΔH 
(kJ/mol) 
TΔS 
(kJ/mol) 
RMSD 
(Å) 
PDB 
KAK 56 ± 50 -41.1 -9.82 20.1 ± 2.0 61.1 ± 0.9 n/a 1JET 
KCK 75 ± 3.4 -40.6 -9.70 7.9 ± 1.3 48.2 ± 1.4 0.167 1B05 
KDK 5900 ± 1200 -29.8 -7.12 8.1 ± 1.3 37.7 ± 0.8 0.121 1B4Z 
KEK 150 ± 16 -38.9 -9.30 11.3 ± 0.9 50.0 ± 1.1 0.337 1JEU 
KFK 53 ± 9.9 -41.5 -9.92 22.0 ± 1.6 63.2 ± 1.6 0.197 1B40 
KGK 1300 ± 460 -33.6 -8.03 14.1 ± 0.36 47.5 ± 0.8 0.384 1B3L 
KHK 130 ± 43 -39.3 -9.39 20.6 ± 3.0 59.8 ± 3.9 0.156 1B3F 
KIK 200 ± 56 -38.3 -9.15 20.5 ± 3.8 58.6 ± 4.4 0.168 1B3G 
KKK 2900 ± 63 -31.6 -7.55 39.4 ± 0.9 70.8 ± 4.4 0.147 2OLB 
KLK 1100 ± 180 -33.9 -8.10 24.6 ± 0.9 58.3 ± 3.1 0.155 1B9J 
KMK 79 ± 17 -40.5 -9.68 14.6 ± 0.8 54.9 ± 1.2 0.118 1B32 
KNK 90 ± 37 -40.2 -9.61 7.7 ± 0.2 47.9 ± 1.1 0.169 1B5I 
KPK 5200 ± 780 -30.1 -7.19 16.6 ± 0.6 46.5 ± 0.4 0.137 1B46 
KQK 37 ± 0.9 -42.4 -10.13 11.4 ± 0.5 53.4 ± 0.5 0.141 1B5J 
KRK 1200 ± 490 -33.8 -8.08 36.0 ± 7.3 69.7 ± 8.3 0.152 1QKA 
KSK 43 ± 5.7 -42 -10.04 8.9 ± 0.7 50.6 ± 0.6 0.174 1B51 
KTK 76 ± 4.9 -40.6 -9.70 17.3 ± 1.7 57.6 ± 1.5 0.333 1B52 
KVK 45 ± 25 -41.9 -10.01 22.4 ± 0.4 64.3 ± 1.3 0.118 1QKB 
KWK 130 ± 11 -39.2 -9.37 29.3 ± 1.0 68.2 ± 1.0 0.145 1JEV 
KYK 260 ± 43 -37.5 -8.96 20.7 ± 3.9 57.9 ± 4.2 0.287 1B58 
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enthalpic and entropic contributions. The RMSD is calculated using KAK as a reference and considering only α-
carbons. For KGK, there are two isoforms and the one with the smallest RMSD was reported. 
 
Table 4 shows the experimentally obtained results, which we are attempting to 
replicate, as recorded in the literature283. The data shows a wide range of interactions, with 
KQK having the strongest binding out of the twenty, while the five worst ones are, in order, 
KDK, KPK, KKK, KGK and KRK, which are three charged residues (two positive and one 
negative) and two amino acids known to cause structural differences in the backbone. One 
thing that is important to notice is that there is a definite difference of two orders of 
magnitude between the worst and best inhibitors, and therefore the MMPB(GB)SA protocol 
should be able to discriminate between the pairs such as KDK (5900 ± 1200 nM, -29.8 
kJ/mol) and KAK (56 ± 50 nM, -41.1 kJ/mol), while it would be harder to separate KAK 
from KFK (53 ± 9.9 nM, -41.5 kJ/mol). The RMSD data also shows ranges of structural 
similarity, albeit with little to no correlation for binding affinity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
 
 
8.3 – Analysis of Mutagenesis Data  
Our approach in the initial stages of this investigation had been to use the same applied 
in the stapled peptide system: a simple qualitative examination of the various species, 
comparing the experimentally observed rankings and those obtained after the application of 
the Parasol Protocol. This had been sufficient to give good correlation in our previous test 
case, and there was the hope that it would prove itself again.  
 
 
Without Crystallographic Waters With Crystallographic Waters 
 
GB (kcal/mol) PB (kcal/mol) GB (kcal/mol) PB (kcal/mol) 
KAK -54.2 ± 4.6 -54.2 ± 7.5 -51.8 ± 4.6 -60.3 ± 7.5 
KCK -55.8 ± 4.6 -54.2 ± 7.2 -52.2 ± 4.6 -58.7 ± 7.2 
KDK -62.8 ± 5.5 -40.7 ± 8.7 -51.9 ± 5.5 -42 ± 8.7 
KEK -64.6 ± 5.9 -40.7 ± 8.4 -57 ± 5.9 -48.2 ± 8.4 
KFK -58.1 ± 5.1 -49.5 ± 7.6 -59.6 ± 5.1 -58.7 ± 7.6 
KGK -50.5 ± 4.6 -53.5 ± 7.2 -49.3 ± 4.6 -60.3 ± 7.2 
KHK -57.4 ± 5.4 -51.5 ± 7.7 -58.1 ± 5.4 -60.4 ± 7.7 
KIK -59.2 ± 4.7 -54.8 ± 7.5 -55.1 ± 4.7 -60.7 ± 7.5 
KKK -64 ± 6 -67.8 ± 9.1 -54.8 ± 6 -60.6 ± 9.1 
KLK -56.7 ± 5.1 -49.4 ± 7.5 -54.3 ± 5.1 -57.1 ± 7.5 
KMK -60.4 ± 4.8 -52.2 ± 7.2 -57.8 ± 4.8 -59.1 ± 7.2 
KNK -54.2 ± 4.7 -49.1 ± 7.3 -54.1 ± 4.7 -58.5 ± 7.3 
KPK -53.9 ± 5 -51.3 ± 7.4 -51.4 ± 5 -59.8 ± 7.4 
KQK -55.1 ± 6.2 -51.3 ± 8.9 -53.1 ± 6.2 -57.3 ± 8.9 
KRK -70.4 ± 5.9 -72.1 ± 9.1 -62.7 ± 5.9 -70.5 ± 9.1 
KSK -54.3 ± 5 -51.1 ± 7.9 -50.5 ± 5 -58 ± 7.9 
KTK -54.2 ± 5 -52.6 ± 7.4 -52.2 ± 5 -58.3 ± 7.4 
KVK -56.4 ± 4.9 -52.3 ± 7.4 -54.3 ± 4.9 -58.8 ± 7.4 
KWK -64.5 ± 5.1 -57.9 ± 7.8 -56.3 ± 5.1 -56 ± 7.8 
KYK -64.8 ± 5.5 -49.8 ± 7.9 -60.7 ± 5.5 -60.2 ± 7.9 
 
Table 5: Computationally generated data for the MMPB(GB)SA binding energy of the twenty analysed peptides. 
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However, using the experimental ranking of the peptides as the “correct” one and 
arranging the computationally obtained data to match it indicates poor correlation between 
the two, and some very serious deviations from the behaviour observed in the laboratory. 
 
Although there is some agreement, most notably with regards to KDK, which tends to 
have a worse interaction than almost all other peptides, other data points are more variable 
and it is harder to determine if there is correlation at all. GB and PB vary greatly between 
them, with GB measurements correctly predicting the poorer affinity of KGK and KPK, 
which are instead incorrectly assessed to be more favourable by the usually more reliable PB. 
Perhaps the greatest discrepancy is the fact that in all computational rankings, KRK is by far 
 
 
Without Crystallographic 
Waters 
With Crystallographic Waters 
Experiment GB PB GB PB 
KQK 1 14 13 13 16 
KSK 2 15 14 19 15 
KVK 3 12 9 11 10 
KFK 4 9 16 3 12 
KAK 5 16 5 17 6 
KCK 6 13 6 15 11 
KTK 7 17 8 14 14 
KMK 8 7 10 5 9 
KNK 9 18 18 12 13 
KHK 10 10 11 4 5 
KWK 11 4 3 7 18 
KEK 12 3 20 6 19 
KIK 13 8 4 8 2 
KYK 14 2 15 2 3 
KLK 15 11 17 10 17 
KRK 16 1 1 1 1 
KGK 17 19 7 20 7 
KKK 18 5 2 9 4 
KPK 19 20 12 18 8 
KDK 20 6 19 16 20 
Table 6: A qualitative comparison between computational and experimental measurements of the 
interaction energy. Arranged in the ranking observed experimentally, the other rankings are coloured to 
indicate their internal rankings, with green being having the best affinity, then yellow, orange and red. 
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the peptide with the most 
favourable interaction, 
more or less closely 
followed by KKK, 
whereas in the 
experimental results both 
of these species show 
decreased affinity in 
comparison to the rest of 
the amino acids. One 
potential way to improve 
the fit is to exclude 
charged residues (KDK, 
KEK, KRK, and KKK) 
from the rankings, as 
these sorts of amino acids 
can often only be handled 
in a limited way by 
computational methods. 
However, even when only 
considering uncharged 
residues, the level of 
correlation does not improve. Figure 20 and Figure 21 show that there is very poor 
correlation between experiment and simulation, regardless of  whether charged residues are 
included in the set or not. Clearly, this method of analysis, which had been sufficient to 
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Figure 20: Correlation between experimental and computational results. The 
graph maps experimental ΔG (x axis) against computational ΔG (y axis). Blue 
(measured with GB) and red (PB) represent data collected without 
crystallographic waters, while green (GB) and purple (PB) data when the 
crystallographic waters were included in the initial structure. The R-squared 
data can also be seen: blue: 0.07, red: 0.007, green: 0.02, purple: 0.01. All 
units in kcal/mol. 
Figure 21: Correlation between experimental and computational results, when 
only uncharged amino acids are considered. Blue: GB, without crystallographic 
waters, R-squared: 0.02. Red: PB, without crystallographic waters, R-squared: 
0.005. Green: GB, with crystallographic waters, R-squared: 0.04. Purple, PB 
with crystallographic waters, R-squared=0.05. All units in kcal/mol. 
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acceptably replicate experimental data in our previous test case, is not enough to study this 
OppA system adequately, and therefore we must broaden the scope of our research. 
Fortunately, a wide variety of experimental data has been recorded in the original 
article. These results include not only the interaction data shown above, but also the analysis 
of structures, such as the backbone RMSD, and crystallographic studies of points of contact 
and active site configuration. However, the comparison between experimental and 
computational values is perhaps made more complicated by the fact that the laboratory results 
are measured on static, crystal images, while those we obtained were from solvated, mobile 
representations of proteins. It is a known limitation in the field that crystal structures of 
proteins may differ, even significantly, from those adopted in solution257,285,286, and it is 
something that we must be aware of when comparing structural information. 
For example, one set of data that we set out to replicate was the RMSD of the protein 
structure from residue 10 to residue 510, considering only α-carbons and in comparison to the 
KAK backbone conformation. This was calculated for all other nineteen tripeptides, as with 
the interaction strength, and measured in terms of the deviation in Å. In order to obtain 
comparable data, the RMSD was calculated in two ways: in the first case, it measured on the 
final structures of each of the ten 1 ns runs for each tripeptide and averaged over them, while 
in the second case it was calculated as an average of the entire run, and then averaged over 
the ten measurements. Similarly to how this was done on the system with the crystallographic 
waters and the system without, the RMSD was calculated for both scenarios. The obtained 
values are reported below. 
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Without Crystallographic Waters With Crystallographic Waters 
 
RMSD of final 
structures (Å) 
RMSD as average 
over trajectory (Å) 
RMSD on final 
structures (Å) 
RMSD as average 
over trajectory (Å) 
KAK n/a n/a n/a n/a 
KCK 0.783 0.771 1.562 1.587 
KDK 0.824 0.788 1.590 1.586 
KEK 0.767 0.790 1.551 1.587 
KFK 0.857 0.827 1.650 1.647 
KGK 0.769 0.762 1.632 1.608 
KHK 0.809 0.783 1.598 1.660 
KIK 0.779 0.770 1.568 1.587 
KKK 0.793 0.758 1.582 1.574 
KLK 0.847 0.804 1.612 1.586 
KMK 0.833 0.807 1.578 1.586 
KNK 0.805 0.763 1.620 1.627 
KPK 0.785 0.770 1.567 1.637 
KQK 0.809 0.781 1.557 1.579 
KRK 0.836 0.783 1.548 1.557 
KSK 0.788 0.765 1.587 1.600 
KTK 0.795 0.777 1.585 1.623 
KVK 0.784 0.772 1.542 1.568 
KWK 0.850 0.807 1.611 1.625 
KYK 0.855 0.830 1.626 1.603 
 
Table 7: Computationally generated data for the backbone RMSD of the twenty analysed peptides. 
 
As with the interaction data, these results were ranked in terms of the magnitude of the 
deviation, and compared with the experimental ranking to determine if there was any 
consensus. 
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 Without Crystallographic Waters With Crystallographic Waters 
Experiment 
RMSD of Final 
structures 
RMSD Average 
over run 
RMSD of Final 
structures 
RMSD Average 
over run 
KAK n/a n/a n/a n/a n/a 
KMK 1 14 17 8 7 
KVK 2 5 8 1 2 
KDK 3 13 13 12 6 
KPK 4 6 6 6 17 
KQK 5 11 10 4 4 
KWK 6 17 16 14 15 
KKK 7 8 1 9 3 
KRK 8 15 11 2 1 
KLK 9 16 15 15 5 
KHK 10 12 12 13 19 
KCK 11 4 7 5 8 
KIK 12 3 5 7 10 
KNK 13 10 3 16 16 
KSK 14 7 4 11 11 
KFK 15 19 18 19 18 
KYK 16 18 19 17 12 
KTK 17 9 9 10 14 
KEK 18 1 14 3 9 
KGK 19 2 2 18 13 
 
Table 8: A qualitative comparison of the RMSD values obtained experimentally with those reported in the 
literature. The colour is used to aid visually. 
The table shows that there is little correlation to be had between the experimental and 
computational structures; in other words, the data that we have generated could hardly be 
thought to be predictive and be used in a serious research setting. As we have said, there are 
many caveats that must be considered when comparing the analysis of static crystal structures 
with those that are dynamic and in solution, but, when coupled with the poor correlation 
shown by the interaction strength data, it makes us question whether our methodology is 
appropriate for this system, whether there is some sort of systematic error in our research, or 
whether it is at all possible to simulate this protein complex in a satisfactory manner using 
molecular dynamics tools. We must therefore carry out further analysis, in order to obtain 
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agreement with experiment or determine potential sources of error and suggest alternative 
venues of research that may be followed in future attempts at tackling this system. 
8.4 – Comparison Between KAK and KRK 
Out of the many discrepancies within this case study, perhaps the one that weighs the 
most heavily is the discordance between the computed and experimentally observed 
behaviour of KRK, the tripeptide with arginine. As mentioned before, KRK is shown to have 
an unfavourable interaction in the laboratory when compared to KAK and many of the other 
tripeptides; instead, computationally, it had by far the 
best interaction out of the twenty, and by a margin that 
leaves no ambiguity. Because arginine is a charged 
amino acid and therefore a much greater departure from 
the small, nonpolar alanine, there was the doubt that the 
Parasol Protocol had artificially introduced errors in the 
system which caused the MMPBSA calculation to 
massively overstate the favourability of the KRK 
interaction. In order to determine if this was the case, we used the crystal structure provided 
in the literature for the arginine tripeptide and simulated it under the same conditions (without 
crystallographic waters) that we had employed for the simulation of KAK: 150 ns, followed 
by ten runs of 1 ns each. The resulting structure was mutated to KAK (1QKA mKAK), and 
that mutant mutated back to the original KRK sequence (1QKA mKRK). The KRK mutant 
generated from the 1JET KAK conformation (1JET mKRK) was also mutated back to the 
original KAK sequence (1JET mKAK). In each case the mutation was carried with the 
Parasol Protocol. The results are collected and shown below. 
 
Figure 22: A close-up of the active site 
with KAK (grey) and KRK (red) 
superimposed. KRK is bigger and 
occupies more of the active site. 
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Table 9: The calculated interaction energy of several OppA systems, derived from the crystal structures of 1JET 
(KAK) and 1QKA (KRK). Each result is averaged over ten runs of 1 ns each. The m in the name of peptide 
indicates that the structure has been mutated via the Parasol Protocol. All units in kcal/mol. 
 
The KRK mutant generated from the KAK crystal structure (1JET), as seen previously, 
shows a much more favourable interaction than KAK, which is contrary to experimental 
observations. Upon mutating it back to KAK, the interaction strength reverts back towards its 
original level. 
When the KRK crystal structure (1QKA) is simulated and then mutated to KAK, the 
interaction again becomes more unfavourable, in line with previous computational results but 
the opposite of what seen experimentally. When mutated back to the original, the interaction 
returns to be stronger (although not to the same level as crystal structure’s, and the PB data is 
not as well defined). 
This behaviour was also observed when the crystallographic waters were included in 
the starting conformation, as seen in the table below. The Parasol Protocol was employed to 
mutate the 1JET structure to KRK (as reported above) and the 1QKA structure to KAK. 
 
 
 
Table 10: The mutations of the 1JET system from KAK to KRK and 1QKA from KRK to KAK. In each case, the 
crystallographic waters were included in the starting conformation. 
 
In both cases and regardless of which crystal structure was used as a starting point, the 
KAK tripeptide was found to have a weaker interaction than the KRK tripeptide, which is not 
what is observed experimentally. In order to exclude the possibility that artefacts have been 
introduced by the Parasol Protocol, we sought validation of our findings by repeating the 
same simulations and using an already established technique, Alanine Scanning Mutagenesis. 
1JET (KAK) 1JET (mKRK) 1JET (mKAK) 
 
1QKA (KRK) 1QKA (mKAK) 1QKA (mKRK) 
GB 
 
GB 
-54.2 ± 4.6 -70.4 ± 5.9 -51.8 ± 5.3 
 
-91.4 ± 5.1 -68.3 ± 5.0 -80.4 ± 5.9 
 
   
 
  
PB 
 
PB 
-54.2 ± 7.5 -72.1 ± 9.1 -58.8 ± 8.3 
 
-131.4 ± 9.4 -91.8 ± 7.4 -93.6 ± 9.1 
1JET (KAK) CW 1JET (mKRK) CW 
 
1QKA (KRK) CW 1QKA (mKAK) CW 
GB 
 
GB 
-51.8 ± 4.7 -62.7 ± 5.4 
 
-59.0 ± 5.0 -50.1 ± 4.2 
 
  
 
 
PB 
 
PB 
-60.3 ± 7.8 -70.5 ± 8.6 
 
-75.2 ± 6.8 -68.0 ± 5.4 
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The 1QKA KRK tripeptide was analysed with the ASM module of the MMPBSA tool to 
determine  
the difference in free energy (the ΔΔG) between the native conformation and the 
alanine mutant. The same was done on the KRK generated from the 1JET system. 
 
Table 11: The Alanine Scanning Mutagenesis results for the KRK to KAK mutation, using the native 1QKA 
system and the mutated 1JET system, measured when the crystallographic waters were kept or removed. 
The results, in every case, whether we include the crystallographic waters or not and 
whether the Parasol Protocol is involved or not to mutate from KRK to KAK, indicate that 
KRK has a much stronger interaction than KAK. In a way, this is comforting, as it seems to 
show that the error does not arise from deficiencies of the Parasol Protocol, but rather from 
intrinsic properties of the system which are not accurately modelled by molecular dynamic 
methods. However, it also indicates that much work is still needed in order to reach satisfying 
results. 
 
8.5 – Calculation of the Entropic Contribution 
On the back of this discrepancy between the experimental and computational results, it 
seemed necessary to re-evaluate our methodology and determine if the difference arises from 
the way the data is collected or if it is an intrinsic error of the system and our current tools are 
insufficient for the task. 
In particular, one statement from the literature highlighted a possible fundamental 
omission on our part: the entropic contribution to the free energy of interaction. The authors 
state that the binding is entropically driven, meaning that any measurement of the same is 
1JET mKRK R519A 1JET mKRK R519A CW 
 
1QKA KRK R519A 1QKA KRK R519A CW 
GB 
 
GB 
+17.2 ± 3.2 +12.8 ± 3.0 
 
+23.5 ± 2.4 +9.5 ± 2.5 
     
PB 
 
PB 
+22.3 ± 6.8 +9.3  ± 5.1 
 
+34.0 ± 4.9 +6.5 ± 3.4 
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likely to be flawed unless entropy is also considered. As we have stated before, entropy in the 
context of MMPB(GB)SA calculations can be problematic to include, expensive to estimate 
and ultimately perhaps unnecessary180. The one-trajectory approach to the interaction energy 
calculation assumes no conformational changes between the species when they are alone and 
in a complex, which minimises the impact of entropy. Additionally, methods for calculating 
entropy require extremely converged and equilibrated systems, which are technically 
challenging to produce. This has contributed to a philosophy where the entropic contribution 
is neglected if assumed to be irrelevant, in part because of the assumption that entropy 
changes are small when examining the binding of small ligands, but also because of the 
complication of the techniques involving them. However, depending on the system, it may be 
necessary to include entropy, and it became apparent that the analysis of enthalpy alone was 
not enough for the OppA system. Thus, we have sought to include methods to measure the 
entropic contribution in our investigation of this complex.  
As we have mentioned in our discussion of entropic methods, there are two common 
techniques for calculating the entropy which are supported in the AMBER MD package287. 
The first is the nmode module, which performs an analysis of the protein system to determine 
its normal modes, which, in turn, can be used to determine the vibrational contribution to the 
entropy; the module also uses the rigid rotor harmonic oscillator model to determine 
translational and rotational contributions288. The second is the quasi-harmonic approximation 
method, which is quicker than nmode but also theoretically less rigorous, and based on the 
analysis of MD simulations in which the covariance between atomic coordinates is assumed 
to be harmonic, which can be used to compute thermodynamic properties of the system. Both 
methods can be very expensive to perform, as they require input structures that are as 
minimised as possible on top of computationally demanding calculations. 
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Because of this reason, we were unable to obtain data from nmode calculations: the 
measurement of the entropy requires a finely minimised conformation, usually first 
minimised to a low gradient via conjugate gradient and steepest descent and then ground to 
an even lower gradient via the Newton-Raphson method, upon which the normal mode 
analysis is performed. Although it was possible to obtain such a minimised structure for the 
KXK tripeptide owing to its small size, it proved impossible to do the same for the protein 
and the complex in a sufficiently short amount of time. 
There was more luck to be had in obtaining results with the quasi-harmonic estimations 
of the entropy. In order to obtain a simulation with enough frames to perform the calculation 
on, a 25 ns simulation with snapshots collected every 1 ps was carried for selected systems. 
The rule of thumb is that at least 3N frames are needed for a system with N atoms, which 
with the OppA system means 25,000 frames; the 1 ps gap between frames was chosen so that 
the snapshots were independent enough to have a meaningful analysis. This amounts to a 
somewhat lengthy 25 ns simulation, followed by an equally lengthy calculation of the 
entropy. Four systems were chosen for this analysis: the “baseline” KAK, KRK, not only for 
the anomalous estimation of the energy noted in the previous section, but also for having the 
second-most favourable entropy of binding, KDK, for having the least favourable entropy of 
binding, and KSK, for having a middle value. Additionally, these four tripeptides represent 
four different categories of amino acid: polar, nonpolar, negatively and positively charged. 
These simulations were performed from the crystal structure of KAK (1JET), keeping the 
crystallographic waters in the system and obtaining the other tripeptides by use of the Parasol 
Protocol. The results are collected in the table below and compared with the entropic 
contribution reported in the literature.  
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The bigger the magnitude of the experimental contribution, the most favourable the 
entropy of binding is; conversely, the more negative the entropy change, the more entropy is 
lost upon complexation, making the binding more unfavourable. 
The first thing to 
notice is that the 
computational results 
somewhat correlate 
with the experimental 
ones. KDK has, in both 
cases, the most 
unfavourable entropic 
contribution, and KAK 
shows good entropic 
contribution on both sides, with KRK as more of an outlier. However, analysis of the 
computational entropic results reveals that they are so close in value that the difference is 
statistically meaningless, and thus we cannot know if this supposed correlation underlies true 
agreement between experiment and simulation, or if it is a random coincidence. It should be 
noted that the computational results consist of a single data point for each of the four 
tripeptides, and therefore may lack the validity that arises from repeats. Furthermore, all of 
those conformations had been minimised for only 100 ns, which may or may not be enough 
to reach the well-minimised structure that is necessary for a quasi-harmonic calculation to be 
1JET KAK 1JET mKRK  1JET mKDK 1JET mKSK 
Experimental Entropic Contribution 
61.1 ± 0.9 69.7 ± 8.3 37.7 ± 0.8 50.6 ± 0.6 
  
 
 
Entropic Contribution Calculated through Quasi-Harmonic approximation 
-31.74 -35.48 -38.04 -36.18 
Table 12: Summary of the Quasi-Harmonic estimation of the entropy for selected tripeptides, compared with the 
entropic contribution (TΔS) reported in the literature. Experimental values are reported in kJ/mol, while 
computational ones are in kcal/mol. Computational results are provided without an error bar because of the tool’s 
limitations. 
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Figure 23: Correlation between experimental (x axis) and computational (y axis) 
results. The line is the result of linear regression with R-squared value (0.412) 
highlighted. 
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run properly. In both cases, the simulation was performed in those ways because of technical 
limitations, as obtaining sufficiently converged structures and simulating enough repeats 
would have been unfeasible within our limited timeframe. If there actually is correlation 
between experiment and simulation, repeats and more rigorous minimisation may be able to 
reveal such a relationship; also, performing the same sort of calculation on all other 
tripeptides as well would be a necessary step to determine if there this apparent agreement is 
only because of limited sampling. However, all of these possible studies require extensive 
computational resources and much more time in order to be fully explored, and therefore 
must remain, for now, only in the future work section. 
 
8.6 – Comparison with Previous Investigations 
It has been mentioned that this is not this group’s first study of the OppA system. A 
previous investigation attempted to estimate the difference in binding energy between 
selected pairs of tripeptides284 by using the MULES protocol described above. The study 
found good correlation between experiment and simulation in some cases but poorer 
agreement in others. The results are summarised below. 
 
 
 
 
Table 13: Previously obtained results for the comparison of binding energies between selected pairs of 
mutations. All values are in kcal/mol. 
The study was done in order to test the strengths and limitations of the MULES 
method. Its purpose is to minimise the error derived from comparing different simulations by 
only calculating change in a localised region, but it does not have an established method for 
generating mutants other than the limited PPM technique. For this study, mutant structures 
were obtained by selectively only removing and changing atoms, which means that all 
Mutation ΔΔG (GB) ΔΔG (PB) ΔΔG Experimental 
E2D 1.32 ± 0.9 2.19 ± 1.2 2.19 
Q2N 2.86 ± 0.6 2.96 ± 0.7 0.53 
Y2F -0.17 ± 0.4 -1.05 ± 0.6 -0.95 
R2K 4.39 ± 0.8 5.11 ± 1.1 0.52 
W2H 4.30 ± 0.5 3.00 ± 0.8 0.00 
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mutations had to be between similar enough residues. The Parasol Protocol, on the other 
hand, has no such limitation. 
Five mutations were identified and included in the study: in each case, it was a like-for-
like mutation and there was a range of different effects. Experimentally, mutations could 
generate slightly more favourable states (Y2F, or mutation of the second residue of the 
peptide from a tyrosine to a phenylalanine, so from KYK to KFK), neutral states (W2H, or 
mutation of KWK to KHK), or cause moderately (Q2N, R2K) and strongly (E2D) 
unfavourable changes. Of these mutations, the MULES protocol correctly predicted the 
difference in interaction energy for E2D and Y2F but not for the others; additionally, 
structural studies and studies on the solvent effect were carried out. 
Our aim was to revisit the simulations in which the solvent was excluded, as they were 
the simpler and quicker ones. Because the MULES uses a localised region in which the 
solvent can be more easily kept track of while the Parasol Protocol does no such thing, it was 
deemed that more luck could be had by excluding the effect of solvent. 
For each mutation, the corresponding crystal structure of the native (1JEU for E2D, 
1B5J for Q2N, 1B58 for Y2F, 1QKA for R2K and 1JEV for W2H) was taken from the PDB 
repository and simulated for 10 ns, keeping the crystallographic waters, after which ten runs 
of 1 ns each were used to generate interaction data. Then, mutations were introduced in the 
tripeptide by the Parasol Protocol, and the resulting mutated structures were simulated for ten 
runs of 1 ns each. The results are summarised in  
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Table 14: 
 
Table 14: Difference in interaction energy for five selected mutations. All results in kcal/mol. In the Raw Data 
column, the top value represents the native and the bottom the mutant one, with their difference reported in the 
ΔΔG column. 
 
Perhaps the first thing to notice is the much greater error in our reported data, which is 
not at all unexpected: after all, these are comparisons between fairly independent simulations, 
and the usual caveats of MMPB(GB)SA’s imprecision must be considered. While the data for 
the native and mutant conformations show relatively small error, it inevitably rises when the 
difference is considered; in contrast, MULES has a much lower error because of its way of 
minimising differences between conformations and localising discrepancies to a small region. 
For the purposes of this investigation, therefore, we will only consider the absolute values, 
and then again only to make qualitative comparisons between them, the previously obtained 
results and the experimental values. 
As reported, the studies performed with MULES managed to get good agreement in 
some cases and poorer correlation in others. They correctly predicted, almost quantitatively, 
 Parasol Protocol MULES Experiment 
Mutation GB PB  
 Raw Data ΔΔG Raw Data ΔΔG ΔΔG (GB) ΔΔG (PB) ΔΔG 
E2D 
-83.4 ± 6.5 
+8.7 ± 9.4 
-71.7 ± 8.6 
+11.4 ± 12.3 +1.32 ± 0.9 +2.19 ± 1.2 +2.19 
-74.7 ± 6.7 -60.3 ± 8.8 
Q2N 
-71.4 ± 4.9 
+5.6 ± 6.9 
-73.6 ± 6.8 
+4.0 ± 9.6 +2.86 ± 0.6 +2.96 ± 0.7 +0.53 
-65.8 ± 4.9 -69.6 ± 6.8 
Y2F 
-66.4 ± 5.5 
+1.3 ± 7.9 
-64.3 ± 8.1 
-0.8 ± 11.5 -0.17 ± 0.4 -1.05 ± 0.6 -0.95 
-65.2 ± 5.6 -65.1 ± 8.2 
R2K 
-103.1 ± 6.5 
+6.9 ± 9.1 
-118.1 ± 8.9 
+8.5 ± 12.5 +4.39 ± 0.8 +5.11 ± 1.1 +0.52 
-96.2 ± 6.5 -109.6 ± 8.7 
W2H 
-98.9 ± 5.7 
+12.0 ± 8.4 
-101.6 ± 8.1 
+14.7 ± 11.9 +4.30 ± 0.5 +3.00 ± 0.8 0.00 
-86.8 ± 6.1 -86.9 ± 8.8 
 Parasol Protocol MULES Experiment 
Mutation GB PB  
 Raw Data ΔΔG Raw Data ΔΔG ΔΔG (GB) ΔΔG (PB) ΔΔG 
E2D 
-83.4 ± 6.5 
+8.7 ± 9.4 
-71.7 ± 8.6 
+11.4 ± 12.3 +1.32 ± 0.9 +2.19 ± 1.2 +2.19 
-74.7 ± 6.7 -60.3 ± 8.8 
Q2N 
-71.4 ± 4.9 
+5.6 ± 6.9 
-73.6 ± 6.8 
+4.0 ± 9.6 +2.86 ± 0.6 +2.96 ± 0.7 +0.53 
-65.8 ± 4.9 -69.6 ± 6.8 
Y2F 
-66.4 ± 5.5 
+1.3 ± 7.9 
-64.3 ± 8.1 
-0.8 ± 11.5 -0.17 ± 0.4 -1.05 ± 0.6 -0.95 
-65.2 ± 5.6 -65.1 ± 8.2 
R2K 
-103.1 ± 6.5 
+6.9 ± 9.1 
-118.1 ± 8.9 
+8.5 ± 12.5 +4.39 ± 0.8 +5.11 ± 1.1 +0.52 
-96.2 ± 6.5 -109.6 ± 8.7 
W2H 
-98.9 ± 5.7 
+12.0 ± 8.4 
-101.6 ± 8.1 
+14.7 ± 11.9 +4.30 ± 0.5 +3.00 ± 0.8 0.00 
-86.8 ± 6.1 -86.9 ± 8.8 
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that the E2D mutation would be strongly unfavourable, while the Y2F would be slightly 
favourable. It predicted that the Q2N mutation would be strongly unfavourable, but, while the 
sign is right, it overstated its magnitude, and also estimated that the R2K and W2H mutations 
would be very unfavourable, when in fact they are, respectively, slightly unfavourable and 
neutral. 
Our calculations also show some agreement. If one considers the E2D and Q2N 
mutations, experimentally, the ΔΔG of the former is larger than that of the latter, which is 
also what is observed in our simulations but not in the ones obtained with MULES. The result 
of the Y2F mutation is perhaps of harder interpretation as the correct sign is predicted by PB 
and not by GB, but if we consider the comparison with E2D, the result is perhaps indicative 
that there is a very different sort of interaction between different mutants, which is also what 
is observed in the laboratory. Furthermore, Q2N and R2K have very similar ΔΔG values 
experimentally, and while there the Parasol results do not approach that, the comparison is far 
more favourable than for the results obtained with MULES. On the other hand, both this 
study and the previous one fail to predict the neutrality of the W2H mutation, in each case 
showing a very unfavourable ΔΔG which does not reflect what is reported in the literature. 
The results we have obtained are marred by the very large error bars which make a 
quantitative comparison quite hard and by the omission of the entropic calculation, which, 
however, was not included in the MULES study as well. Also, the MULES study included 
further, more nuanced investigations in which the solvent was closely monitored but which 
were not deemed repeatable with the Parasol Protocol. Despite these deficiencies, the new 
investigation has obtained some preliminary, qualitative agreement with the experimental 
results, in some cases improving upon the previous data or confirming previous observations. 
 
8.7 – Summary 
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In this chapter, we have detailed the many approaches taken in order to replicate the 
experimentally obtained data about the OppA system. On paper, it appeared to be an 
excellent test case, given the abundance of structural and binding results that we could 
compare. However, it has proven to be a hard system to analyse. This was not entirely 
unexpected – a similar conclusion was reached when studies were previously attempted in the 
group on the same system284. Although there had been some localised successes, it was 
challenging to obtain agreement between experiment and simulation, and we have found this 
to still be true. 
That is not to say that our investigation was completely devoid of agreement: for 
example, the binding estimation of poorly interacting tripeptides such as KDK, KPK and 
KGK was generally found to be in line with laboratory results. As noted above, however, 
there was a serious discrepancy with some tripeptides, most prominently how KRK, which 
experimentally had a poor interaction, was found to be instead far better than KAK in 
computational simulations. This was shown to be the case whether the Parasol Protocol or 
another established method such as Alanine Scanning Mutagenesis was employed, which 
perhaps underlies a more serious intrinsic problem about this system rather than an error with 
the tool we developed. 
The calculation of the entropic contribution to the interaction energy, which was 
considered fundamental in the literature, was an additional challenge in this investigation. 
Previous studies within this group had neglected it and it is a somewhat uncommon approach 
in the field, given that it can be computationally very demanding to reach useful results. 
Indeed, it proved to be too much for us to simulate in a sufficiently short amount of time, and, 
when we could obtain data, it was unsatisfactory and in need of further testing in order to be 
validated. We have laid the groundwork for future investigations, but it will be necessary to 
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return again with greater resources if the entropic contribution for this system is to be 
properly determined. 
An attempt to replicate previously obtained results was also carried, using the Parasol 
Protocol where the MULES method had been employed. The investigation managed to 
predict the relationship between some mutations, in some cases even improving on what had 
been reported before. Although the agreement is largely qualitative and there are some flaws 
in the sampling that need more work (poor accuracy, lack of entropic contribution), it can be 
seen as a starting point for future investigations and an encouraging result in what has been 
an otherwise challenging system.  
To what, then, can we ascribe the difficulties we have encountered when investigating 
this system? Perhaps the most important reason is the lack of entropic calculations, which, 
once again, were deemed by the original authors to be driving the binding; another reason, 
which was also proposed in our previous studies, is that our methods are inadequate to 
properly describe charged species, and changes involving them are still poorly understood 
and replicated by computational methods. This could perhaps explain the discrepancy 
between the observed and simulated behaviours of KRK, KKK, and KEK, although it does 
not explain why nonpolar species also show minimal correlation with the experimental 
results. Additionally, while the OppA complex is by no means a large system to analyse, it is 
certainly bigger than our previous successful case, the stapled peptide system. In that 
situation, mutations involved the creation of long aliphatic chains and the interaction was 
mostly driven by the binding and burial of a large, hydrophobic residue, as opposed to the 
less straightforward interaction that there may be between the tripeptide and the protein in 
OppA. The system appears to be more complicated, with the binding determined by multiple 
factors, only a fraction of which was looked at by our studies. 
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This is the second time we investigate OppA, using different approaches and improved 
techniques. We have in some cases managed to predict laboratory results, but a satisfactory 
agreement with experiment remains, for now, mostly elusive. Future work can be carried with 
more resources, examining more closely the crucial entropic contribution and attempting to 
elucidate the exact nature of the relationship between the tripeptide and the protein.  
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Chapter 9: Test Case 3 — Antibody System 
9.1 – Principles and Background of Antibodies 
In recent years, antibodies have seen renewed interest and research in the field of drug 
discovery and development289,290. Antibodies are, of course, proteins that are used by the 
immune system of humans and many other species in order to combat disease and 
infections291. When a foreign agent or molecule, known as an antigen, penetrates the body, 
antibodies can bind to it, either impeding the antigen’s function or directing other self-
defence mechanisms 
of the body to deal 
with the threat, and 
thus they play an 
extremely important 
role when combating 
disease and infection. 
Antibodies have 
a constant region, 
which is largely the 
same for all antibodies 
produced by an organism, and a hypervariable region placed at the tips of its characteristic Y-
shape: through a 
combination of 
polymorphic gene 
expression and error-
prone DNA transcription, antibodies with randomly mutated variable regions can be 
produced292. By having a vast range of antibodies with different variable region sequences, 
Heavy Chain 
Light Chain 
Antigen 
Fc 
Fab 
Figure 24:  A schematic representation of a typical antibody. In its full form, it is 
composed of two identical heavy chains and two identical light chains, arranged in 
a Y shape. The Fc (fragment, crystallisable) region interacts mediates 
physiological effects with the rest of the body, while the Fab (fragment, antigen-
binding) region interacts with foreign matter. The blue part is the constant region, 
identical in every individual and the yellow part is the hypervariable region, 
sometimes called Fv (fragment, variable) where the CDRs (complementarity 
determining regions) are located. 
142 
 
known as paratopes, the body maximises the chance that an antibody can match with a 
feature of an antigen, known as an epitope. The binding of the paratope to the epitope is the 
basis of antibody-antigen recognition, and it is important that this interaction is as specific as 
possible. Thanks to the huge number of antibodies, each with a different paratope, it is 
generally possible to have high specificity, with an antibody that recognises an antigen and 
no other. 
This specificity is the most attractive feature of antibodies for therapeutic purposes103. 
To have a molecule that can selectively bind with great affinity to its target allows many 
strategies, ranging from the antibody interacting directly with it, to the stimulation of the 
immune system in the patient, to the use of radionuclides or cytotoxic entities293. In fact, 
antibodies represent one of the most viable ways to achieve the “magic bullet” approach 
envisioned in the early 20th century294. To have a drug that can bind to its target cleanly, 
quickly, selectively, with high affinity and little to no collateral effects is the overarching goal 
of medicine, and antibodies can, theoretically, promise that. 
However, there are significant issues with the use of antibodies as therapeutic agents. 
Apart from the familiar problems involved in proteins as drugs, such as poor delivery, 
biostability and cell permeability, extensive engineering might be required in order to have 
antibodies that are not rejected as foreign by the body, leading to complicated procedures to 
generate chimeric antibodies295. These procedures also have to include the generation of 
mutant paratopes through the use of the experimental mutagenesis techniques described 
above296, as well as several steps of expression, purification and selection in order to have the 
final, utilisable product. The expertise involved and the length of these protocols all 
contribute to make antibodies very expensive therapeutic agents to work with297. Even when 
starting from a known interaction, several iterations of the process may be needed in order to 
obtain an antibody that possesses the appropriate characteristics. Inevitably, some mutants 
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that do not improve the properties and do not further the development of the drug will be 
generated and must also be taken into account when considering how costly and time-
consuming the process can be. 
It is in this regard that we believe that computational studies can be the most helpful in 
the development of antibodies. A quick, cheap method can be employed to generate 
preliminary results that can give a direction to the investigation. The lengthy process of 
maturation and purification of the antibodies can be done on sequences that have been pre-
determined to have the desired properties, avoiding those that do not. It would not replace 
testing, but complement it, allowing to access a greater volume of data than it would be 
available with experiment alone, with an increased ability to make rational, reasoned choices 
in protein design. 
In this test case, then, we analysed an existing antibody system that had been supplied 
by our funders. Supplied with a crystal structure and interaction data detailing the binding 
strength of several mutant sequences, we sought to replicate these experimental findings 
computationally, in the same way that we have done for the other test cases. 
 
9.2 – Antibody System: 9DPJS 
The analysed system, which was obtained from our sponsoring company, MedImmune, 
is much more challenging to analyse computationally than the relatively straightforward 
protein and peptide systems that were investigated so far. The target of this antibody is a 
nerve growth factor (NGF) dimer sandwiched between two antibody fragment antigen-
binding (Fab) regions, one on either side. This is shown in Figure 25. Even though only a 
portion of the total antibodies is represented in the crystal structure, the fact that there are two 
antibodies interacting at the same time means that the overall size of the system is much 
larger than other previously discussed test cases. This consequently means that it is quite 
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expensive and time-consuming to simulate this complex, and the generation of data can be 
slow and inefficient. Furthermore, having two antibody chains interacting at the same time 
with the same protein between them leaves open the possibility of symmetry and allostery 
effects, which could potentially make this interaction hard to analyse. In an experimental 
setting, as it is only one sequence that is being tested in an assay, both antibodies on either 
side would have the same variable region, which must be accounted for when attempting to 
replicate the system computationally: having one side different from the other might give 
insight on the interaction, but it would not be easy to reproduce in the laboratory. Given the 
complexity of the system and the many variables involved, many different conditions had to 
be tested in order to obtain satisfactory results; the studies were also hindered by the 
relatively long time required by each simulation, and overall this system was far more 
challenging than other test cases. Although not all the data obtained is unambiguous and 
correlates well with experiment, our understanding of how to handle these problematic 
Figure 25: The 9DPJS system, seen from the front (left), the side (middle) and in a stylised manner (right). 
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systems has deepened. Additionally, several improvements to the Parasol Protocol had to be 
implemented, which have expanded its functionality.  
Because of confidentiality issues, we are restricted from publishing the full set of data 
that was provided to us. We can, however, describe qualitatively the included results. A 
crystal structure was sent to us corresponding to the LOT3.36 conformation, which is a 
mutant derived from the parent LOT3. Interaction data between the NGF dimer and several 
LOT3 variants (the parent, LOT3.1, LOT3.2, all the way to LOT3.36) were also sent. IC50 
values were very similar between the variants but all very distinguishable from the parent. 
LOT3.36 had the best interaction, which is why it was used as the basis for further studies. 
Our aim was to replicate that data. 
In the next few sections, the process of the computational investigation will be outlined. 
 
9.3 – Computational Analysis of 9DPJS 
9.3.1 – Simulation and Mutation of the Crystal Structure 
The biggest challenge when simulating the 9DPJS system was to produce a consistent 
baseline that could be used as a starting point for further mutations and investigations. 
The crystal structure that was selected as a starting point was that of the LOT3.36 
mutant, which had been the one with the strongest measured interaction. Even though 
LOT3.36 is technically the mutant, we considered it to be the “native” because it was the 
crystal structure we were starting from. Its parent sequence, LOT3, was considered the 
“mutant”. LOT3 had a weaker interaction by a magnitude that should allow even the 
imprecise MMPB(GB)SA to detect it, whereas other mutants that had been tested 
experimentally were much closer in energy level to LOT3.36, and therefore it would have 
been harder to discriminate between them. Additionally, the difference in primary structure 
between LOT3.36 and LOT3 was confined to a seven amino acid change in the 
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complementarity determining region 3 (CDR3) of the heavy chain of the antibody, seven 
sequential residues in a noticeable loop jutting against the NGF dimer in the middle. Because 
it was believed that it would be possible to observe the difference in free energy change and 
because the mutations were few in number and localised to a small portion of the system, it 
seemed a relatively uncomplicated starting point for the investigation. By mutating that seven 
amino acid sequence from LOT3.36 to LOT3 seen in Figure 26, therefore, the expected result 
was to see a less favourable interaction.  
However, it was problematic to establish a baseline from the crystal structure of 
LOT3.36. In order to properly compare the strength of the interaction before and after the 
mutation and determine how it had been affected by the change, there needed to be a baseline 
that could be relied on to be constant and representative of the crystal structure. Because each 
system had two antibodies, one on either side of the NGF dimer, for each simulation four sets 
LOT3.36  
LOT3  
ALA  LEU  ASN  PRO  SER  LEU  THR  —
  
—
  
—
  
—
  
—
  
—
  
TYR TYR
 
  
ALA  GLY  GLY  ASP  HIS  —
  
—
  
—
  
—
  
—
  
—
  
Figure 26: The comparison between LOT3.36 and LOT3, showing the seven amino acid loop that differentiates 
between them in text as well as in the system of LOT3.36 (left) and LOT3 (right). 
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of data were collected: the free energy of the first antibody (AB1) measured with the GB 
method and then measured with the PB method, and the same for the second antibody (AB2). 
This was done over ten 1 ns runs following minimisation (500 steps of steepest descent and 
500 of conjugate gradient), then a 250 ps temperature equilibration and a 250 ps pressure 
equilibration. Since AB1 and AB2 had been exactly superimposable in the crystal structure, it 
was expected that they would have the same interaction, but this was not found to be the case. 
In fact, when simulating the crystal structure for ten runs of 1 ns each, there was a noticeable 
difference in free energy between AB1 and AB2, with AB1 having a more favourable 
interaction than the other side. 
NATIVE 
AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) 
-86.8 ± 8.7 -78.4 ± 8.4 
AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) 
-94.8 ± 9.5 -88.0 ± 9.8 
 
Table 15: Results for the 9DPJS system, simulated from the native crystal structure, in which both sides are 
LOT3.36, measured in kcalmol-1. These data points are averaged over ten runs of 1 ns each. In the GB and PB 
calculation, as per the thermodynamic cycle above, the complex was taken to be the whole system (sans waters 
and counterions, of course); for AB1, AB1 was the ligand and AB2+D was the receptor, and the opposite for AB2. 
For ease of reference, in this and future table all data referring to the same systems has been coloured: AB1 
measured with GB (pink), AB1 measured with PB (grey), AB2 measured with GB (green) and AB2 measured with 
GB (orange). 
If the two had had the same strength of binding, one could have been used as a control 
by mutating only one side at the time, and comparing how the mutation affects the 
interaction. Regardless, the comparison of the interaction of the unmutated antibody before 
and after the mutation of its counterpart can serve as an internal benchmark to gauge the 
dynamics of the system. With this in mind, AB1 was mutated from LOT3.36 to LOT3, while 
AB2 was kept constant. The results are shown in the table below. 
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AB1 mutated (but not AB2) 
AB1 LOT3 (GB) AB2 LOT3.36 (GB) 
-119.5 ± 8.0 -119.6 ± 9.7 
AB1 LOT3 (PB) AB2 LOT3.36 (PB) 
-107.8 ± 9.1 -119.5 ± 10.1 
 
Table 16: Results for the 9DPJS system, simulated after mutating AB1 to LOT3 but keeping AB2 constant. All 
values in kcalmol-1. 
As we have stated before, that mutation was expected to produce a much weaker 
interaction for AB1, whereas in the computational simulations the opposite behaviour was 
observed. What was particularly puzzling was that AB2, which had not been mutated, also 
showed a significantly stronger interaction. 
 
AB2 mutated (but not AB1) 
AB1 LOT3.36 (GB) AB2 LOT3 (GB) 
-120.7 ± 8.8 -130.4 ± 8.4 
AB1 LOT3.36 (PB) AB2 LOT3 (PB) 
-117.2 ± 9.9 -128.5 ± 9.9 
 
Table 17: Results for the 9DPJS system, simulated after mutating AB2 to LOT3 but keeping AB1 constant. All 
values in kcalmol-1. 
A similar situation happened when AB2 was mutated while AB1 was kept constant, 
with AB2 showing very strong binding when compared to the native system. Again, AB1 
also displayed a stronger interaction despite remaining the same as it is in the crystal 
structure. Coupled with the fact that the free energy change is massive (a difference of several 
dozens of kcalmol-1 as is shown here indicates a difference of dozens of orders of magnitude 
in the experimental IC50), these results indicated that there was some kind of error or bias in 
the investigation that did not allow for a straightforward comparison between mutated and 
unmutated structures. 
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MUTATED 
AB1 LOT3 (GB) AB2 LOT3 (GB) 
-124.2 ± 9.4 -131.4 ± 10.5 
AB1 LOT3 (PB) AB2 LOT3 (PB) 
-124.3 ± 10.9 -131.4 ± 12.0 
 
Table 18: Results for the 9DPJS system, simulated after mutating first AB1 to LOT3, and then AB2 to LOT3. All 
values in kcalmol-1. 
When both sides were mutated from LOT3.36 to LOT3, a decrease in the strength of 
binding was observed experimentally, but computationally a much stronger interaction was 
measured, as well as a reversal of which side has the stronger interaction. Comparison with 
the native conformation was marred by the huge, unexpected swing, and deemed 
fundamentally unreliable. 
One possibility was that the issue was one of sampling and that the energy was simply 
tending downwards as a normal process of equilibration; if all the measurements of the 
interaction had been carried before the system had reached the global minimum, this could 
have been an explanation for the observed behaviour. It was decided to repeat the same 
mutations back and forth in an effort to reach a more equilibrated state. 
NATIVE MUTANT (FORWARDS) NATIVE (BACKWARDS) 
MUTANT (FORWARDS 
AGAIN) 
NATIVE (BACKWARDS 
AGAIN) 
AB1 LOT3.36 
(GB) 
AB2 LOT3.36 
(GB) 
AB1 LOT3 
(GB) 
AB2 LOT3.36 
(GB) 
AB1 LOT3.36 
(GB) 
AB2 LOT3.36 
(GB) 
AB1 LOT3 
(GB) 
AB2 LOT3.36 
(GB) 
AB1 LOT3.36 
(GB) 
AB2 LOT3.36 
(GB) 
-86.8 ± 8.7 -78.4 ± 8.4 -119.5 ± 8.0 -107.8 ± 9.1 -122.3 ± 8.7 -115.2 ± 15.7 -127.7 ± 9.5 -135.6 ± 9.9 -129.8 ± 9.5 -113.4 ± 8.5 
AB1 LOT3.36 
(PB) 
AB2 LOT3.36 
(PB) 
AB1 LOT3 
(PB) 
AB2 LOT3.36 
(PB) 
AB1 LOT3.36 
(PB) 
AB2 LOT3.36 
(PB) 
AB1 LOT3 
(PB) 
AB2 LOT3.36 
(PB) 
AB1 LOT3.36 
(PB) 
AB2 LOT3.36 
(PB) 
-94.8 ± 9.5 -88.0 ± 9.8 -119.6 ± 9.7 -119.5 ± 10.1 -122.2 ± 10.6 -127.6 ± 15.3 -134.1 ± 10.3 -144.1 ± 11.2 -139.2 ± 10.8 -123.1 ± 9.0 
 
Table 19: Results for the 9DPJS system, simulated after mutating AB1 to LOT3, then back to LOT3.36, and then 
forwards and backwards again. All values in kcalmol-1. 
In this set of simulations, AB1 was mutated from the native LOT3.36 to the LOT3, then 
back again to LOT3.36 and forward again to LOT3, all the while keeping AB2 constant. At 
every measurement of the free energy, there seemed to be little to no correlation with the 
transformation that had just occurred, and even the energy of the AB2 interaction was 
fluctuating wildly despite its structure being untouched throughout, as is shown in Figure 27. 
This indicated a deeper error which would require more simulations in order to be solved. 
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9.3.2 – Variation of Temperature and Box Size 
In order to increase the sampling, the system was simulated for 100 ns at 300 K, then 
for 10 ns at 400 K in one instance and 500 K in a second simulation before both were 
simulated again at 300 K, after which they were mutated using the Parasol Protocol. In a 
conceptual analogue to simulated annealing, the greater temperature was used as a means to 
escape a potential local minimum and allow the system to equilibrate. Both of these measures 
proved to be insufficient, and mutating from LOT3.36 to LOT3 resulted in a much more 
favourable interaction. 
MUTANT (AFTER 400 K) MUTANT (AFTER 500 K) 
AB1 LOT3 (GB) AB2 LOT3.36 (GB) AB1 LOT3 (GB) AB2 LOT3.36 (GB) 
-132.3 ± 8.9 -117.7 ± 9.4 -134.0 ± 8.3 -119.3 ± 8.6 
AB1 LOT3 (PB) AB2 LOT3.36 (PB) AB1 LOT3 (PB) AB2 LOT3.36 (PB) 
-125.6 ± 11.8 -126.1 ± 10.1 -134.4 ± 9.6 -117.4 ± 10.0 
 
Table 20: Results for the 9DPJS system, simulated after mutating AB1 to LOT3 but keeping AB2 constant, after 
simulating for a longer time and varying the temperature. All values in kcalmol-1. 
After these conflicting and inconclusive simulations, it was clear that there needed to be 
a more thorough analysis of the system. One potential issue was that of the solvent shell, 
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Figure 27: The time dependence of the free energy across different systems. Starting from 
the native crystal structure (first column), AB1 was mutated from LOT3.36 to LOT3 
(second column) and then back to the native conformation (third column). That was once 
again mutated (fourth column) and returned to native (fifth column). At each step, the free 
energy of binding of either antibody, measured with GB or PB varied wildly. All units in 
kcalmol-1. The colours of the lines are the same as in the tables.  
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which had been unchanged in size throughout all of the simulations that had been done with 
the Parasol Protocol, even in other systems. Uniformly, the various complexes had been 
solvated so that any one point was not more than 8 Å away from the edge of the box, which 
had been an appropriate number for the small and mid-sized systems analysed so far. 9DPJS, 
however, was much larger, which had not been taken this into account when adding a solvent 
shell. The simulation of the crystal structure over 200 ns was carried with a solvent shell 
twice the size, 16 Å, as well with a square box instead of a truncated octahedral one. 
NATIVE (16 Å OCTAHEDRAL) NATIVE (16 Å SQUARE) 
AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) 
-50.1 ± 7.9 -60.5 ± 9.4 -73.4 ± 9.4 -85.2 ± 10.8 
AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) 
-73.5 ± 8.4 -77.9 ± 8.8 -82.6 ± 10.5 -92.5 ± 11.6 
 
Table 21: Results for the 9DPJS system, using the native, untouched crystal structure. The octahedral results are 
averaged over a single 200 ns simulation (left), whereas the square is averaged over 10 runs of 1 ns each (right). 
All values in kcalmol-1. 
When using a larger solvent box, the pattern of interaction between the two was 
reversed: AB2 now had a stronger interaction than AB1, the opposite of which had instead 
been observed fairly consistently throughout the previous simulations. It also seemed to 
indicate a strong effect of the solvent on the free energy change. 
NATIVE (16 Å OCTAHEDRAL) MUTATED (16 Å) 
AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) AB1 LOT3 (GB) AB2 LOT3.36 (GB) 
-50.1 ± 7.9 -60.5 ± 9.4 -111.9 ± 9.5 -107.9 ± 8.5 
AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) AB1 LOT3 (PB) AB2 LOT3.36 (PB) 
-73.5 ± 8.4 -77.9 ± 8.8 -107.0 ± 11.0 -112.6 ± 10.4 
 
Table 22: Results for the 9DPJS system, simulated after mutating AB1 to LOT3 but keeping AB2 constant, and 
using a 16 Å solvent shell. All values in kcalmol-1. 
However, the same behaviour previously observed was seen upon mutating AB1 to 
LOT3 (which had also been performed with a larger solvent shell throughout the application 
of the Parasol Protocol). Once again, the energy had dropped for the entire system, even for 
the antibody that had remained constant, in a way that made comparison with the native 
conformation highly questionable. Our priority at this juncture was to determine whether 
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these unreliable results were due to a technical error, due to the application of the Parasol 
Protocol or an intrinsic problem of the system in question. 
 
9.3.3 – Variation of Mutations 
Several different systems were tested in order to ascertain a cause of error. In an 
attempt to eliminate potential sources of discrepancy, smaller mutations were carried, and 
other variables were more closely examined. Firstly, a single residue on the CDR3 loop was 
mutated; in a second test case, an identical mutation was carried on an amino acid far away 
from the interface, unlikely to contribute to the interaction energy. In both cases, the mutation 
was from a leucine to a valine, carried with the Parasol Protocol, and both sites were on AB1, 
with AB2 remaining untouched. 
NATIVE (16 Å OCTAHEDRAL) L4V (Parasol) L105V (Parasol) 
AB1 (GB) AB2 (GB) AB1 (GB) AB2 (GB) AB1 (GB) AB2 (GB) 
-50.1 ± 7.9 -60.5 ± 9.4 -80.6 ± 8.3 -108.2 ± 7.9 -66.0 ± 9.3 -107.4 ± 7.7 
AB1 (PB) AB2 (PB) AB1 (PB) AB2 (PB) AB1 (PB) AB2 (PB) 
-73.5 ± 8.4 -77.9 ± 8.8 -87.3 ± 9.1 -112.9 ± 9.1 -80.4 ± 10.3 -113.5 ± 9.4 
 
Table 23: Results for the 9DPJS system, simulated after mutating 4-leucine to valine and 105-leucine to valine in 
AB1, while keeping AB2 constant, and using a 16 Å solvent shell. All values in kcalmol-1. 
As it can be seen, in both cases, after a single application of the Parasol Protocol, the 
strength of the interaction greatly increased when compared to the simulation performed on 
the native structure (as seen in Table 21, left side) even in the case of AB2, which had 
remained unmutated, and even in the case of the mutation happening in a location distant 
from the active site. In order to determine whether the Parasol Protocol was inserting some 
artefact in the simulation, it was decided to use a different mutagenesis tool to carry out the 
same transformations. The PDB file was manipulated to remove the extraneous methyl 
groups and used LEaP to insert an extra one to go from leucine to valine. 
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Once more, the strength of the interaction had increased in both cases, and in a way that 
is inconsistent with the previously observed results. This time, however, the Parasol Protocol 
had not been applied, which could therefore not be the cause of this behaviour. There 
remained only one variable which had not been considered: the solvent shell and the ions. 
 
9.3.4 – Variation of Solvent Shell and Ions 
Throughout these simulations, all water molecules and counterions had been removed 
after each simulation and added again by re-solvating at every step of the way. Part of it is 
because it is not a common practice to load an already solvated structure in LEaP, and we had 
not considered the ramifications of continuously changing the solvent shell. Another reason is 
that the system with the 16 Å solvent shell that had been used for the previous simulations 
exceeded 100,000 atoms, which is a hard limit for atoms in a PDB to be loaded in LEaP: the 
six digit number means that there are numerical overflow errors for a program expecting 
99,999 atoms at most, and such systems could not be loaded while fully solvated. This meant 
that in order to have further manipulations with those systems, they had to be desolvated prior 
to being added in LEaP and resolvated, which led to wildly fluctuating numbers of waters in 
the system. As the solvation shell depends on the shape of the protein, even modest 
conformational changes and simple dynamic motions in a complex so large meant that the 
number of molecules of water that were needed to fully solvate it could change in the 
thousands between a system and the other. The systems that we were attempting to compare 
NATIVE (16 Å OCTAHEDRAL) L4V (PDB Manipulation) L105V (PDB Manipulation) 
AB1 (GB) AB2 (GB) AB1 (GB) AB2 (GB) AB1 (GB) AB2 (GB) 
-50.1 ± 7.9 -60.5 ± 9.4 -64.6 ± 6.8 -88.1 ± 7.9 -64.2 ± 6.5 -92.2 ± 8.3 
AB1 (PB) AB2 (PB) AB1 (PB) AB2 (PB) AB1 (PB) AB2 (PB) 
-73.5 ± 8.4 -77.9 ± 8.8 -82.5 ± 7.7 -96.6 ± 9.4 -79.3 ± 8.5 -98.6 ± 9.5 
Table 24: Results for the 9DPJS system, simulated after manipulating the PDB file to change the 4-leucine to a 
valine and the 105-leucine to a valine in AB1, while keeping AB2 constant, and using a 16 Å solvent shell. All 
values in kcalmol-1. 
 
154 
 
in the previous case could differ by tens of thousands of atoms, which might have had an 
impact on the free energy of the interaction. 
In order to be certain of the effect of the solvent shell on the free energy change of the 
9DPJS system, more simulations were performed. The final structure of the 16 Å box 
simulation was taken as the starting point for further investigations. In a first test case, the 
solvent shell and the counterions were completely stripped from the system, and then a new 
solvent shell and ions were added; in the second, only the water molecules were removed and 
the counterions were kept; in the third, water and ions were removed, but only the solvent 
was added. No mutations were introduced at all in any of these simulations. 
 
 
Table 25: Results for the 9DPJS system, simulating an untouched structure while changing the solvent shell 
around it. The ions were also analysed in these simulations. All values in kcalmol-1. 
As it can be seen, in every case a new solvent shell was added to the system and the 
energy of the interaction dropped noticeably, which would appear to indicate a much stronger 
interaction even though nothing had been changed in the protein itself. Furthermore, the same 
results were obtained whether the ions were changed or kept constant or not even added at 
all. This led us to believe that, to have a baseline on which further manipulations could be 
introduced and have reasonable certainty that they alone would be responsible for any 
changes in the free energy, the solvent shell around the system needed to be kept the same for 
any mutation. 
 
 
 
NATIVE (16 Å OCTAHEDRAL) NEW SOLVENT, NEW IONS NEW SOLVENT, SAME IONS NEW SOLVENT, NO IONS 
AB1 (GB) AB2 (GB) AB1 (GB) AB2 (GB) AB1 (GB) AB2 (GB) AB1 (GB) AB2 (GB) 
-50.1 ± 7.9 -60.5 ± 9.4 -66.5 ± 7.5 -89.1 ± 7.4 -64.2 ± 7.1 -81.7 ± 8.1 -62.1 ± 6.8 -84.2 ± 8.0 
AB1 (PB) AB2 (PB) AB1 (PB) AB2 (PB) AB1 (PB) AB2 (PB) AB1 (PB) AB2 (PB) 
-73.5 ± 8.4 -77.9 ± 8.8 -80.8 ± 8.7 -99.1 ± 8.8 -78.1 ± 8.6 -92.3 ± 8.8 -78.4 ± 8.6 -93.8 ± 8.2 
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9.3.5 – Simulations with a Constant Solvent Shell 
Based on this new find, a new simulation was set up, returning to an 8 Å octahedral 
box, even though the larger box is probably required to fully solvate the system: 8 Å was 
necessary to have a solvent shell and also remain under the 100,000 atom mark, so that the 
system could be loaded in LEaP again. This system was simulated for 50 ns, with the free 
energy change averaged over this length of time. 
NATIVE 
AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) 
-55.7 ± 8.0 -46.8 ± 9.4 
AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) 
-73.6 ± 9.5 -66.2 ± 11.1 
 
Table 26: Results for the 9DPJS system, simulating the native structure for 50 ns and using an 8 Å solvent shell. 
All values in kcalmol-1. 
 
That structure was then manipulated using the Parasol Protocol, mutating 4-leucine and 
105-leucine to valine while taking care of keeping the solvent shell around constant. 
L4V L105V 
AB1 (GB) AB2 (GB) AB1 (GB) AB2 (GB) 
-55.6 ± 6.9 -53.9 ± 6.6 -55.4 ± 6.2 -53.9 ± 7.5 
AB1 (PB) AB2 (PB) AB1 (PB) AB2 (PB) 
-75.5 ± 8.0 -72.0 ± 8.5 -75.0 ± 7.6 -70.7 ± 9.0 
 
Table 27: Results for the 9DPJS system, after mutating 4-leucine and 105-leucine respectively to valine with the 
Parasol Protocol while keeping the solvent shell around the complex the same as in the original starting point. All 
values in kcalmol-1. 
As it can be seen from the tables above, the results are far more comparable between 
each other, being quite close especially regarding AB1. There is some discrepancy in AB2, 
but this is not as large as it was when the solvent shell was constantly being changed. This 
difference may be due to the difference in sampling, as the results for the native were 
obtained as the average over one 50 ns run, whereas the other data is the average of ten 1 ns 
runs. Despite this, these results support the observation that the solvent shell can be the 
source of a fluctuation of the free energy of substantial magnitude, and that changing the 
solvation shell of such a large system can make comparison nearly impossible. 
156 
 
9.3.6 – Mutations with a Constant Solvent Shell 
Thanks to the efforts described in the previous section, it had been determined that the 
solvent shell remaining constant was likely a necessary requirement to properly assess the 
difference between mutated and unmutated structures. Therefore, the transformation of AB1 
and AB2 from LOT3.36 to LOT3 was carried again with this consideration. Using the same 
structure that is reported in Table 26 as a starting point, the Parasol Protocol was employed to 
mutate the seven relevant residues. 
NATIVE AB1 MUTATION (NOT AB2) 
AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) AB1 LOT3 (GB) AB2 LOT3.36 (GB) 
-55.7 ± 8.0 -46.8 ± 9.4 -45.4 ± 5.8 -54.2 ± 6.9 
AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) AB1 LOT3 (PB) AB2 LOT3.36 (PB) 
-73.6 ± 9.5 -66.2 ± 11.1 -68.2 ± 7.8 -73.1 ± 8.8 
 
Table 28: Results for the 9DPJS system, simulated after mutating AB1 to LOT3 but keeping AB2 constant, 
compared to the native result. The solvent shell was kept constant throughout the entire process. All values in 
kcalmol-1. 
In this simulation, AB1 was mutated while AB2 was kept constant. As it can be seen, 
AB1 showed a less favourable interaction upon mutation to LOT3, which is line with 
experimental observations. AB2 showed a more favourable interaction on the other hand, 
which is harder to explain as it was not manipulated. The resulting system was then used as a 
starting point for more investigations: in one case, AB2 was also mutated to LOT3, while in 
another AB1 was mutated back to LOT3.36. 
BACKWARDS TO NATIVE AB1 AND AB2 MUTATED 
AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) AB1 LOT3 (GB) AB2 LOT3 (GB) 
-39.9 ± 5.8 -44.0 ± 6.4 -47.1 ± 5.6 -42.9 ± 6.3 
AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) AB1 LOT3 (PB) AB2 LOT3 (PB) 
-61.5 ± 7.3 -65.0 ± 9.1 -69.6 ± 8.1 -64.3 ± 8.5 
 
Table 29: Results for the 9DPJS system, using the system with AB1 mutated to LOT3 as a starting point. On the 
left, AB1 was mutated back to LOT3.36; on the right, AB2 was also mutated to LOT3. The solvent shell was kept 
constant throughout the entire process. All values in kcalmol-1. 
When regenerating the native structure after two successive mutations, the expectation 
would have been to see values similar to the ones observed in the initial measurements; but, 
as it can be seen, they have changed rather noticeably for AB1 (although AB2 has a strength 
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of binding comparable to the one in the native complex). When both sides are mutated to 
LOT3, the expected behaviour can be observed: both have worse interaction compared to the 
native, although the gap is larger for AB1 than AB2. 
One factor that may have been neglected during these studies and that may be of great 
importance has been that of symmetry effects. Mutations from LOT3.36 to LOT3 and vice 
versa have been performed residue by residue, and on one side at a time. It is possible that 
passing through intermediates, however briefly, may introduce unwanted bias in the 
measurements, especially in the case of one side being mutated while the other is not, which 
is experimentally unverifiable. These issues were partially addressed with a modification of 
the Parasol Protocol that allowed it to perform simultaneous mutations on different residues, 
provided that it is the same type of mutation (for example, mutating two leucines to tyrosine, 
at the same time). By changing both AB1 and AB2 simultaneously, it could be possible to 
avoid allosteric effects that might have occurred by having one side that is mutated and one 
that is not. 
In a manner similar to the OppA study, the 9DPJS system was simulated from the 
crystal structure for 150 ns to allow it to properly equilibrate, monitoring its parameters to 
ensure that convergence has been achieved. An 8 Å box is used, again, to remain underneath 
the 100,000 atom mark. Then, the final structure is simulated for ten runs of 1 ns each, and 
the free energy averaged over those. 
NATIVE 
AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) 
-64.7 ± 5.5 -58.3 ± 6.1 
AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) 
-85.0 ± 7.2 -71.2 ± 8.1 
 
Table 30: Results for the 9DPJS system, simulating the native crystal structure. 
The results shown here are in line with previously reported data: with this solvent shell 
size, AB1 has a more favourable interaction than AB2. Then, keeping the same solvent shell 
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as the previous simulations, both sides were manipulated at the same time, mutating the seven 
residues on the CDR3 loop to go from LOT3.36 to LOT3. 
MUTATED 
AB1 LOT3 (GB) AB2 LOT3 (GB) 
-61.4 ± 6.2 -40.1 ± 6.1 
AB1 LOT3 (PB) AB2 LOT3 (PB) 
-80.5 ± 8.0 -60.1 ± 8.1 
 
Table 31: Results for the 9DPJS system, after mutating both sides to LOT3. 
Upon mutation, the energy of binding changes in a way that means that the interaction 
is now less strong, which agrees with the experimentally-obtained data. The change is much 
more noticeable for AB2 than for AB1, but we felt it was a step in the right direction. In order 
to further validate these findings, the system was mutated back to the original state, changing 
the LOT3 antibodies to LOT3.36. 
NATIVE (BACKWARDS) 
AB1 LOT3.36 (GB) AB2 LOT3.36 (GB) 
-60.5 ± 6.2 -36.2 ± 6.7 
AB1 LOT3.36 (PB) AB2 LOT3.36 (PB) 
-80.3 ± 8.2 -58.8 ± 7.2 
 
Table 32: Results for the 9DPJS system, mutating the mutant reported in Table 31 back to the native 
conformation. All values in kcalmol-1. 
The resulting interaction energy is however much more comparable in level to the 
mutant LOT3 rather than the native LOT3.36 with which it shares a sequence; perhaps bias 
had been introduced by the Parasol Protocol after all. This casts a shadow upon our previous 
findings: what we had believed was the effect of the mutations we had introduced may 
perhaps be due to other factors which are yet unidentified. The only thing that is clear at this 
point is that further investigations are needed to truly replicate experimental observations.  
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AB1 GB AB2 GB AB1 PB AB2 PB 
(1) Native -86.8 ± 8.7 -78.4 ± 8.4 -94.8 ± 9.5 -88.0 ± 9.8 
(2) Mutate only AB1 from (1) -119.5 ± 8.0 -107.8 ± 9.1 -119.6 ± 9.7 -119.5 ± 10.1 
(3) Mutate only AB2 from (1) -120.7 ± 8.8 -130.4 ± 8.4 -117.2 ± 9.9 -128.5 ± 9.9 
(4) Mutate both from (2) -124.2 ± 9.4 -131.4 ± 10.5 -124.3 ± 10.9 -131.4 ± 12.0 
(5) Return to native from (2) -122.3 ± 8.7 -115.2 ± 15.7 -122.2 ± 10.6 -127.6 ± 15.3 
(6) Mutate only AB1 from (5) -127.7 ± 9.5 -135.6 ± 9.9 -134.1 ± 10.3 -144.1 ± 11.2 
(7) Return to native from (6) -129.8 ± 9.5 -113.4 ± 8.5 -139.2 ± 10.8 -123.1 ± 9.0 
(8) Heat (1) to 400K, mutate AB1 -132.3 ± 8.9 -117.7 ± 9.4 -125.6 ± 11.8 -126.1 ± 10.1 
(9) Heat (1) to 500K, mutate AB1 -134.0 ± 8.3 -119.3 ± 8.6 -134.4 ± 9.6 -117.4 ± 10.0 
(10) Simulate (1) 16 Å octahedral box -50.1 ± 7.9 -60.5 ± 9.4 -73.5 ± 8.4 -77.9 ± 8.8 
(11) Simulate (1) 16 Å square box -73.4 ± 9.4 -85.2 ± 10.8 -82.6 ± 10.5 -92.5 ± 11.6 
(12) Mutate only AB1 from (10) -111.9 ± 9.5 -107.9 ± 8.5 -107.0 ± 11.0 -112.6 ± 10.4 
(13) L4V from (10), using Parasol -80.6 ± 8.3 -108.2 ± 7.9 -87.3 ± 9.1 -112.9 ± 9.1 
(14) L105V from (10) using Parasol -66.0 ± 9.3 -107.4 ± 7.7 -80.4 ± 10.3 -113.5 ± 9.4 
(15) L4V from (10), using PPM -64.6 ± 6.8 -88.1 ± 7.9 -82.5 ± 7.7 -96.6 ± 9.4 
(16) L105V from (10) using PPM -64.2 ± 6.5 -92.2 ± 8.3 -79.3 ± 8.5 -98.6 ± 9.5 
(17) New solvent, new ions from (10) -66.5 ± 7.5 -89.1 ± 7.4 -80.8 ± 8.7 -99.1 ± 8.8 
(18) New solvent, same ions from (10) -64.2 ± 7.1 -81.7 ± 8.1 -78.1 ± 8.6 -92.3 ± 8.8 
(19) New solvent, no ions from (10) -62.1 ± 6.8 -84.2 ± 8.0 -78.4 ± 8.6 -93.8 ± 8.2 
(20) New native -55.7 ± 8.0 -46.8 ± 9.4 -73.6 ± 9.5 -66.2 ± 11.1 
(21) L4V from (20), using Parasol -55.6 ± 6.9 -53.9 ± 6.6 -55.6 ± 6.9 -53.9 ± 6.6 
(22) L105V from (20) using Parasol -55.4 ± 6.2 -53.9 ± 7.5 -55.4 ± 6.2 -53.9 ± 7.5 
(23) Mutate only AB1 from (20) -45.4 ± 5.8 -54.2 ± 6.9 -68.2 ± 7.8 -73.1 ± 8.8 
(24) Return to native from (23) -39.9 ± 5.8 -44.0 ± 6.4 -61.5 ± 7.3 -65.0 ± 9.1 
(25) Mutate both from (23) -47.1 ± 5.6 -42.9 ± 6.3 -69.6 ± 8.1 -64.3 ± 8.5 
(26) New native -64.7 ± 5.5 -58.3 ± 6.1 -85.0 ± 7.2 -71.2 ± 8.1 
(27) Mutate both simul from (26) -61.4 ± 6.2 -40.1 ± 6.1 -80.5 ± 8.0 -60.1 ± 8.1 
(28) Return to native simul from (27) -60.5 ± 6.2 -36.2 ± 6.7 -80.3 ± 8.2 -58.8 ± 7.2 
 
Table 33: A summary table of all the simulations reported in the study of the 9DPJS system. 
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9.4 – Summary, Outlook and Conclusions 
Perhaps the only thing that can be said with any certainty about the 9DPJS system is 
that it is a very difficult system to analyse, due to a number of factors. The large size is a 
hindrance that slows down the gathering of data and does not allow for a rapid testing of 
different conditions and parameters, and the system is also complicated by the potential 
symmetry effects given by having two antibodies interacting at the same time. 
Despite these difficulties, preliminary data has been gathered and important facts and 
requirements that will be useful in future investigations have been established. The first is 
that there appears to be a difference in the strength of binding between the two antibodies 
AB1 and AB2 and the NGF dimer. In all of the simulations that have been performed, a 
substantial difference in interaction strength was observed. Even though in individual runs 
the pattern may be inverted, AB1 on average had a more favourable interaction than AB2; the 
opposite was seen when larger solvent boxes were used. This is tied to the overall effect of 
solvation on this system, which was established to be crucial in order to obtain relevant 
results. 
Some of the inherent limitations of LEaP did not allow a full analysis of the system in a 
way that is perhaps closer to experiment. The size of the solvent shell, it was found, affected 
which of AB1 or AB2 had the stronger interaction, which may in turn affect how the data is 
examined; a larger box is probably closer to experimental conditions, but in order to keep the 
shell constant, a smaller size had to be employed. For further studies, there needs to be a way 
to use a large solvation box constantly throughout simulations, which would probably involve 
a recoding of LEaP itself. 
Another factor that may have influenced the collection of the data but which was only 
analysed very briefly is the structural change in the CDR3 loop brought on by the mutations 
that are introduced when mutating from LOT3.36 to LOT3. In particular, the mutation of the 
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serine-proline segment to a glycine-glycine segment is one that deserves further investigation. 
Glycine and proline tend to have an effect on the backbone conformation rather than directly 
contribute to the interaction, and thus structural studies may be required to fully elucidate 
their impact in this system. In such a tight interface, it is possible that the crystal structure is 
folded in a way that is optimal for the serine-proline sequence, and a mutation to glycine-
glycine may not have the space necessary to sample the conformational space. In other 
words, the structure remains stuck in a local minimum of the PES and the mutation does not 
generate an appropriate conformation because of the constraints of mutating within an 
already established interface. Indeed, when the same mutation is carried on the antibody on 
its own, the loop in question appears to adopt a different conformation to the one it takes 
when mutated as part of a complex, as it is shown in Figure 28. Although these studies are at 
a very early stage, they may be an indication of where research in the future ought to focus. 
Figure 28: A comparison of the 9DPJS structure. Ten runs of 1 ns each are compared for three systems: in blue, 
the native conformation from the crystal structure, in orange the LOT3 conformation mutated while within a 
complex and in red the LOT3 conformation mutated while on its own. From a simple visual inspection, it can be 
seen that the CDR3 loop, in the detail box, has similar conformations when in complex, whether mutated or not, 
but if allowed to have more freedom may adopt a looser structure, while the rest of the backbone is fairly 
constant. 
Native sequence in a complex 
Mutant sequence in a complex 
Mutant sequence alone 
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In this system more than others, the docking of the correct conformation may be crucial in 
understanding what affects the interaction. A simple visual inspection indicates that if the 
loop is unconstrained, i.e. it is not simulated in a complex, then the mutation makes it adopt a 
looser structure, whereas the rest of backbone remains more or less constant throughout. 
Since the mutation necessarily happens in a complex, our calculations of the interaction 
strength do not take into account this potential structural rearrangement. Further studies can 
quantify this behaviour and allow for a more reasoned approach that can lead to a better 
understanding of this interaction. 
Despite this being a very complicated system, several valuable observations were made 
about how this complex should be approached. We have collected a wealth of interaction data 
in a variety of different scenarios and conditions, determining that the solvent shell plays a 
crucial role in this system and that several precautions need to be taken in order to obtain 
comparable values for before and after the mutation. Progress was at times hindered by 
technical limitations: a larger solvent shell was deemed to be desirable, but its use is 
incompatible with the current implementation of LEaP. In future versions of the AMBER 
package, these issues may be addressed and therefore this system can be approached with 
improved tools. 
Our data can be considered preliminary at this stage, but we have identified several 
venues for further research; the docking of the antibody with the dimer, in particular, could 
be the key to understanding this interaction. As mentioned, the effect of the solvent shell can 
be investigated in more detail, and there are other mutations of the same antibody complex 
that may also merit investigation. The results that we have reported here will serve as a 
starting point for future research, using better tools and the accumulated insight of our first 
attempts. 
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Chapter 10: Summary and Outlook 
10.1 – The Parasol Protocol 
The aim of this project was to develop a tool to perform computational site-directed 
mutagenesis, specifically in the context of screening PPIs as a way to complement 
experimental work. A review of existing methods had identified methodological and 
implementation flaws that made them less than ideal to use in a virtual scanning capacity; 
either they were not rapid enough to be employed in a routine, automated manner, or they 
relied on a theoretical basis that may be insufficient to properly model the analysed systems. 
We had established several requirements that we believed to be important for virtual 
scanning, and our intention was to develop a new protocol that could incorporate them all. 
We wanted this tool to rely on molecular mechanics principles to generate dynamics, we 
needed it to be cheap enough to be used on non-specialised machines, we required it to be 
quick to allow the collection of a large volume of data faster and more easily than it would 
take to do experimentally, and we designed it to be easy to use so that it could be employed 
by personnel without extensive computational expertise. Our inspiration for the mechanism 
came from FEP, specifically its approach of using non-chemical (alchemical) intermediates to 
have a smooth transition from one amino acid to another. By using gradual, dynamic 
transformations, we hoped that it would allow us to model mutations better and more 
efficiently than by introducing sudden changes. We also wanted to implement it within the 
framework of the AMBER package, so that it could both take advantage of a well-established 
and wide-ranging suite of additional tools and also have compatibility with a broadly used 
MD tool, as well as relying on a solid theoretical basis. Summing all of these requirements 
and needs, we have developed the Parasol Protocol. 
We have detailed the underlying mechanism of the Parasol Protocol at length, how a 
careful manipulation of parameters such as bonds, angles, dihedrals and charges can be used 
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to transform one species into another. All of the natural amino acids have been implemented 
within the protocol in this manner, so that mutations between any pair of residues can be 
accomplished through the correct addition or removal of functional groups. Furthermore, the 
protocol can be easily expanded to cover other non-natural amino acids, increasing the range 
of possible mutations that can be done with this method. 
The algorithms that we use can be customised in the same way that AMBER allows 
users to experiment with different time lengths and conditions, and we have determined that 
for mid-sized systems the standard parameters for the Parasol Protocol can be remarkably 
quick in generating the needed data. Additionally, this has been done without having access 
to dedicated machines or powerful computer clusters, but employing very cheap options that 
are easily within the reach of most researchers. 
Satisfied with the development of our protocol and of its ability to mutate amino acids 
at will, quickly and economically, we have sought to validate it and test it by comparing it to 
experimentally obtained data. We have not limited ourselves to simple systems, but have 
instead analysed very different complexes that presented different challenges and tested not 
only our method but also our understanding of PPIs. Even when the data that we generated 
computationally did not quite correlate with the results measured in the laboratory, it still 
furthered the study of those systems, and it helped us determine the limitations of our 
protocol, as well as those inherent to the process of analysing proteins and their properties 
with molecular dynamics simulations.  
The Parasol Protocol has proved to be versatile enough to be able to handle many kinds 
of systems, manipulating all sorts of amino acid mutations in different contexts. The ability to 
incorporate non-natural residues is, we feel, a great strength of our protocol. In some cases, 
non-natural amino acids may introduce peculiar functionalities or specific structural changes 
that would greatly enhance the protein or peptide’s properties, but the bias towards natural 
165 
 
residues has made these species comparatively more expensive and less routinely used. 
Explorative work involving them is therefore more expensive and risky to carry, but the use 
of a protocol like Parasol to test it beforehand can remove some of the uncertainty associated 
with this sort of research and enable new venues of experimentation. 
We have accomplished with our Parasol Protocol, we feel, what we had set out to do at 
the beginning of this project: we have developed a quick, cheap method to mutate amino 
acids within the AMBER framework and relying on molecular dynamics. Our test cases, 
although with varying degrees of success, have begun the validation of the protocol, 
demonstrating the ability to generate mutants and begin the investigation of PPIs and protein 
complexes. Despite the high volume of data that has been generated so far, there is much to 
be done; the expertise that we have gained and the automation and implementation of the 
Parasol Protocol can make further studies easier and speedier. 
 
10.2 – Strengths and Limitations 
Regarding what we had set out to include in the Parasol Protocol, we have achieved all 
that had been our original goal. We have devised a generalised method for the gradual 
removal or growth of functional groups that works within the limits of AMBER and 
AMBERTools programs, we have automated and streamlined the process and put together all 
the relevant algorithms to have a robust and (mostly) bug-free method. The scripts are 
general enough that adding new functionalities and updating them is easy. Most importantly 
of all, the protocol works: it can introduce mutations quickly and cheaply and it does so in a 
programmed manner that can be controlled even by non-specialised users. From this point of 
view, the Parasol Protocol has been a success. 
The limitations that we have found when applying the protocol to different case studies 
are perhaps more general limitations intrinsic to the AMBER package and the MD analysis of 
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proteins, as well as challenges specific to the systems that we have examined. While the 
stapled peptide system had great correlation with experiment and gives us hope that testing 
alongside laboratory work may be possible in the near future, the OppA and antibody systems 
revealed that there is still much we do not know about PPIs, and this hinders the application 
of the Parasol Protocol. 
In particular, the size of the investigated complexes remains a significant barrier that 
can slow down and make harder to collect the relevant data, and also be an important factor 
that must be considered when measuring the properties of the system. As we have seen, the 
solvent shell around a protein can have a considerable impact on the calculation of the free 
energy, and, if not properly accounted for, it may introduce artefacts and inaccuracies that 
may make comparison between native and mutants much harder. The issue of docking, i.e. 
how two proteins come together to interact, is also something that we have only very briefly 
examined but which can be of great importance. Due to a number of reasons we have already 
discussed, the analysis of PPIs through molecular dynamics means is heavily biased towards 
systems already in a complex, meaning that the dynamics of the species in isolation as well as 
the mechanism of how they come together and form an interface are rarely accounted for. In 
some cases, this may be extremely important, but the Parasol Protocol and the other tools we 
have used are poorly equipped to deal with these issues. 
The truth is, it is impossible for any single method or approach to be sufficient in the 
analysis of a chemical system. Beginning with the choice of using QM or MM, every tool can 
be more appropriate for certain tasks and may be less suited for others; depending on what 
data is sought, certain packages and methodologies may give better results, and determining 
which one is an important part of any research. In fact, multiple approaches to the same 
problem may be necessary to fully explain effects and results, complementing each other 
while working on different levels of accuracy. Indeed, this is what we have done ourselves: 
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while we have generated dynamics with an MM-based mechanism for mutations, the analysis 
of the interactions has been done through MMPB(GB)SA, conscious of the strengths and 
weaknesses of using that particular method.  
It would have been overly optimistic to expect the Parasol Protocol to have exact 
correlation with experiment in all these test cases, but we believe that these results are 
encouraging. Our intention was to develop a new method for a specific application, the 
virtual scans of PPIs, and we wanted it to become a possible tool in the arsenal of methods 
that can be used for this purpose. It may very well be that some systems do not easily lend 
themselves to a quick analysis: in the case of the 9DPJS antibody system, for example, 
extensive experimentation was needed in order to determine the most appropriate simulation 
conditions that can then be used for a virtual scan. Even with these results, the Parasol 
Protocol did not perform at a sufficiently high level to convince us that it has predictive 
power in this context, and it is possible that it may never will. Perhaps because of the size of 
the system, or perhaps because of the specific interaction of 9DPJS, there are many variables 
that need to be tested before a definitive verdict can be reached. The results were much better 
for the stapled peptide system, which allows us to hope that applying this protocol to other 
PPIs like it would have a similar degree of success. In this case, it was perhaps the smaller 
and more drug-like interaction as well as the more limited scope that perhaps allowed us to 
obtain data that compares so favourably with experiment. 
The Parasol Protocol has been developed with success, but its application and use in a 
research setting is still at an early stage. Learning how to better integrate a mutagenesis tool 
in this sort of investigation is not only an issue of improving the protocol itself but also a 
question of understanding how PPIs can be computationally analysed. Our method is only a 
small piece of a larger process. What we have done so far can help in developing in silico 
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techniques that can be employed alongside experimental work, but much still needs to be 
done. 
 
10.3 – Future Developments 
Although the Parasol Protocol is in a state where it can be easily distributed and shared, 
with all of its scripts being automated and requiring only minimal user input, there are still 
many improvements that we feel can be added to the method, as well as many changes that 
could be made to the existing body of work in order to make it a better tool. 
Perhaps the most important modification that needs to be made to the Parasol Protocol 
if it needs to become a routine tool part of the AMBER package is a complete rewrite of the 
scripts in a more appropriate coding language such as python or FORTRAN. Currently, the 
bash scripts exist on top of the AMBER implementation, utilising the programs that are part 
of it but not being incorporated in them. Although easier to write and edit as these scripts 
require far less specialist knowledge than a computer language, this makes the Parasol 
Protocol quite inefficient at times, as well as inconsistent with the rest of the AMBER tools 
and software. In some cases, however, a rewrite of existing programs may be needed, such as 
the ageing LEaP, and therefore this may be more of a long-term plan. It would still be very 
important to have a more streamlined code, and therefore we think this is a top priority. 
In terms of further improvements in how the protocol is employed, one addition that 
has always interested us has been the ability to carry two mutations at the same time. We 
have already explained how the dimeric nature of the 9DPJS antibody system has made us 
change the code to allow two simultaneous mutations if they involve the same initial and 
final amino acids, so the next step would be to devise a way to expand this capability to 
different mutations. There might some logistical challenges as to how two mutations can be 
allowed at the same time, considering that some may need multiple intermediates, but there is 
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no issue in the Parasol methodology that makes this impossible in principle. Carrying 
multiple mutations at the same time would allow us not only to have shorter simulations 
overall but also potentially eliminate bias that may derive from having to go through 
intermediates, and thus it would be a worthwhile improvement to the protocol. 
Another area that can be of interest is that of non-natural amino acids, which, as we 
have already discussed, can be easily incorporated in the Parasol Protocol and could be useful 
in experimental work. In particular, given the success we have had with stapled peptides, the 
design and incorporation of different staple structures is an attractive venue for further 
research.  
One of the biggest issues, however, is the measurement of the free energy, which we 
have seen in many cases to be imprecise and lacking in the needed accuracy. MMPB(GB)SA 
is our method of choice because it is well implemented within AMBER and it offers a 
reasonable trade-off between speed and accuracy, but we have to recognise its limitations and 
attempt to go beyond them. A solution could be to use a different protocol to calculate 
binding energies, but an alternative would be to implement the Parasol Protocol within an old 
technique of ours, MULES. We have described how this method used two regions within a 
complex, mutating one of them and keeping the other constant, so that discrepancies in the 
interaction arose necessarily from dissimilarities in those regions. It showed promise as a 
method, but it was limited to using PPM as a way to generate new structures, and thus only 
certain mutations were possible. By combining the Parasol approach of non-chemical 
manipulation of the parameters and the MULES use of two regions to improve sampling 
accuracy, one could feasibly generate molecular dynamics simulations where a mutation has 
been introduced organically in a system, and the comparison between mutant and native is 
simplified. Indeed, we have briefly attempted to do this and, as a proof of principle, we have 
carried a very easy mutation from an isoleucine to a valine (which involves the simple 
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shrinking of a methyl group) using the Parasol Protocol in a LES region, while the other was 
kept as the native. Like the MULES technique before it, the process was hindered by the lack 
of established and automated algorithms, and all the file manipulation had to be done by 
hand, tediously and laboriously. However, the experiment worked, and a mutated structure 
was generated alongside the native one, which gives us hope that it may be a possible venue 
for further development. There are still several issues, both in the technical sense that 
extensive work needs to be done before it can be used in an automated manner, and 
theoretical, as such a method would neglect mutations effects outside the region of interest. 
Despite these considerations, the fusion of the Parasol Protocol and MULES may let each 
method overcome some of its limitations and provide an overall better tool, and thus it is an 
attractive prospect to pursue. 
Another possible approach to the calculation of the free energy is to measure the 
interaction on a continuous simulation that incorporates the mutation rather than relying on 
assessment of discrete states; this would make it more similar to FEP. Our philosophy 
throughout has been that the intermediates are alchemical in nature and therefore liable to 
give skewed results of the free energy, and therefore measurements have been done on initial 
and final structures, without examining the transitions. However, it may prove valuable to 
incorporate the Parasol Protocol in a longer, continuous simulation, where the native form is 
modelled at the beginning, then the mutation is carried out, and then the altered state is 
modelled, allowing us to measure the free energy change throughout and monitor it as it is 
affected by dynamics of the system. Studies would have to be done to prove the reliability of 
looking at the obviously non-chemical nature of the intermediate, but this approach may give 
more information than the current way where only the endpoints are examined. 
Even though we are satisfied with the current progress of the Parasol Protocol, there are 
still many areas that merit further study and investigation. In time, it may become possible to 
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implement some of all of these, and maybe it will become a standard tool part of the AMBER 
package.  
 
 
10.4 – Conclusion 
Proteins and peptides are extremely important biomolecules, and the interactions 
between these species are relevant in a wide variety of contexts, from medical to industrial 
applications. The use of computational tools to analyse them can be of great value, due to 
their greater speed and lesser cost when compared to equivalent experimental techniques; in 
silico methods have been applied with success to complement laboratory studies, to give 
direction, explain results and predict activities. 
We have reviewed existing methods used for this purpose, and we have found them 
wanting. In particular, we had identified the need for a mutagenesis protocol implemented 
within the AMBER package that can be employed quickly and cheaply in virtual scans. 
Combining the alchemical approach of methods like FEP and the use of MD parameters to 
describe systems, we have developed the Parasol Protocol.  
The Parasol Protocol, implemented as a series of scripts that make use of the existing 
AMBER architecture, is a fast and inexpensive protocol that can be used to mutate between 
any pair of natural amino acids and that can handle the manipulation of many different types 
of functional groups. It is automated and easy to use, and it can be used on any system to 
reliably generate mutant structures. 
To validate our protocol, we have tested in a series of different case studies, attempting 
to use this computational tool to replicate experimental observations. In some cases, the 
results we obtained compared very favourably with what we had found in the literature, while 
in others extensive work was needed before the correct conditions for simulations were 
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reached. In each case, the Parasol Protocol performed admirably, and it could be used quickly 
and consistently to rationally mutate the studied systems; flaws and failures of our 
investigations stemmed more from the general underlying approximations of analysing PPIs 
with computational methods. Though there is still much that we do not know and more 
studies are necessary to fully understand the principles of interaction and how we can 
measure them, the Parasol Protocol promises to be a useful tool in this field. 
We have already identified new systems, new improvements and new studies that we 
can do to further our understanding and continue with the development of our technique. We 
hope that one day the Parasol Protocol may become a routine method used in computational 
mutagenesis, and we believe it has the capability to do so. 
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